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Thyroid cancers are the most common endocrine malignancies and their incidence 
continues to rise.  Over-expression of the human pituitary tumor transforming gene (hPTTG) in 
thyroid carcinomas is a prognostic indicator of tumour recurrence.  hPTTG is multifunctional with 
roles in mitotic control, DNA repair, genetic instability, cell transformation and apoptosis. 
Importantly, hPTTG transactivates expression of growth factors implicated in proliferation and 
angiogenesis, and represses the sodium iodide symporter (NIS), which is essential to radioiodine 
treatments in thyroid cancer.  hPTTG interacts with a binding factor (PBF) which is an 
independent transforming gene and also represses iodine uptake.    
Work described in this thesis provides evidence for the existence of thyroidal autocrine 
regulatory pathways involving hPTTG and growth factors in vitro. We directly investigated the 
role of hPTTG in thyroid tumourigenesis through the generation and characterisation of a murine 
transgenic model with thyroid-targeted hPTTG over-expression (hPTTG-Tg mice). Unexpectedly, 
hPTTG over-expression was not sufficient for thyroid tumourigenesis. Investigations performed 
in hPTTG-Tg and Pttg-/- knockout mice indicated a particularly important relationship between 
hPTTG and the epidermal growth factor (EGF) in vivo. hPTTG and PBF were confirmed as 
repressors of NIS in vivo following studies in hPTTG-Tg and PBF-Tg mice respectively. The 
studies described in this thesis highlight the therapeutic potential of targeting hPTTG and PBF in 
thyroid cancer. To this effect, specific tyrosine kinase inhibitors prevented autocrine induction of 
hPTTG by growth factors, and siRNA depletion of PBF restored NIS function to normal levels in 
hPBF-Tg thyrocytes. 
Based on these data, hPTTG appears to play a dual role in endocrine tumourigenesis, 
being involved in both tumour initiation and subsequent progression towards more aggressive 
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1.1 Pathogenesis of thyroid cancer 
 
1.1.1 Epidemiology and classification 
 
Thyroid cancers are the most common endocrine malignancies and have the fastest 
rising incidence of all cancers (Howlader et al. 2011).  In the United Kingdom, thyroid 
carcinomas have an annual incidence of 2.6 per 100,000, affecting 1 in 1200 adults (British 
Thyroid Association and Royal College of Physicians 2007), while in the USA, they account 
for 0.85 % and 2.5 % of new cancer cases in men and women respectively (Jemal et al. 2003).  
Most patients have a favourable prognosis following surgery and administration of 
radioiodine, resulting in low mortality rates of 0.21 % and 0.3 % for men and women 
respectively (Schneider and Ron 2005).   However, thyroid cancer incidence has been steadily 
rising over the past 30 years and has approximately tripled in the USA and other developed 
regions during this time (Albores-Saavedra et al. 2007; Davies and Welch 2006; Burgess and 
Tucker 2006; Colonna et al. 2007).  The increase in incidence is generally attributed to 
advances in diagnostic approaches including high-resolution imaging, as well as the increased 
use of fine-needle aspiration (FNA) biopsies and susbsequent cytologic examination.  
However, exposure to ionizing radiation due to wider use of medical radiation or nuclear 
power accidents such as Chernobyl are well known risk factors in thyroid cancer that may 
also contribute to increased incidence (Rabes et al. 2000; Nikiforov et al. 1997; Bounacer et 
al. 1997; Smida et al. 1999; Hamatani et al. 2008; Takahashi et al. 2007).   
Three to five percent of thyroid cancers arise from parafollicular or C cells and give rise 
to medullary thyroid carcinomas.  All other thyroid cancers originate in thyroid follicular 
epithelial cells and are further classified as well-differentiated papillary (80-85 %) and 
follicular carcinomas (10-15 %), poorly differentiated or insular carcinoma (< 2 %) and 
anaplastic or dedifferentiated carcinoma (1-2 %).  Follicular adenomas are benign entities that 




may develop into follicular carcinomas.  Disease progression and subsequent dedifferentiation 
of follicular carcinomas can result in development of insular or anaplastic carcinomas, 
although these subtypes can also develop de novo (Nikiforov and Nikiforova 2011; Nikiforov 
2009; Delellis et al. 2004).   
In contrast to thyroid cancer, benign thyroid disease in the form of diffuse or nodular 
thyroid enlargement, termed goitre, is highly prevalent.  Goitres are characterised by 
hyperplasia, which is typically driven by elevated levels of thyroid stimulating hormone 
(TSH), growth factors and circulating stimulatory antibodies.  While erroneous thyroidal 
metabolism, dietary goitrogens and goitrogenic chemicals can cause goitres, nutritional iodine 
deficiency represents the major cause of TSH-induced goitrogenesis worldwide.  
Consequently, incidence rates of goitre are highly influenced by the iodine status of a 
population, but goitre occurrence remains prevalent even in iodine-sufficient regions.  For 
example, the Whickham survey described a comprehensive population survey of 2,749 people 
in Northern England and identified that 15.5 % of the participants had a palpable goitre (8.6 
% had a small goitre) with a female to male ratio of 4.5:1 (Tunbridge et al. 1977). 
   
1.1.2 Molecular genetics of thyroid cancer 
     
External irradiation is a well-defined pathogenetic factor associated with thyroid 
carcinoma, but others such as hormonal (oestrogen and TSH), dietary, environmental and 
genetic factors have all been implicated (Schneider and Ron, 2005).  Most malignant thyroid 
cancers are monoclonal in origin, meaning that transforming events are caused by genetic 
alterations in a single cell, giving rise to clonal cell populations conferred with a growth 
advantage (Moniz et al. 2002; McCarthy et al. 2006; Fagin 2005b).  Subsequent propagation 
of tumour growth is driven by extracellular growth factors regulating critical growth and 




survival pathways.  Molecular components of these highly complex and intricate pathways 
may act as oncogenes or tumour suppressor genes.  In recent years, we have enhanced our 
knowledge of genetic aberrations that cause activation of oncogenes or inactivation of tumour 
suppressor genes, which appear to have important roles in thyroid tumourigenesis (Fagin 
2005b; Nikiforov and Nikiforova 2011).   
 
1.1.3 Oncogenes in thyroid cancer 
 
Initiation and progression of thyroid cancer occurs through gradual accumulation of 
genetic alterations.  Various critical genes, mutated by single point mutations or chromosomal 
rearrangements, are associated with specific etiologic factors in thyroid carcinogenesis.  The 
prevalence of these genetic alterations are summarised in Table 1-1 and discussed in detail in 
subsequent sections.   
 
Table 1-1: Summary of thyroid cancer classifications and associated genetic mutations.  Adapted 















Cell type origin Follicular Follicular Follicular Follicular C cell
Prevalence (%) 80-85 10-15 < 2 1-2 3-5











































Familial: RET > 95
Sporadic: RET 40-50
RAS 25




1.1.3.1 Tyrosine receptor kinase rearrangements 
 
The Rearranged in Transformation (RET) gene encodes a receptor tyrosine kinase for 
members of the glial cell line-derived neurotrophic factor family of extracellular signalling 
molecules and is usually only expressed in neuronal, neuro-endocrine and kidney cells 
(Knowles et al. 2006).  Rearranged in transformation/papillary thyroid carcinomas (RET/PTC) 
is a clonal chromosomal rearrangement observed in 10-20 % of papillary thyroid cancers 
(PTCs) (Zhu et al. 2006; Guerra et al. 2011; Santoro et al. 1992), where its presence is 
associated with a high risk of development of metastases (Jhiang et al. 1992).  Detection of 
RET/PTC rearrangements are very common in small PTCs, leading to speculation that it 
represents an early event in thyroid cell transformation (Kim et al. 2003).  In these 
rearrangements, a fragment of the RET gene coding for the C-terminal tyrosine kinase domain 
of the RET protein forms chimeric fusion genes with active promoters of other genes.  
Transgenic mouse models have demonstrated that this results in the expression of a 
constituitively active RET/PTC protein that persistently stimulates mitogen-activated protein 
kinase (MAPK), independent of ligand-binding, thereby promoting thyroid tumourigenesis 
(Jhiang et al. 1996; Santoro et al. 1996; Powell et al. 1998).   
Neurotrophic tyrosine receptor kinase type 1 (NTRK1) codes the receptor for nerve 
growth factor (NGF).  NTRK1 forms fusion genes with at least 3 different partner genes in 
thyroid papillary carcinomas, but is significantly less prevalent than RET/PTC rearrangements 
(Radice et al. 1991; Greco et al. 1992; Miranda et al. 1994; Bongarzone et al. 1989).      
 
1.1.3.2  Nuclear receptor mutants 
 
The PAX8/PPARγ rearrangement results in a fusion gene between part of the thyroid 
transcription factor gene, paired box gene 8 (PAX8), and the peroxisome proliferator-activator 




receptor γ1 (PPARγ) gene, which encodes a DNA-binding nuclear receptor that is involved in 
regulating adipocyte differentiation and lipid metabolism (Kroll et al. 2000; Powell et al. 
2004; Evans et al. 2004).  Although the transforming mechanisms of PAX8/PPARγ are poorly 
understood, this genetic translocation occurs in 30-35 % of follicular thyroid carcinomas 
(French et al. 2003; Nikiforova et al. 2003b; Dwight et al. 2003).   
In addition, mutations in the thyroid hormone receptor (TR) α1 and β1 transcripts have 
been reported in papillary thyroid cancers (Puzianowska-Kuznicka et al. 2002).  Aged 
transgenic mice with thyroid targeted expression of a mutant TRβ that is inactive (TRβPV/PV 
mice), develop invasive follicular thyroid cancers, suggesting a role for TRβ in thyroid cancer 
progression (Suzuki et al. 2002).   
 
1.1.3.3 RAS mutations 
 
Human Harvey rat sarcoma viral oncogene (HRAS), Kirsten rat sarcoma viral oncogene  
(KRAS) and neuroblastoma rat sarcoma viral oncogene (NRAS) encode G‐proteins which are 
involved in the transduction of intracellular signalling from cell surface receptor tyrosine 
kinases and G-protein coupled receptors, to the nucleus (Marshall 1996).  RAS proteins 
hydrolyse GTP to GDP and activate MAPK, phosphoinositide 3-kinase (PI3K) and other 
pathways to stimulate cell proliferation and suppress differentiation (Mendoza et al. 2011; 
Marshall 1996).  Activating point mutations in RAS genes have been identified in various 
thyroid tumours, including 10-20 % of papillary carcinomas, 40-50 % of follicular carcinomas 
and 20-40 % of insular and anaplastic carcinomas (Suarez et al. 1990; Esapa et al. 1999; 
Motoi et al. 2000; Manenti et al. 1994; Namba et al. 1990; Karga et al. 1991; Ezzat et al. 
1996).  The presence of RAS mutations in benign follicular adenomas (Esapa et al. 1999; 
Motoi et al. 2000; Namba et al. 1990) and in thyroid malignancy as above, suggests that 




aberrant control of RAS may drive thyroid tumour progression from benign to well-
differentiated to anaplastic thyroid tumour subtypes.   
 
1.1.3.4 BRAF mutations 
 
Serine/threonine-protein kinase (BRAF) is one of the three isoforms of the serine-
threonine kinase RAF, which is activated by RAS, resulting in its translocation to the cell 
membrane where it phosphorylates and activates the MAPK pathway.  In thyroid cancer, 
BRAF can become constituitively active following point mutations or chromosomal 
rearrangements.  The most common mechanism of BRAF activation is caused by a point 
mutation resulting in a valine-to-glutamate replacement at residue 600 (BRAF
V600E
) (Kimura 
et al. 2003; Cohen et al. 2003).  This particular mutation represents 99 % of all BRAF 
mutations found in thyroid cancer, where it occurs in 40-45 % of papillary carcinomas (Xing 
2005; Fukushima et al. 2003; Nikiforova et al. 2003a; Fagin 2005a) and in 20-40 % of insular 
and anaplastic carcinomas (Namba et al. 2003; Nikiforova et al. 2003a; Begum et al. 2004; 
Ricarte-Filho et al. 2009).  The results of the various studies above imply that BRAF
V600E 
mutations are an early event, predisposing tumours to progressive dedifferentiation and 
development of an anaplastic disease state.  In support of this, transgenic mice with thyroid 
targeted BRAF
V600E 
expression develop goitre and papillary thyroid cancers, which 
progressively transitions to poorly differentiated carcinomas  (Knauf et al. 2005).   
 
1.1.3.5 Accumulation of other oncogene mutations 
 
In addition to BRAF and RAS mutations, a number of additional oncogenic mutations 
have been identified in poorly differentiated and anaplastic carcinomas, but not in well-
differentiated tumour types, suggesting these mutations are late events in thyroid 




tumourigenesis.  The catenin (cadherin-associated protein) beta 1 (CTNNB1) gene encodes a 
β-catenin involved in cell-adhesion and Wnt signalling, and a point mutation in this gene has 
been found in up to 60 % of anaplastic carcinomas (Garcia-Rostan et al. 1999; Garcia-Rostan 
et al. 2001; Kurihara et al. 2004).  In addition, studies have demonstrated that poorly 
differentiated and anaplastic carcinomas harbour mutations of PI3K pathways components 
including phosphoinositide-3-kinase catalytic alpha polypeptide (PIK3CA) itself (10-20%), 
phosphatise and tensin homologue (PTEN) (5-15%) and v-akt murine thymoma viral 
oncogene homolog 1 (AKT1) (5-10%) (Ricarte-Filho et al. 2009; Garcia-Rostan et al. 2005; 
Santarpia et al. 2008; Hou et al. 2007; Dahia et al. 1997). 
 
1.1.4 Tumour suppressor genes in thyroid cancer 
Tumour suppressor genes serve to arrest cell division and/or induce apoptosis in 
response to genetic mutations.  Mutations of the important cell cycle regulator tumour protein 
p53 (TP53) exist in over 50 % of all cancers (Hollstein et al. 1994).  p53 is stabilised in 
response to DNA damage and elicits protective effects by activating downstream target genes 
that prevent cell cycle progression, such as p21 (Dulic et al. 1994).  Mutations of p53 have 
been found in 50-80 % of anaplastic carcinomas where its inactivity results in unrestrained 
tumour cell growth (Fagin et al. 1993; Donghi et al. 1993; Dobashi et al. 1994; Ito et al. 
1992).  The rare occurrence of this mutation in preceding tumour stages suggests that p53 
mutations are a late event in thyroid tumourigenesis.   
 Another tumour suppressor gene is p16, a direct inhibitor of cyclin-dependent kinase 4 
(CDK4), inactivation of which is associated with the development of spontaneous neoplasms 
and increased sensitivity to carcinogenic stimuli (Serrano et al. 1996).  The expression of p16 
has been shown to be reduced in papillary thyroid cancer (Liang et al. 2009).   




1.1.5 Prognosis of thyroid cancer 
 
Retrospective studies have enabled us to recognise certain factors that adversely affect 
prognosis of thyroid cancer and risk is assessed in patients with DTC using a prognostic 
scoring system.  Tumour size, Node metastases and distant Metastases (TNM) is the most 
frequently used system and is summarised in Table 1-2.  While most patients have a good 
prognosis following surgery and administration of radioiodine, BTA guidelines suggest 10 
year disease specific mortality for stage I as 1.7 %, rising to 60.9 % for stage IV disease 
(British Thyroid Association and Royal College of Physicians 2007; Loh et al. 1997).  5-30% 
of patients will develop locoregional recurrence (British Thyroid Association and Royal 
College of Physicians 2007; Jonklaas et al. 2006; Mazzaferri and Jhiang 1994), with 
subsequent five year survival of 87 %.  If distant metastases are present, five year survival 
falls to 72 % (Jonklaas et al. 2006).  The prognostic accuracy of the staging and grading 
systems used in differentiated thyroid cancer has increased (D'Avanzo et al. 2004).  Factors 
associated with a worse prognosis are male gender, age greater than 40 years and tumours of 
the follicular subtype or greater than 1 cm in size (British Thyroid Association and Royal 
College of Physicians 2007; Mazzaferri and Jhiang 1994).   





Table 1-2: Table summarising Tumour size, Node metastases and distant Metastases 
(TNM) prognostic scoring system and associated mortality rates.  Adapted from (British 
Thyroid Association and Royal College of Physicians 2007; D'Avanzo et al. 2004; Loh et al. 
1997) 
 
The gold standard for diagnosing thyroid malignancy remains FNA cytology (FNAC).  
Recent advances in molecular analysis of FNA present novel approaches to providing 
individualised treatment strategies to patients.  Currently, indeterminate cytology indicating 
an inability to conclusively discern benign from malignant nodules is found in 10-20 % of 
patients with thyroid nodules and malignancy is diagnosed in only 20 % of these.  
Consequently, unnecessary surgery is performed in 60-90 % of these patients (Baloch et al. 
2002; Baloch et al. 2008; Mazzaferri 1993).  Advances in the molecular analysis of the 
Disease
Stage




- Any T, any N, M0 - pT1, N0, M0 1.7
STAGE II
-Any T, any N, M1 -pT2, N0, M0




- Any pT, N1, M0
30.0
STAGE IV
- Any pT, any N, M1 60.9
*  Undifferentiated or anaplastic carcinomas are all STAGE IV.  
Primary tumour
pT1 Intrathyroidal tumour, ≤ 1 cm in greatest dimension
pT2 Intrathyroidal tumour, >1-4 cm in greatest dimension
pT3 Intrathyroidal tumour, > 4 cm in greatest dimension
pT4 Tumour of any size, extending beyond thyroid capsule
pTX Primary tumour cannot be assessed
Regional lymph nodes (cervical or upper mediastinal)
N0 No nodes involved
N1 Regional nodes involved
If possible, subdivide
N1a Ipsilateral cervical nodes
N1b Bilateral, midline or contralateral cervical nodes or mediastinal nodes
NX Nodes cannot be assessed
Distant metastases
M0 No distant metastases
M1 Distant metastases
MX Distant metastases cannot
be assessed




mutational markers described above (see section 1.1.3), represent opportunities to identify 
specific cancer subtypes and to provide highly improved diagnostic accuracy and to avoid 
unnecessary surgical procedures.  For example, the collective results of 22 studies of thyroidal 
FNA samples revealed that in 1,117 nodules deemed positive for the BRAF
V600E 
mutation, 
99.3 % were subsequently histologically classified as papillary carcinomas, thereby 
demonstrating the irrefutable accuracy of BRAF
V600E
 mutations as an indicator of cancer 
(Nikiforova and Nikiforov 2009; Kim et al. 2010; Kim et al. 2011; Nam et al. 2010).   
 
1.2 Identification of the Pituitary Tumor Transforming Gene (PTTG) 
 
Rat Pttg was first cloned using mRNA differential display polymerase chain reaction, 
where mRNA was exclusively expressed at high levels in rat pituitary tumour cells (GH4) but 
not in normal pituitary tissue (Pei and Melmed 1997).  A human homologue of PTTG was 
cloned from a foetal liver cDNA library by using rat Pttg cDNA as a screening probe, and 
subsequently 89 % sequence homology was shown between rat and human PTTG (hPTTG) 
(Zhang et al. 1999b).  Contemporaneously, a human homologue was cloned from thymus 
(Dominguez et al. 1998) and testis (Kakar and Jennes 1999).  A further two hPTTG 
homologues have now been identified, including hPTTG2 on chromosome 4p12 (Kakar and 
Jennes 1999; Prezant et al. 1999) and hPTTG3 on 8q22 (Prezant et al. 1999), which are 91 % 
and 89 % homologous to hPTTG1 respectively.  A further variant of hPTTG1 with altered 
functional capabilities was also detected (Wang and Melmed 2000b).  However, hPTTG1 on 
chromosome 5q33 (Zhang et al. 1999b) is the most abundant variant that is highly associated 
with oncogenesis and hence the most extensively studied form of hPTTG1.  All of the studies 
described in subsequent chapters are focused on hPTTG1 and is denoted as hPTTG in 
accordance with convention.   
 




1.2.1 Characterisation of hPTTG 
 
Following observation of hPTTG over-expression in tumour cells, several studies have 
demonstrated the potent transforming capabilities of both rat and hPTTG in vitro and in vivo.  
Stable transfection of hPTTG in NIH3T3 mouse fibroblast cells caused an increase in cellular 
proliferation, augmented anchorage-independent growth in soft agar and induced tumour 
formation after subcutaneous injection into athymic nude mice (Pei and Melmed 1997; Zhang 
et al. 1999b; Kakar and Jennes 1999).  Thus, the identification of hPTTG as a novel 
transforming gene has prompted many studies investigating its potential involvement in 
carcinogenesis. 
 
Figure 1-1: Characterisation of hPTTG as a potent transforming gene in vitro and in vivo.  A  
Colony formation of NIH3T3 cells transfected with vector only (pCI-neo), wild type or mutant hPTTG 
expression vector on soft agar. The transforming ability of hPTTG, abrogated by mutation of its 
TUMOUR WEIGHT (mg)
N1 0 1000 100
N2 0 560 0
N3 0 670 0
N4 0 770 0
N5 0 940 0









proline rich domain is observed by the formation of large and abundant colonies. B. Tumour 
formation induced following subcutaneous injection of NIH3T3 stable transfectants into nude mice. 
Each mouse was injected with 3 x 105 control (n = 5), wild type (n = 5) or mutant hPTTG-over-
expressing (n = 5) cells. After 2 weeks mice were photographed, sacrificed and their tumours excised 
and weighed (weight data in C) (Adapted from (Zhang et al. 1999b)). 
 
1.2.1.1 Structure of hPTTG 
 
hPTTG has an open reading frame of 609 bp that encodes a 202 amino-acid protein 
(Zhang et al. 1999b).  hPTTG is functionally divided into an N-terminal basic domain and a 
C-terminal acidic domain that harbour regulatory and functional domains respectively 
(Dominguez et al. 1998; Zhang et al. 1999b; Kakar and Jennes 1999). 
   
 
Figure 1-2: Schematic representation of the hPTTG protein. The following functional domains are 
displayed in pink (amino acids are given in brackets): KEN box (9 - 11), Destruction box (61 - 68), 
PBF binding domain (123 - 154) and SH3-interacting domain (163 - 173). The DNA binding domain 
is found between amino acids 61 and 118 and a transactivation domain lies between 119 and 164.  
The red star indicates the phosphorylation site of human PTTG.   
 
In the regulatory N-terminal domain, a KEN box (amino acids 9-11) and a destruction 
box (DB) (amino acids 61-68) are substrates for the anaphase promoting complex (APC), and 
together are important for ubquitination of hPTTG by the APC to allow progression from 
metaphase to anaphase during mitosis (Zou et al. 1999; Zur and Brandeis 2001).  
Ubiquitination of hPTTG was unaffected or only partially inhibited by sole mutations in the 
KEN box and DB respectively.  In contrast, double mutations of both motifs resulted in 
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completely abolished hPTTG degradation, suggesting they act in unison to ensure hPTTG 
levels are regulated correctly (Zou et al. 1999; Zur and Brandeis 2001).   
Incorporating the DB box, a DNA binding domain is  present from amino acids 61-
118 with a transactivational region immediately downstream of this (Zhang et al. 1999b; Pei 
2000; Wang and Melmed 2000b), allowing hPTTG to act as a transcription factor.  
Interestingly, prospective transcriptional targets of hPTTG include growth factors such as 
vascular endothelial growth factor (VEGF) and fibroblast growth factor-2 (FGF-2) (Kim et al. 
2006a; Zhang et al. 1999b) the sodium iodide symporter (NIS) (Boelaert et al. 2007) and the 
proto-oncogene c-myc (Pei 2001).  Although the transactivational properties of hPTTG 
require its presence in the nucleus, hPTTG is predominantly a cytoplasmic protein (Chien and 
Pei 2000) without a consensus nuclear localisation sequence.  Studies have implicated a role 
for both MAPK phosphorylation cascades (Pei 2000) and an interaction with a specific 
hPTTG binding factor (PBF) (Chien and Pei 2000) for the nuclear translocation of hPTTG 
(see section 1.5.1).  The PBF interacting domain lies within the transactivating domain (amino 
acids 123-154) (Chien and Pei 2000).   
hPTTG contains a proline-rich region (amino acids 163-173) in the C-terminal that is 
critical to its transactivational and transforming capabilities (see sections 1.3.6 and 1.4).  Two 
PXXP motifs confer a highly conserved and putative Src-homology-3 (SH-3) interacting 
domain (Zhang et al. 1999b) that when mutated result in abrogation of hPTTG-mediated 
transformation in vitro, tumourigenesis in vivo and growth factor induction (Zhang et al. 
1999b; Pei 2000; Wang and Melmed 2000b; Ishikawa et al. 2001; McCabe et al. 2002; 
Boelaert et al. 2003a).  The serine at residue 165 is within the SH-3 interacting domain and is 
the only reported phosphorylation site of hPTTG, which is thought to be important for the 
actions of hPTTG during mitosis (Pei 2000; Ramos-Morales et al. 2000; Boelaert et al. 2004). 




1.2.1.2 hPTTG expression in human tissues 
 
hPTTG is expressed at low levels in most normal adult tissues including colon, small 
intestine, pancreas, brain and thymus (Zhang et al. 1999b; Pei 1999).  It is abundantly 
expressed in the testis, with evidence for a role during spermatogenesis (Pei 1999).  Following 
the discovery of high hPTTG expression in pituitary adenomas (Pei and Melmed 1997), 
increased hPTTG expression has been found in various neoplasms including those of the 
thyroid (Heaney et al. 2001; Boelaert et al. 2003a), breast (Puri et al. 2001), colon (Heaney et 
al. 2000), ovary (Puri et al. 2001), oesophagus (Shibata et al. 2002), lung (Kakar and Malik 
2006) and liver (Jung et al. 2006).  Other studies report hPTTG over-expression in 
haematopoietic neoplasms (Dominguez et al. 1998; Saez et al. 2002),  astrocytomas (Tfelt-
Hansen et al. 2004) and in metastatic gastric carcinomas (Wen et al. 2004).  Furthermore, high 
hPTTG expression is present in all transformed cell lines (Zhang et al. 1999b; Yu and 
Melmed 2001; McCabe and Heaney 2003; Yu and Melmed 2004).  With over-expression so 
frequently observed in tumour tissues, hPTTG presents itself as a potentially crucial proto-
oncogene.   
 
Figure 1-3: hPTTG expression in normal tissues.  Northern blot analysis of hPTTG (top panel) 
and human β-actin (bottom panel showing relative amounts of RNA on each lane) mRNA expression in 





































































































1.2.1.3 hPTTG expression in thyroid cancer 
 
Several studies have independently demonstrated the over-expression of hPTTG in 
thyroid cancer.  hPTTG mRNA and protein was found to be significantly over-expressed in 
thyroid tumours compared to normal tissue controls with particularly high levels in 
hyperplastic thyroid lesions and follicular tumours (adenomas and carcinomas) (Heaney et al. 
2001).   In this study, over-expression of hPTTG was less marked in papillary carcinomas 
than in hyperplastic or follicular lesions, a result that contrasts with our own findings of 
hPTTG over-expression in 19 papillary as well as 8 follicular carcinomas, but not in 38 
hyperplastic thyroid lesions compared to normal tissue controls (Boelaert et al. 2003a).  In 
this study, hPTTG was identified as an independent prognostic indicator of early tumour 
recurrence (Boelaert et al. 2003a).  An additional study using immunohistochemistry showed 
high expression of hPTTG in 65 % of differentiated thyroid carcinoma tissue samples that 
were associated with nodal and distant metastases, as well as disease persistence (Saez et al. 
2006).   
 
Figure 1-4: hPTTG is over-expressed in differentiated thyroid cancer.  A  Qualitative RT-PCR 
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goiter (MNG), 13 Graves’ disease, and 27 cancer specimens.  B  Western blot analysis of hPTTG 
protein expression in two representative samples of normal thyroid, two MNGs, two Graves’ disease 
specimens, and two thyroid cancers showing markedly increased expression of PTTG in thyroid 
cancer. JEG-3 choriocarcinoma cells served as a positive control (+VE).  ** p < 0.01.  NS = non-
significant.  (Adapted from (Boelaert et al. 2003a)).   
 
1.2.1.4 Regulation of hPTTG expression 
 
Thus far, no mutations have been discovered in either the coding or non-coding 
regions of hPTTG (Zhang et al. 1999b; Kanakis et al. 2003), suggesting hPTTG upregulation 
rather than mutational events underly its pathological effects described in section 1.2.1.2.  The 
following sections describe studies that have investigated various mechanisms of hPTTG 
regulation.   
 
1.2.1.4.1 Regulation of hPTTG by hormones 
 
Oestrogen was the first hormonal regulator of Pttg to be identified when it was shown 
to induce pituitary Pttg expression in vitro and in vivo (Heaney et al. 1999).  In vitro, Pttg 
mRNA expression was induced in rat pituitary GH3 cells at 24 hours following treatment with 
the synthetic oestrogen, diethylstilboestrol (0.1-10 nM).  This effect was abolished by 
addition of the oestrogen-receptor antagonist, anti-E4-hydroxytamoxifen (Heaney et al. 1999).  
GH3 cells transiently transfected with full length mouse Pttg and treated with oestrogen, 
demonstrated an approximate 220 % increase in Pttg promoter activity, as determined by 
luciferase reporter assays.  This induction was shown to be via the action of oestrogen upon 
oestrogen response elements (EREs) (Heaney et al. 1999).  Subsequent studies have 
confirmed the presence of EREs in the hPTTG promoter (Kakar and Jennes 1999).   
In vivo, ovariectomised Fischer 344 rats develop pituitary lactotroph tumours 4 weeks 
after treatment with oestrogen coincident with increased levels of circulating prolactin (PRL).  




Pttg mRNA and protein expression was optimally induced by a 1000 ng dose of oestrogen 
after 48 hours of administration via an osmotic pump (Heaney et al. 1999).  Notably, the 
highest Pttg expression was observed at an early stage of pituitary transformation, consistent 
with a role for hPTTG in the initiating events of tumourigenesis (see section 1.3).  
Furthermore, the increased pituitary Pttg expression at this stage coincided with induction of 
pituitary Vegf and Fgf-2 expression, as well as the development of pituitary arterial networks, 
supporting the hypothesis that elevated hPTTG expression contributes to tumour progression 
(Heaney et al. 1999).  A subsequent study by the same group provided further support for 
these findings, demonstrating cyclical expression of Pttg, Vegf and Fgf-2, concordant with 
oestrogen levels during the oestrus cycle of Fischer 344 rats (Heaney et al. 2002).  There was 
an approximately 3-fold induction of pituitary Pttg, Vegf and Fgf-2 mRNA during pre-oestrus 
and oestrus, concomitant with increased proliferating cell nuclear antigen (PCNA) expression 
during maximal pituitary growth proliferation.   
 Having observed that treatment of primary human pituitary tumour cells with anti-
oestrogen suppressed hPTTG expression in vitro, reduced Pttg expression was demonstrated 
in vivo following co-administration of oestrogen and anti-oestrogen via osmotic mini-pump in 
rats.  Furthermore, serum levels of PRL were reduced by 88 % and pituitary tumour growth 
was suppressed by 41 %, suggesting anti-oestrogens could be an important therapeutic tool in 
treatment of pituitary tumours through repression of hPTTG expression (Heaney et al. 2002). 
TSH has been directly implicated in the regulation of thyroidal hPTTG, where treatment 
of rat thyroid FRTL-5 and human primary follicular thyroid cells with TSH resulted in a 
significant induction of rat Pttg and hPTTG mRNA respectively (Heaney et al. 2001).  
Adding further complexity to our understanding of the regulation of hPTTG by hormones is 
the finding that oestrogen can stimulate increased TSH secretion in women (Clark et al. 1985; 




McTiernan et al. 1984; Prestonmartin et al. 1987; Prestonmartin et al. 1993).  It is therefore 
possible that oestrogen’s regulation of hPTTG in thyroid cells is through increased serum 
TSH levels.  Thyroid cancer is approximately 3 times more common in women (Fagin 2005b) 
and 25 % of thyroid cancers express oestrogen receptors (Clark et al. 1985), in keeping with a 
potential role for oestrogen in thyroid neoplasia.  It is clear that further investigation is 
required to elucidate the exact interactions between hPTTG and hormones and to determine 
whether such hormones are in fact primary tumour promoters. 
 Other studies have demonstrated a role for insulin in the regulation of hPTTG.  There 
was an approximate 2.5-fold increase in hPTTG mRNA expression following treatment with 
insulin in human breast cancer, MCF-7 cells.  Luciferase reporter assays revealed a dose-
dependent increase in the hPTTG promoter activity following insulin treatments and pre-
treatment with the transcription inhibitor actinomycin-D completely abrogated induction of 
hPTTG mRNA expression, suggesting that hPTTG regulation by insulin is transcriptionally 
driven (Thompson and Kakar 2005).  Another study reported upregulation of hPTTG mRNA 
and protein expression by insulin in U87MG and U138MG malignant astrocytes.  This effect 
was completely abrogated by treatment with the PI3K inhibitors LY294002 and Wortmannin, 
but only partially blocked by the MAPK inhibitor PD98059.  However, Pttg was not induced 
by insulin in non-tumourous primary rat embryonal astrocytes suggesting that insulin 
regulation of hPTTG may differ between malignant and non-malignant cell types (Chamaon 
et al. 2005).   
 
1.2.1.4.2 Regulation of hPTTG by growth factors 
 
There is increasing evidence that hPTTG has an important relationship with growth 
factors, where its expression is induced by various growth factors and hPTTG itself is capable 




of transactivating expression of some of these mitogenic factors (see sections 1.4.3 and 1.4.4).   
 One study described over-expression of hPTTG in astrocytomas and subsequently 
demonstrated hPTTG induction by the epidermal growth factor receptor (EGFR) ligands, 
epidermal growth factor (EGF) and transforming growth factor alpha (TGF-α), in 
xenotransplantable U87 human glioma cells.  This effect was abrogated by treatment with the 
specific EGFR inhibitor, AG1478.  The c-met ligand, hepatocyte growth factor (HGF), also 
induced hPTTG expression but to a lesser extent (Tfelt-Hansen et al. 2004).  A subsequent 
study demonstrated similar regulation of hPTTG by EGF and TGF-α in pituitary 
folliculostellate TtT-GF cells.  Once again, these effects were blocked following inhibition of 
EGFR, by treatment with either AG1478 or gefitinib.  Rapid phosphorylation of EGFR and 
subsequent activation of the MAPK and PI3K pathways was demonstrated, suggesting that 
these pathways are important in hPTTG regulation.  EGF induction of hPTTG was cell-cycle 
dependent where its expression peaked at the S-G2 transition and the effect was absent 
following early S-phase blockade (Vlotides et al. 2006).   
 Insulin-like growth factor 1 (IGF-1) has been shown to regulate hPTTG expression in 
human breast cancer MCF-7 cells (Thompson and Kakar 2005) and in malignant and non-
malignant astrocytes (Chamaon et al. 2005).  In both studies, hPTTG induction by IGF-1 was 
partially or completely blocked by treatment with either of the specific PI3K inhibitors, 
LY294002 and Wortmannin, or the specific MAPK inhibitor PD98059.  Interestingly, the 
latter study demonstrated interactions between both kinases and endogenous hPTTG in both 
malignant astrocytes and non-tumourous neuronal cells.  In addition to enhancement of 
hPTTG transcription following treatment with IGF-1, it was speculated that a second and 
more direct route of hPTTG regulation may be mediated via direct binding to MAPK or PI3K 
(Chamaon et al. 2005).   




 The relationship between hPTTG and FGF-2 is well established (see sections 1.4.1 
and 1.4.3) with studies demonstrating induction of hPTTG by FGF-2 treatment in NIH3T3 
cells (Heaney et al. 1999) and in primary cultures of uterine leiomyomas, benign tumours of 
myometrial smooth muscle tissue (Tsai et al. 2005).  
 
1.2.1.4.3 Transcription factors involved in regulation of hPTTG 
 
Promoter studies of the mouse (Wang and Melmed 2000a), rat (Pei 1998) and human 
(Kakar and Jennes 1999) PTTG homologues have revealed the presence of one or more 
conserved specificity protein 1 (SP1) box motifs, implying that this transcription factor may 
play a role in regulating hPTTG expression.  Mutation of the SP1 binding site -520 bp 
upstream of the hPTTG translational start site resulted in 70 % reduced overall promoter 
activity, whereas over-expression of SP1 in human PC-3 prostate cancer cell and HS27 
fibroblast cells significantly increased hPTTG promoter activity (Clem et al. 2003).  However, 
site-directed mutagenesis targeting the SP1 binding site in the rat Pttg promoter did not 
significantly affect promoter activity (Pei 1998).   
hPTTG mRNA and protein expression were repressed by triiodothyronine (T3) in 
hepatocellular carcinoma (HCC) cell lines and this was dependent on expression of thyroid 
hormone receptors (TRs) and mediated through repression of SP1 (Chen et al. 2008).  Further, 
stable short hairpin RNA (shRNA) knockdown of SP1 resulted in reduced hPTTG expression 
and reduced proliferation.  Stable shRNA knockdown of hPTTG directly, had a similar effect 
on proliferation.  In vivo, Pttg and Sp1 expression were repressed in the livers of 
thyroidectomised rats treated with T3.  Furthermore, in human HCCs, hPTTG and SP1 were 
over-expressed while TR expression was reduced in comparison to matched normal liver, 
providing a potential mechanism for hPTTG over-expression in HCC, through modulation by 
thyroid hormone. (Chen et al. 2008). 




A recent study treated various thyroid cancer cell lines with drugs synthetically 
derived from the triterpenoid glycyrrhetinic acid, CDODA-Me and CF3DODA-Me, and 
reported inhibition of their growth (Chintharlapalli et al. 2011).  This was at least in part due 
to reduced expression of specificity proteins (SPs), including SP1.  Reduced SP1 expression 
was associated with subsequent repression of hPTTG, FGF-2, VEGF and c-myc, as well as 
induction of apoptosis (Chintharlapalli et al. 2011).  As well as providing further evidence for 
hPTTG regulation by SP1, these findings provide additional support for the relationship 
between hPTTG, growth factors and other proto-oncogenes (see sections 1.3.6 and 1.4).   
Further studies of the hPTTG promoter identified four CAAT boxes, which are 
binding sites for the nuclear factor Y (NF-Y) transcription factor (Clem et al. 2003).  
Interestingly, there is evidence to suggest that NF-Y and SP1 act in unison to control 
transcriptional activation on various gene promoters (Inoue et al. 1999; Chang et al. 1999; Hu 
et al. 2000; Xiong et al. 2000; Kim et al. 2001).  Two studies have described direct interaction 
between NF-Y and SP1 (Roder et al. 1999; Yamada et al. 2000).  The interaction between 
NF-Y and SP1 appears to be significant in hPTTG regulation where mutation of the NF-Y 
binding site in the hPTTG promoter caused a 25 % repression of promoter activity, whereas a 
double mutation of both NF-Y and SP1 binding sites caused 90 % reduced promoter 
activation (Clem et al. 2003).  A further study proposed a potential mechanism for hPTTG 
downregulation by p53 (see section 1.3.5), whereby p53 was shown to interact with NF-Y 
thereby preventing initiation of transcription on the hPTTG promoter (Zhou et al. 2003).   
Several studies have reported a role for transcription factor 4 (TCF-4), a downstream 
effector of β-catenin signalling pathways, in the regulation of hPTTG.  A TCF-4 binding 
element was identified in the hPTTG promoter and binding of TCF-4 to this region was 
demonstrated (Zhou et al. 2005; Hlubek et al. 2006; Pan et al. 2007).  Subsequently, stable 




transfectants of β-catenin in human embryonic kidney 293 (HEK293) cells demonstrated 
increased hPTTG mRNA and protein expression (Zhou et al. 2005) and siRNA transfections 
against β-catenin in colorectal carcinoma cells resulted in reduced hPTTG mRNA expression 
(Hlubek et al. 2006).  In both of these studies, an accumulation of β-catenin correlated with 
over-expression of hPTTG in human esophageal squamous cell carcinomas [ESCCs] (Zhou et 
al. 2005) and in human colorectal adenomas and carcinomas (Hlubek et al. 2006), 
respectively.  Regulation of hPTTG and the proto-oncogene c-myc by γ-catenin was observed 
in colon cancer cell lines, following both over-expression and siRNA knockdown studies (Pan 
et al. 2007).   
 Another study provides strong evidence for the involvement of a further transcription 
factor, Octamer-binding transcription factor-1 (OCT-1), in the regulation of hPTTG 
expression.  Two OCT-1-binding motifs were identified in the hPTTG promoter and 
chromatin immunoprecipitation assays using HEK293 cells demonstrated direct binding of 
OCT-1 to these regions.  Over-expression of OCT-1 resulted in increased hPTTG promoter 
activity and a subsequent 4-fold increase in hPTTG mRNA and protein expression.  
Conversely, siRNA knockdown of OCT-1 resulted in reduced hPTTG mRNA and protein 
expression.  Furthermore, confocal immunofluorescent imaging showed a strong correlation 
between OCT-1 and hPTTG expression in 75 % of pituitary tumours (n=79), 61 % of breast 
tumours (n=77) and 65 % of colorectal tumours (n=71) (Zhou et al. 2008).   
 Other transcription factors may have a role in hPTTG expression.  Additional motifs 
present in the hPTTG promoter include activator protein 1 (AP1) and 2 (AP2) binding 
sequences, a cyclic-AMP (cAMP) response element sequence, a cell cycle dependent element 
(CDE) motif  as well as a cell cycle homology region (CHR) motif (Kakar 1999).  Further 
studies are required to determine the functional significance of these promoter elements.   




1.2.1.4.4 Epigenetic mechanisms and hPTTG expression 
 
No mutations in the coding nor in the non-coding regions of hPTTG were identified by 
RT-PCR in pituitary tumours (Zhang et al. 1999b), and following studies of the hPTTG 
promoter in 25 pituitary adenomas (Kanakis et al. 2003) respectively.  A small number of 
studies have investigated epigenetic mechanisms that may be involved in the control of 
hPTTG expression.   
One investigation treated prostate cancer cells with 5-Azacytidine to cause genome 
wide demethylation, but reported no effect on hPTTG protein expression (Hidalgo et al. 
2008).  A CpG island comprised within a 650 bp region was identified as having high 
probability of being subject to epigenetic control.  However, subsequent methylation-specific 
PCR analysis revealed unmethylated CpG island in both differentiated thyroid carcinomas 
and matched normal samples.  Furthermore, loss of heterozygosity (LOH) studies using 
Affymetrix microarray technology and FRET analysis did not identify any allelic imbalances 
encompassing the hPTTG locus (Hidalgo et al. 2008).   
However, histone modifications have recently been implicated in hPTTG regulation, 
where over-expression of histone acetyltransferase (HAT) p300 resulted in increased hPTTG 
promoter activity, as well as mRNA and protein expression in 293T cells.  The HAT activity 
of p300 was crucial for its regulation of hPTTG and chromatin immunoprecipitation assays 
revealed increased histone H3 acetylation on the hPTTG promoter following over-expression 
of p300.  Further, treatment of 293T cells with histone deacetylase (HDAC) 3 resulted in 
reduced hPTTG expression and conversely, treatment with an HDAC inhibitor caused 
upregulation of hPTTG.  Interestingly, co-expression of NF-YA and NF-YB with p300 
synergistically increased hPTTG promoter activity, providing further insights into the 




involvement of NF-Y transcription factors in hPTTG regulation, whereby they possibly bind 
and recruit p300 to the hPTTG promoter (Tian et al. 2009).   
 
1.2.1.4.5 Cell-cycle dependent subcellular localisation of hPTTG 
 
Various studies have demonstrated that hPTTG expression is cell-cycle dependent.  
An early study identified hPTTG as the vertebrate securin, where levels of hPTTG protein 
were shown to increase during S-phase and peak in G2- and M-phase in HeLa S3 cells (Zou et 
al. 1999).  Consistent with this, extracts from HeLa cells arrested in each stage of the cell 
cycle revealed low hPTTG expression in S, increasing expression in G2 and highest 
expression in M-phase, before returning to low levels once more in G1 (Ramos-Morales et al. 
2000).  Furthermore, in both HeLa and COS-7 cells, hPTTG expression was low following 
serum starvation, elevated during rapid proliferation following addition of serum and 
downregulated once again as cells became confluent (Ramos-Morales et al. 2000).  Another 
study confirmed increased hPTTG mRNA and protein expression progressively through S-, 
G2- and M-phase as above, and subsequently these observations were elegantly supported 
following live cell imaging in synchronised human choriocarcinoma JEG-3 cells (Yu et al. 
2000b).  Following over-expression of hPTTG or hPTTG-EGFP in JEG-3 cells, 
immunofluorescent staining during live cell imaging revealed that hPTTG was largely 
localised to the nucleus during interphase with only a small amount of cytosolic hPTTG 
detected.  Predominantly nuclear hPTTG expression in JEG-3 cells was confirmed by 
Western blots of nuclear and cytoplasmic cell fractions following transfection with hPTTG-
EGFP (Yu et al. 2000b).   
Although the same study replicated these findings in NIH-3T3, GH3 and AtT20 rat 
pituitary tumour, SKOV-3 human ovarian cancer, MCF-7 and COS-7 cell lines, there are 




contrasting data to suggest otherwise.  Early studies using subcellular fractionation in Jurkat T 
lymphoma cells (Dominguez et al. 1998) and immunohistochemistry in pituitary adenomas, 
and in lung and breast adenocarcinomas (Saez et al. 1999) indicated that hPTTG was 
predominantly localised to the cytoplasm, with only partial nuclear expression (see Figure 
1-5).  A further study used fluorescence microscopy to demonstrate that transfection of 
pCMX-GFP-hPTTG resulted in predominantly nuclear hPTTG in HeLa, COS-7 and DU145 
cells, but that hPTTG expression was diffuse throughout the cytoplasm and nucleus in A549, 
DLD-1 and NIH3T3 cells (Mu et al. 2003).  It therefore seems possible that the subcellular 
localisation of hPTTG is cell-specific and dependent on experimental techniques employed.  
Thus far, no functional role for cytoplasmic hPTTG has been identified and its presence here 
is considered to be a form of negative regulation of hPTTG presence in the nucleus where it 
has functional outputs.  Indeed, hPTTG’s presence in the nucleus is essential for all its 
functions described in subsequent sections.  hPTTG itself does not have a nuclear localisation 
signal (NLS) (see section 1.2.1.1), but is thought to be able to diffuse freely across the nuclear 
membrane given its small molecular weight.  However, an hPTTG binding factor (PBF) has 
been identified and shown to specifically interact with hPTTG and facilitate its nuclear entry 
via its own NLS (Chien and Pei 2000). 





Figure 1-5: Contrasting data of hPTTG localisation during interphase.  A  Interphase localisation 
of hPTTG in JEG-3 cells. Cells were transfected with plasmids encoding WT-hPTTG-FLAG or EGF-
hPTTG. hPTTG protein was visualised using immunofluorescent staining and EGFP-hPTTG protein 
was visualised directly (left) and was localised mainly in the nucleus. Cells were also stained with 
Hoechst 33258 to highlight the nuclei and chromosomes and to determine the cell cycle (middle). The 
images of cells expressing hPTTG or hPTTG-EGFP were overlaid with images of the cells stained 
with Hoechst (right), again illustrating hPTTG mainly to be localised to the nucleus (figure adapted 
from (Yu et al, 2000b)).  B  Immunohistochemical detection of hPTTG in pituitary adenomas (left), 
lung adenocarcinomas (middle) and breast adenocarcinomas (right), demonstrating predominantly 
cytoplasmic localisation of hPTTG, with rare staining of nuclear PTTG indicated by the black arrow 
(right) (figure adapted from (Saez et al. 1999)).   
 
Interestingly, observations from one study imply that hPTTG is a secreted protein.  
hPTTG expression was observed in the Golgi apparatus and vesicles in both human pituitary 
adenomas and mouse pituitary AtT-20 cells, consistent with a potential role in membrane 
trafficking mechanisms.  Further, secreted hPTTG was detected in the cell culture supernates 
taken from pituitary tumour cell lines (Minematsu et al. 2007).  The authors speculated that 
hPTTG itself may be a signalling molecule involved in pituitary autocrine and paracrine 









pathways.  However, additional studies are required to validate this finding and to identify 
specific functions for secreted hPTTG.   
The live cell imaging studies in JEG-3 cells described previously, made the critical 
observation that hPTTG co-localised with the mitotic spindles while it was upregulated during 
mitosis (Yu et al. 2000b).  Similar studies by the same group reported that hPTTG localised to 
mitotic chromosomes in H1299 cells (Yu et al. 2003).  These observations are consistent with 
hPTTG’s primary function as the human securin involved in mitotic regulation (see section 
1.3.1) and further support for this was provided by a study that reports the phosphorylation of 
hPTTG during this phase of the cell cycle (Ramos-Morales et al. 2000). 
 
1.2.1.5 Phosphorylation of hPTTG 
 
In the study described above, where hPTTG protein expression in HeLa cell extracts 
was cell cycle dependent, it was also demonstrated in Western blot analyses that hPTTG 
migrated as a doublet in M-phase extracts compared to a single band observed in other 
phases, indicating that hPTTG is phosphorylated during mitosis (see Figure 1-6).  These 
findings were confirmed in studies incubating M-phase HeLa cell extracts with an alkaline 
phosphatase in the presence or absence of a phosphatase inhibitor.  In the absence of 
phosphatase inhibitor, expression of the heavier band representing phospho-hPTTG was 
reduced and there was a concomitant upregulation of the lighter band representing non-
phosphorylated hPTTG.  Addition of the inhibitor prevented this, suggesting the effect was 
specific to phosphorylation status of hPTTG.  Further support for mitotic phosphorylation of 
hPTTG was provided by demonstrating enhanced phosphorylation of purified recombinant 
hPTTG in vitro following incubation with mitotic HeLa cell lysates compared to interphase 
lysates (Ramos-Morales et al. 2000).  hPTTG contains putative phosphorylation sites for 




cAMP- and cGMP-dependent protein kinases, casein kinase II, AKT and protein kinase C 
(PKC) (Dominguez et al. 1998) but thus far, the Ser165 residue on hPTTG is the only 
confirmed phosphorylation site of hPTTG.  This residue is located within the first PXXP 
motif (see Figure 1-2) and is a consensus site (T/SPXK/R) for cyclin-dependent kinase 2 
(CDC2) (Moreno and Nurse 1990; Nigg 1991; Zhou et al. 1994; Ramos-Morales et al. 2000), 
which is important for mitotic progression (Nurse 1994; Yu et al. 2000a).  Immunodepletion 
of the kinase CDC2 in mitotic cell lysates resulted in reduced hPTTG phosphorylation and, 
conversely, immunopurified CDC2 from mitotic cell lysates increased hPTTG 
phosphorylation in phosphorylation assays in vitro.  Treatment with the specific CDC2 
inhibitor, butyrolactone I, significantly reduced hPTTG phosphorylation in vitro.  
Furthermore, mutation of the Ser165 residue abolished CDC2-mediated phosphorylation of 
hPTTG (Ramos-Morales et al. 2000).  CDC2 is a regulator of many downstream targets 
involved in crucial mitotic events and so the finding that CDC2 directly phosphorylates 
hPTTG could be indicative of a requirement for hPTTG to be phosphorylated to perform its 
role as a securin (see section 1.3.1).    
 
Figure 1-6: Cell cycle-dependent expression and phosphorylation of hPTTG protein. A  Western 
blot of HeLa cell extracts arrested in the different phases of the cell cycle demonstrating the double 
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band during mitosis. B  Densitometry of the immunoblot indicating highest levels of hPTTG 
expression during mitosis (figure adapted  from(Ramos-Morales et al. 2000)). 
 
Phosphorylation of hPTTG by the DNA-dependent protein kinase (DNA-PK) was 
reported as part of a mechanism that involves hPTTG in DNA damage responses (see section 
1.3.5).  However, further studies are required to identify the site of hPTTG phosphorylation 
by this kinase, as well as the exact functional output following DNA-PK induced 
phosphorylation (Romero et al. 2001).    
The presence of a consensus MAPK phosphorylation site (Pro-X-Ser/Thr-Pro) 
(Alvarez et al. 1991) in the transactivation domain of Pttg, prompted one group to investigate 
the regulation of Pttg by Mapk activation.  It was found that rat Pttg is phosphorylated by 
Mapk at Ser162, which is the analogous site to human Ser165, and this was mediated by a 
direct interaction between an N-terminus Pttg Sh3-interacting domain and mitogen-activated 
protein kinase kinase 1 (Mek1).  Phosphorylation of Ser162 by Mapk facilitated nuclear 
translocation and subsequent transactivational function of Pttg, as determined by increased 
Fgf-2 transcription (see section 1.3.6).   Point mutations in either Mek1 or Mapk interacting 
regions of Pttg resulted in cytoplasmic retention of Pttg and loss of its transactivational 
functions (Pei 2000).   
Together, these results suggest that phosphorylation of hPTTG is important for its 
nuclear translocation where it has multiple roles including those as a mitotic regulator and 
gene transactivator.  Given the presence of other putative phosphorylation sites on hPTTG, it 
is clear that further studies are required to identify alternative mechanisms of hPTTG 
phosphorylation and to resolve the various functional outputs of phosphorylated hPTTG.    
 
 




1.3 hPTTG initiates tumourigenesis 
 
1.3.1 hPTTG as a securin  
 
The findings of the various studies described above, that hPTTG is periodically 
expressed and phosphorylated in the nucleus throughout the cell cycle, peaking at the 
metaphase-anaphase boundary when it colocalises with mitotic spindles, are indicative of a 
crucial role for hPTTG in mitosis.   
Securins are proteins that are involved in the prevention of premature separation of 
sister chromatids during the metaphase to anaphase transition in mitosis.  In normal cell 
division, chromosomes are replicated before sister chromatids are segregated to opposite 
poles of the cell, ensuring production of diploid daughter cells that are genetically identical to 
the parent cell (Nasmyth et al. 2001; Nasmyth 2001; Nasmyth 2002).  Failure of the 
mechanisms that control the timely separation of sister chromatids results in inappropriate cell 
division causing aneuploidy and genetic instability.   
Eukaryotic chromosomal replication occurs during S-phase and sister chromatids are 
bound together by cohesin complexes that oppose the splitting forces exerted by microtubules 
(Michaelis et al. 1997; Zur and Brandeis 2001).  The cohesion complex is made up of 
multiple subunits of which mutation has been reported to cause improper separation of sister 
chromatids (Nasmyth 2001; Peters 2002).  The cysteine protease, separase, is involved with 
proteolytic degradation of cohesins during mitosis (Nasmyth et al. 2001; Nasmyth 2001; 
Nasmyth 2002).  Separase is a large 2121 amino-acid protein that is critically phosphorylated 
at Ser1126 and mediates its proteolytic activity through the key catalytic residue cys2029, 
which is conserved in all proteases (Uhlmann et al. 2000; Chestukhin et al. 2003).   In the first 
instance, cohesins are largely removed from the long arms of chromosomes during prophase 
and prometaphase by the actions of the kinases Aurora B and polo-like kinase 1 (PLK1) 




(Losada et al. 1998; Losada et al. 2002; Waizenegger et al. 2000; Hauf et al. 2001; Peters 
2002; Sumara et al. 2002).  Subsequently, separase is activated at the start of anaphase and is 
required for the degradation of remaining cohesin complexes that are preferentially located 
proximally to centromeres, to allow the segregation of sister chromatids (Waizenegger et al. 
2000; Hauf et al. 2001; Peters 2002).   
Throughout most of the cell cycle, the proteolytic activity of separase is inhibited by a 
direct interaction with securin/hPTTG (Jallepalli et al. 2001; Jallepalli and Lengauer 2001).  
As described previously in human cells (see sections 1.2.1.4.5 and 1.2.1.5), hPTTG 
accumulates during G1 and G2 phases, with maximal expression in M-phase before an abrupt 
decline of hPTTG expression at the end of metaphase immediately prior to the onset of 
anaphase.  hPTTG expression diminishes rapidly at this stage as it is a substrate of the APC, 
which is a large cell cycle regulated ubiquitin-protein ligase made up of at least 11 subunits.  
The APC ubiquitinates a number of proteins involved in cell cycle regulation, resulting in 
their degradation at the 26S proteasome (Zachariae and Nasmyth 1999; Nasmyth 2001).  
Regulation of hPTTG/securin in this way allows the release of functional separase to 
breakdown remaining cohesins and ultimately, the progression to anaphase (Zou et al. 1999; 
Jallepalli et al. 2001).  APC substrates possess D-box and KEN box consensus sequences 
essential for their recruitment to the APC and mutations of both of these domains in hPTTG 
abolished hPTTG degradation during mitosis (Zou et al. 1999; Zur and Brandeis 2001; 
Glotzer et al. 1991; Pfleger and Kirschner 2000; Peters 2002).  Co-activators, such as CDC20 
and CDH1 bind to the the D-box and KEN box of APC substrates before assembling with the 
APC as part of a degradation recruitment mechanism.  In early mitosis, MAD2 (mitotic arrest 
deficient 2) inhibits Cdc20-APC assemblies as part of a complex spindle checkpoint system 
that prevents premature separase activity while chromosomes align correctly on mitotic 




spindles (Peters 2006; Nasmyth 2001; Michel et al. 2001).  Once this checkpoint is passed, 
Cdc20-APC becomes active until the end of anaphase when Cdh1-APC activity is reported to 
be more prominent and continues until the next G1-phase is reached (Peters 2002). 
 
Figure 1-7: Schematic diagram and simplified representation of metaphase to anaphase transition 
during mitosis. hPTTG is ubquitinylated at the destruction box (DB) by the APC, which in turn is 
controlled by CDC20 and CDH1.  Following the degradation of hPTTG, separase cleaves the 
cohesins and both sister chromatids migrate to one side of the mitotic spindle. 
 
The APC complex mediates proteolysis of various other mitotic regulators including 
cyclins A and B (Zachariae and Nasmyth 1999; Nasmyth 2001; Peters 2002).  Cyclin B 
(CCNB1) is the regulatory subunit of CDC2 and together they inactivate separase by direct 
phosphorylation at Ser1126.  The CDC2/CCNB1 complex cannot phosphorylate separase 
while it is associated with hPTTG, suggesting that the APC complex releases active separase 
by proteolysis of hPTTG and cyclin B in two independent regulatory pathways (Gorr et al. 

















multiple regulatory mechanisms provides a possible explanation for cell viability in the 
absence of hPTTG in vitro and in vivo (Jallepalli et al. 2001; Wang et al. 2001).   
 
1.3.2 hPTTG over-expression and genetic instability 
 
Thyroid cancers originate from a single transformed cell that acquires enhanced 
activity of proliferation and survival pathways.  Genomic instability in a cell can initiate 
further genetic aberrations including chromosomal imbalances, amplifications, deletions and 
translocations (Cooper 1995).  A number of studies have highlighted the presence of genetic 
instability in thyroid cancer, including the identification of specific chromosomal regions that 
are susceptible to allelic deletions in thyroid tumours (Kubo et al. 1991; Zedenius et al. 1995; 
Grebe et al. 1997; Marsh et al. 1997; Tung et al. 1997; Ward et al. 1998).  Aneuploidy is a 
common form of chromosomal instability (CIN) whereby various chromosomal 
rearrangements occur, including the complete loss or gain of whole chromosomes.  As a result 
of such aberrations, daughter cells may over-express oncogenes or under-express tumour 
suppressor genes.  Indeed, aneuploidy is characteristic of differentiated thyroid tumours and 
transformed thyroid cancer cell lines (Joensuu et al. 1986; Joensuu and Klemi 1988) and is 
associated with high mortality rates in papillary thyroid carcinomas (Sturgis et al. 1999).  
Mitosis is a complex process that is stringently regulated in order to ensure diploid cell 
division and genomic stability (Nasmyth et al. 2001; Nasmyth 2001; Nasmyth 2002).  The 
complexity of the processes required for the segregation of sister chromatids during 
metaphase and anaphase depends on multiple proteins that if aberrantly expressed may cause 
aneuploidy.  Identification of hPTTG as the human securin directly involved in sister 
chromatid segregation (see section 1.3.1) meant hPTTG was presented as a strong candidate 
for inducing aneuploidy in thyroid cancer when aberrantly expressed (see Figure 1-8).    





Figure 1-8: Proposed model of hPTTG-induced aneuploidy. Left: normal mitosis, where the 
degradation of securin by the APC at the end of metaphase releases tonic inhibition of separin (now 
known as separase) thereby allowing cohesin degradation and equal distribution of chromatids 
between 2 daughter cells. Right: Abnormal mitosis in cells over-expressing hPTTG, when aneuploidy 
results from dysregulated sister chromatid separation (figure from(Yu et al. 2003)). 
 
 
Studies have shown induction of aneuploidy following transient or stable over-
expression of EGFP-tagged hPTTG in MG-63 osteosarcoma cells, as determined by increased 
frequency and severity of micronuclei, macronuclei and chromosomal bridges.  Untransfected 
or EGFP control transfected MG-63 cells had very low levels of basal aneuploidy (Yu et al. 
2000a).     
 One important study employed an approach of single cell live imaging to study the 
effects of hPTTG over-expression on mitosis, where they were able to use a CCD digital 
camera to capture phase-contrast or fluorescence images every minute (during metaphase and 
anaphase) or every few hours (post-telophase) over a 48-hour period (Yu et al. 2003) (see 
Figure 1-9).  Individual human lung cancer H1299 cells with low endogenous hPTTG 
expression were utilised for the study, where untransfected or EGFP control transfected cells 




displayed normal cell division resulting in diploid daughter cell production (see Figure 1-9 
A).  Cells transfected with hPTTG-EGFP demonstrated effects dependent on expression 
levels.  In cells where hPTTG-EGFP levels were low, hPTTG was typically degraded before 
anaphase and normal mitosis ensued.  However, high levels of hPTTG-EGFP over-expression 
resulted in a prolonged prophase and metaphase, asymmetric cytokinesis, ultimately causing 
catastrophic cell division (see Figure 1-9 B).  Most frequently, total failure to segregate 
metaphase chromosomes led to all chromosomes moving towards one pole in conjunction 
with cell elongation and development of a midline furrow.  Consequentially, one daughter cell 
contained all the parental DNA content forming a macronucleus and the other was a non-
viable cell without a nucleus.  In other cells, hPTTG-EGFP over-expression caused partial 
segregation of sister chromatids.  This resulted in development of ‘anaphase bridges’ where 
chromatin breakages between partially fused chromatids occur under the opposing forces 
exerted by microtubules and ultimately leading to the appearance of micronuclei.  
Furthermore, over-expression of a mutated hPTTG lacking the KEN box and D-box domains 
that allow it to be targeted for degradation by the APC (see section 1.3.1), also resulted in 
asymmetrical cytokinesis (Yu et al. 2003).  The results discussed above strongly indicate that 
that over-expression of hPTTG or lack of hPTTG degradation results in inappropriate cell 
division and a state of aneuploidy.   





Figure 1-9: Live-imaging of single H1299 cells with phase-contrast microscopy and EGFP 
fluorescent-microscopy.  A  Visualisation of normal cell division of a single H1299 cell expressing 
EGFP alone into 2 daughter cells during mitosis.  Time when images were taken is shown for each 
frame; Bar: 10 m.  B  Chromosome non-segregation and aneuploidy resulting from failure of 
hPTTG-EGFP degradation. Single live H1299 cells expressing hPTTG-EGFP were continuously 
observed. The complete absence of cytokinesis results in one daughter cell with a macronucleus and 
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To assess the importance of hPTTG in inducing genetic instability in thyroid cancer, our 
group employed a fluorescent intersimple sequence repeat PCR assay (FISSR-PCR) which 
was first used to measure intra-chromosomal instability in sporadic colorectal cancers (Basik 
et al. 1997).  We demonstrated that genomic instability was variable, but overall higher in 
thyroid cancer tissue samples compared to normal tissue controls (increased genomic 
instability index of 6.7-72.7 %).  Importantly we found a very strong correlation (R
2
 = 0.8, p = 
0.007) between hPTTG expression and genomic instability in thyroid cancers (Kim et al. 
2005).  Furthermore, over-expression of hPTTG in FTC133 human thyroid follicular 
carcinoma cells induced genetic instability in a dose-dependent manner (Kim et al. 2005).  
These findings strengthen evidence for a relationship between hPTTG and genetic instability 
in vitro and in vivo, indicating that hPTTG at least in part, may be a causal factor in the 
chromosomal aberrations observed in differentiated thyroid cancers.   
 
1.3.3 hPTTG over-expression in mouse models 
 
Two studies have directly investigated the effects hPTTG over-expression in vivo 
through studies in transgenic mice.  hPTTG was targeted to the pituitary glands of mice using 
the α-subunit of glycoprotein hormone (α-GSU) promoter, which is the earliest expressing 
pituitary hormone gene product.  Female αGSU.PTTG mice had significantly enlarged 
pituitary glands and elevated serum IGF-1 levels compared with WT mice.  However, the 
study focused on a more aggressive phenotype in male αGSU.PTTG mice, which 
demonstrated plurihormonal focal pituitary transgene expression with LH-, TSH- and, 
unexpectedly, also GH-cell focal hyperplasia and adenoma, associated with increased serum 
LH, GH, testosterone, and IGF-I levels.  MRI scans demonstrated large and irregularly shaped 
pituitary glands in αGSU.PTTG mice (see Figure 1-10).  Some of these mice died prematurely 




from urinary tract obstruction, caused by prostate and seminal vesicle hyperplasia due to 
elevated serum hormone levels.  Critically, this study provided evidence of a role for hPTTG 
over-expression in enhanced pituitary cell growth and specifically in the promotion of 
differentiated polyhormonal cell focal expansion (Abbud et al. 2005).   
 
Figure 1-10: Enlarged pituitary glands in αGSU.PTTG mice.  Sagittal (A) and coronal (B) MRI 
images of representative WT and αGSU.PTTG mice.  White arrows indicate the pituitary gland.  
Adapted from (Abbud et al. 2005).  
 
  Following observation of hPTTG over-expression in ovarian cancers (Puri et al. 
2001), a transgenic mouse model was developed to directly investigate the effect of hPTTG 
over-expression in the ovary (El-Naggar et al. 2007).  Increased hPTTG expression was 
evident in the ovarian surface epithelium and granulosa cells of transgenic mice, driven by the 
Mullerian inhibitory substance type II receptor gene promoter (MISIIR).  Although female 
MISIIR-PTTG transgenics did not develop ovarian tumours,  the study reported an overall 
increased mass of the corpus luteum, generalised hypertrophy of the myometrium of uteri, 
with cystic glandular and hyperplasia of the endometrium.  The study concluded that hPTTG 








creating pre-cancerous conditions, but its over-expression alone is not sufficient for ovarian 
tumourigenesis (El-Naggar et al. 2007).   
 
1.3.4 hPTTG under-expression and genetic instability 
 
Following the identification of hPTTG as the human securin with a crucial role in 
regulating sister chromatid segregation thereby ensuring the maintenance of euploidy, it was 
predicted that cells lacking hPTTG would not be viable.  It was therefore surprising that both 
hPTTG-null cells and Pttg knockout mice are viable (Jallepalli et al. 2001; Wang et al. 2001).   
Human colorectal HCT116 cells, which have a stable karyotype and intact DNA 
damage and mitotic spindle checkpoints, were used to establish an hPTTG-null cell line 
(hSecurin
-/-
) by means of homologous recombination.  Although hSecurin
-/- 
cells generally 
grew more slowly, the percentage of cells in apoptosis, mitosis or interphase was almost 
identical to that of hSecurin
+/+
 cells, thereby indicating their viability.  Multiplex fluorescent 
in situ hybridisation (M-FISH) was used to analyse chromosome number and structure in 
metaphase spreads and loss of chromosomes was revealed in greater than 80 % of hSecurin
-/-
 
cells.  Time-lapse microscopy studies were used to analyse key mitotic events and over one 
third of hSecurin
-/-
 cells failed to separate metaphase chromosomes.  Despite non-completion 
of anaphase, hSecurin
-/-
 cells eventually exited mitosis after an extensive delay at the 
metaphase to anaphase transition and daughter cells were associated with budded nuclei, 
chromosomal instability and gross aneuploidy (Jallepalli et al. 2001).   
 Subsequently, the development of a Pttg knockout (Pttg
-/-
) mouse has provided insight 
to the effects of the absence of Pttg in vivo (Wang et al. 2001; Wang et al. 2003).  Pttg
-/-
 mice 
are viable and fertile, despite females being deemed subfertile following observation of 
reduced average litter sizes.  Major characteristics of Pttg
-/-
 mice are testicular and splenic 




hypoplasia, thymic hyperplasia and thrombocytopenia.  Although the reason for these 
phenotypes is unclear, Pttg levels are abundant in normal testes and thymus, so the organ-
specific varying phenotypes described in this study indicate cell type specific regulation of 
growth by Pttg.  Mouse embryonic fibroblasts (MEFs) derived from Pttg
-/-
 mice had a 
shortened G1-phase and a prolonged G2- to M-phase transition.  Interestingly, the phenotype 
of a high percentage of Pttg
-/-
 MEFs being in G2- and M-phase, was reversed by retroviral 
introduction of Pttg.  Cytogenetic analyses revealed that Pttg
-/-
 MEFs had frequently damaged 
nuclei, chromosomal abnormalities particularly in centromeric regions and up to 15 % of 
nuclei were bi- or multinucleated.  Metaphase chromosomal spreads revealed premature 
centromere division, up to 6 % chromosomal abnormality including quadriradial and triradial 
chromosome formations and overall 10-15 % aneuploidy in Pttg
-/-
 MEFs compared to Pttg
+/+
 
MEFs (Wang et al. 2001).   
 The results of the studies described above clearly lend further support to the function 
of hPTTG as a securin, though the viability of hSecurin
-/-
 HCT116 cells and Pttg
-/-
 mice is 
indicative of the existence of alternative mechanisms driving cell cycle progression and 
survival when hPTTG expression is lacking.  As discussed in section 1.3.1, one potential 
mechanism is the inhibitory phosphorylation of separase at Ser1126 by the CCNB1/CDC2 
complex, where separase is only activated once cyclin B (CCNB1) is ubiquitinylated by the 
APC (Stemmann et al. 2001; Gorr et al. 2005; Holland and Taylor 2006).  Supporting this, a 
further study in hSecurin
-/-
 HCT116 cells demonstrated that progression to anaphase and 
specifically the event of centromere separation, was dependent on an active proteasome 
(Gimenez-Abian et al. 2005).   
 Further work using hSecurin
-/-
 HCT116  cells revealed that the characteristic loss of 
chromosomes in these cells, as discussed above (Jallepalli et al. 2001), is in fact overcome 




following continued passaging of these cells.  Despite persistently low separase activity, cells 
regained chromosomal stability and normal cell division with complete segregation of sister 
chromatids (Pfleghaar et al. 2005).  Another study highlighted the redundancy of Pttg and 
separase in mitotic regulation by mutating the Ser1121 phosphorylation residue of separase in 
Pttg
-/-
 MEFs, thereby generating double mutant securin 
-/-
 separase  
-/S1121A 
MEFs.  Following 
arrest of asynchronously growing cells in G2-/M-phase through nocodazole treatments, it was 
apparent that sister chromatids were separated prematurely in double mutant cells, though 
cells remained viable.  However, only a small degree of activation of separase was observed 
suggesting other mechanisms of separase inhibition may exist, at least in MEFs (Huang et al. 
2005).  Although the studies described above indicate Pttg function is subject to redundancy, 
a complex phenotype observed in 6 month old male Pttg
-/-
 mice suggests that this is not true 
for all cell types.  These mice exhibit hyperglycaemia and insulinopaenia typical of diabetes, 
though collectively the phenotype did not conform to either Type I or Type II diabetes.  The 
observed features were due to impaired proliferation in Pttg
-/-
 pancreatic β-cells, where the 
presence of macronuclei were also observed, consistent with aberrant cell division due to lack 
of Pttg (Wang et al. 2003).  Further investigations of this phenotype revealed that p21 was 
activated in young mice and genes associated with DNA damage were progressively 
upregulated in adult Pttg
-/-
 mice.  It was concluded that reduced pancreatic β-cell mass was 
caused by a combination of apoptosis and senescence, secondary to DNA damage 
(Chesnokova et al. 2009).   
 Despite some evidence for hPTTG redundancy, the studies described above clearly 
demonstrate that lack of hPTTG causes genetic instability.  Taken together with the 
abundance of studies demonstrating genetic instability as a result of hPTTG over-expression 
(see section 1.3.2), it is possible that hPTTG represents an important gene at an early stage of 




tumourigenesis, where genetic instability is widely recognised as a critical factor of tumour 
development (Melmed 2003).   
 
1.3.5 hPTTG, P53, apoptosis and DNA damage responses 
It is possible that over-expression of hPTTG can further contribute to initiating events 
in thyroid cancer, as well as to subsequent phases of disease progression, through interactions 
with vital cell cycle and DNA repair genes.  p53 is mutated in over 50 % of malignancies and 
is therefore of particular importance in many cancers (Hollstein et al. 1994).  It is a tumour 
suppressor gene that is activated in response to DNA damage and elicits protective effects 
through induction of cell cycle arrest, DNA repair and apoptotic pathways (Levine 1997; 
Vousden 2000).  The protective activities of p53 are mediated through transcriptional 
activation of downstream target genes (El-Deiry 1998; Lakin and Jackson 1999; Wahl and 
Carr 2001) and loss of p53 activity or the ability to induce a p53 response can cause malignant 
progression (Vousden 2006).  Over-expression of oncogenes causes cellular stress through 
DNA damage, as is true for over-expression of hPTTG in cells (see section 1.3.2) and thus 
elicits protective cellular responses.  Interestingly, several studies have described interactions 
between hPTTG and p53 in association with apoptosis.   
hPTTG induction of apoptosis was initially observed following over-expression of 
EGFP-hPTTG in JEG-3 cells (Yu et al. 2000b).  In a subsequent study by the same group, 
over-expression of hPTTG in MCF-7 cells with WT levels of p53 caused induction of 
apoptosis following upregulation and nuclear translocation of p53.  This effect was enhanced 
by contransfections with p53 and abrogated by expression of the p53 inactivator, human 
papillomavirus E6 protein.  However, hPTTG over-expression in p53 null MG-63 cells also 
resulted in apoptosis suggesting that hPTTG over-expression activates apoptotic pathways via 




p53-dependent and p53-independent mechanisms.  Moreover, hPTTG induced aneuploidy in 
p53 null MG-63 cells, but not in MCF-7 or JEG-3 cells with WT p53 expression, suggesting 
p53 is capable of preventing hPTTG-induced aneuploidy (Yu et al. 2000a).  Another study 
provided further support for p53-mediated hPTTG induction of apoptosis, where over-
expression of either hPTTG or p53 in HEK293 cells caused apoptosis.  hPTTG was shown to 
indirectly mediate p53 transcription via activation of c-myc expression, which subsequently 
bound directly to the p53 promoter.  Enhanced expression of the well established pro-
apoptotic p53 effector, BAX, was representative of increased p53 function following hPTTG 
over-expression (Hamid and Kakar 2004; Nagashima et al. 2003).  Together, these results 
suggest that cells can respond to potentially harmful levels of hPTTG over-expression through 
induction of apoptotic pathways.  However, failure of these mechanisms could support 
survival of aneuploid cells and sustained tumour growth.   
The relationship between hPTTG and p53 is ambiguous due to contrasting data 
between studies.  Pull-down and coimmunoprecipitation assays demonstrated a direct and 
specific interaction between hPTTG and p53 in vitro and in vivo (Bernal et al. 2002).  This 
interaction blocked p53 binding to DNA, p53 transcriptional capabilities and in contrast to the 
findings above, p53-induced apoptosis was prevented by over-expression of hPTTG.  In 





 human colorectal HCT116 cells), 
highlighting the physiological relevance of this interaction (Bernal et al. 2002).  Adenoviral 
vector delivery of siRNA against hPTTG in SH-J1 hepatoma cells resulted in activation of 
p53 leading to increased p21 levels and induction of apoptosis.  Further, in vivo study of SH-
J1 tumor xenografts established in nude mice observed reduced tumour growth following 
intra-tumour delivery of adenoviral hPTTG siRNA (Jung et al. 2006).  Apoptosis was induced 




by UV irradiation in HeLa cells, and apoptosis was enhanced in cells with depleted hPTTG 
levels following siRNA knockdown and reduced in cells over-expressing hPTTG (Lai et al. 
2007).  In the context of hPTTG inhibition of p53-mediated apoptosis, reduced apoptosis in 
tumour cells with high hPTTG expression could explain the prolonged survival of these cells, 
thereby promoting tumourigenesis. 
The relationship between hPTTG and p53 is further complicated by the finding that 
hPTTG is itself a transcriptional target of p53.  Doxorubicin and bleomycin are drugs known 
to cause double stranded DNA breaks (Povirk 1996; Gewirtz 1999).  Treatment of cells with 
these drugs induced DNA damage and repression of hPTTG expression was reported, an 
effect that was entirely dependent on the presence of p53.  Further analysis of the hPTTG 
promoter indicated that following DNA damage, functionally activated p53 prevents NF-Y 
binding to the hPTTG promoter and subsequent regulation of its transcription (Zhou et al. 
2003).  An additional study has since demonstrated direct binding of p53 to the hPTTG 
promoter resulting in hPTTG suppression (Kho et al. 2004).  Repression of hPTTG 
expression following DNA damage induced by UV irradiation was commonly observed in 
multiple cell lines and occurred independently of p53.  Instead, reduced hPTTG expression 
was attributed to two independent mechanisms involving decreased hPTTG protein synthesis 
and increased proteasomal degradation of hPTTG.  hPTTG was however required for cell 
cycle arrest following UV irradiation and lack of hPTTG resulted in premature mitosis and 
increased apoptosis (Romero et al. 2004).  hPTTG degradation was thought to be APC-
mediated due to the stability of a double D-box and KEN box mutant (Romero et al. 2004), 
though more recently, SKP1-CUL1-βTrCP E3 was identified as the ubiquitin ligase that 
mediates hPTTG degradation following UV irradiation (Limon-Mortes et al. 2008).  In 
contrast, hPTTG was induced in both RKO (wild-type p53) and SW480 (mutant p53) 




colorectal carcinoma cells following X-ray radiation.  Further, cytotoxicity and apoptosis was 
increased in hPTTG-null HCT116 cells compared with wild-type HCT116 cells (Chiu et al. 
2007).  Together these results suggest that increased levels of hPTTG in colorectal carcinoma 
cells following X-ray radiation may be associated with protective induction of apoptosis. 
Further evidence for the critical role of hPTTG in DNA damage response pathways is 
the finding that hPTTG can form complexes with Ku heterodimers (Romero et al. 2001).  The 
Ku heterodimer containing Ku70 and Ku80 binds to DNA and facilitates non-homologous 
DNA end-joining (NHEJ) repair of double-strand DNA breaks through recruitment of the 
catalytic component of DNA-PK (Kharbanda et al. 1998; Smith and Jackson 1999).   hPTTG 
binds to Ku70 at a region located at its N-terminal forming an inhibitory complex; in the 
presence of DNA damage, Ku70 dissociates to allow DNA-PK-dependent DNA repair.  The 
ability of DNA-PK to phosphorylate hPTTG may facilitate its dissociation from Ku70 
(Romero et al. 2001).  Concordant with this, hPTTG over-expression inhibits Ku70 DNA 
binding and represses repair of double-stranded DNA breaks (Kim et al. 2007b).  Together, 
these data suggest that hPTTG over-expression can cause aberrant sequestration of Ku 
proteins and thus inhibit appropriate DNA repair mechanisms, leading to further genetic 
instability.  Consistent with this, studies observed reduced cellular proliferation rates 
accompanied by altered patterns of end resection in NHEJ assays following DNA damage in 
hPTTG-null HCT116 cells compared with normal HCT116 cells (Bernal et al. 2008).   
It is clear that we only have a partial understanding of the complex and intricate 
relationship between hPTTG, p53 and other DNA repair mechanisms and these remain to be 
elucidated in the context of the thyroid.  This is a fascinating and important area of research 
since the progression of many cancers requires cells to escape normal regulation of apoptosis 
by p53 and the activation of DNA repair pathways, which could indeed be a fundamental 




consequence of hPTTG over-expression observed in differentiated thyroid cancer, causing 
prolonged cell survival and increased genetic instability.   
 
1.3.6 hPTTG as a gene transactivator 
 
The early observations that hPTTG has a similar peptide sequence to DNA binding 
proteins, and shows partial nuclear localisation, suggested that hPTTG may transactivate other 
genes (Dominguez et al. 1998).  A fusion protein of hPTTG and the DNA binding protein 
GAL4 was able to activate GAL4 responsive elements to drive expression of the his3 and 
lacZ genes in yeast, as well as the luciferase gene in mammalian cells.  Deletion of amino 
acids 124-202 abolished the transactivational ability of hPTTG, whereas mutation of the N-
terminus (amino acids 1-122) did not, confirming that the C-terminal part of hPTTG is 
responsible for this function (Dominguez et al. 1998).   
Indeed, the C-terminus of hPTTG is an acidic region containing multiple glutamic 
acid and proline residues, which are characteristic of transactivation domains (Dominguez et 
al. 1998; Wang and Melmed 2000b; Pei 2000).  Within the proline-rich region, there are two 
PXXP motifs that are putative SH3-interacting sites; highly conserved regions that govern 
transduction of intracellular signalling pathways.  Crucially, point mutations in the PXXP 
motifs resulted in abolished transcriptional activation, as well as hPTTG’s in vitro 
transforming and in vivo tumour-inducing activity (Zhang et al. 1999b).  Similarly, point 
mutation of a key proline residue in murine Pttg abrogated transcriptional activity and 
transforming capability in NIH3T3 cells (Wang and Melmed 2000b), suggesting that the 
transactivation and transforming abilites of hPTTG are intrinsically linked.  Interestingly, in 
vitro studies demonstrated that Egf stimulation of the Mapk cascade resulted in nuclear 
translocation of rat Pttg and subsequent transcriptional activity.  These effects were dependent 




on Mapk phosphorylation of Ser162 within the transactivation domain, in addition to a 
specific interaction between Mek1 and an SH3-interacting domain located between amino 
acids 51 and 54 (Pei 2000).  The corresponding residue in hPTTG, Ser165, has thus far only 
been described as a phosphorylation target for CDC2 (Ramos-Morales et al. 2000) and the 
association with MAPK remains to be verified (see section 1.2.1.5).   
 
1.3.6.1 hPTTG and c-Myc 
 
 Several transcriptional targets of hPTTG have been identified, including genes 
involved in cellular growth and angiogenesis, as will subsequently be discussed (see section 
1.4).  Initially, cDNA PCR array analysis was performed in order to broadly identify 
transcription targets of hPTTG.  A number of genes were upregulated in cell lines following 
induction of rat Pttg including Mek1, mitogen-activated protein kinase kinase 3 (Mek3), 
protein-kinase C beta (Pkcβ-1) and heat shock protein 70 (Hsp70).  However, the c-Myc 
oncogene was identified as a major Pttg transcription target and was subject to further 
investigation (Pei 2001).  c-Myc is a transcription factor that is deregulated in various human 
tumour types (Patel et al. 2004), possibly through its critical role in control of cellular 
proliferation, with over-expression of c-Myc resulting in cell-cycle progression, cell 
transformation and block of differentiation (Henriksson and Luscher 1996).  Induction of Pttg 
in HeLa cells resulted in increased proliferation and transformation following activation of c-
Myc expression by direct binding to the c-Myc promoter in a complex with the ubiquitously 
expressed upstream stimulatory factor (USF1).  Interestingly, Pttg-mediated c-Myc activation 
was dependent on phosphorylation of Pttg, suggesting Pttg phosphorylation may be of 
importance in Pttg gene transactivation (Pei 2001).  Induction of p53 by hPTTG (see section 
1.3.5) was shown to be an indirect effect dependent on prior activation of c-Myc, which 




formed heterodimers with its binding partner MAX to drive the p53 promoter (Hamid and 
Kakar 2004).   
Given the similar effects of hPTTG and c-Myc over-expression, in addition to the 
dependency of some hPTTG effects on c-Myc activation, it is possible that hPTTG’s 
oncogenic actions are mediated via c-Myc.  However, high levels of hPTTG expression in 
pituitary tumours was not associated with increased c-Myc expression (Boggild et al. 1994; 
Woloschak et al. 1994; Saez et al. 1999; Zhang et al. 1999a).  Furthermore, hPTTG is 
predominantly expressed during G2/M-phase (see section 1.3.1), whereas c-Myc is an S-
phase protein (Thompson 1998) suggesting they are independently expressed throughout the 
cell-cycle.  Although these observations suggest hPTTG has tumourigenic effects independent 
of c-Myc, it remains plausible that hPTTG induction of c-Myc plays a role in tumour 
initiation.   
 
1.3.6.2 hPTTG and other interacting factors 
 
Chromatin immunoprecipitation (ChIP)-on-Chip experiments were used to 
simultaneously assess 20,000 gene promoters in JEG-3 cells, and demonstrated a global 
transcriptional effect of hPTTG (Tong et al. 2007).  Binding of hPTTG was observed in a 
total of 746 promoters with functions relating to cell cycle, metabolic control and signal 
transduction.  SP1 binding sites were frequently identified in hPTTG-binding promoters and 
subsequent co-immunoprecipitation and pull-down assays confirmed a specific interaction 
between hPTTG and SP1 both in vivo and in vitro via hPTTG’s N-terminal (amino acids 1-
120).  The results of this study show that hPTTG exhibits properties of a global transcription 
factor and may act through formation of transcription factor complexes by binding other 
proteins (Tong et al. 2007).   




Yeast two-hybrid systems were designed to identify proteins physically associating 
with hPTTG in human testicular cells.  In vitro binding assays and co-immunoprecipitation 
assays identified a specific interaction, conferred by the C-terminal of Pttg, between rat Pttg 
and the molecular chaperone HSJ2 and ribosomal protein S10.   The functional significance of 
these interactions remain unknown, but Pttg was expressed at specific stages of 
spermatogenesis suggesting it has an important role in this process (Pei 1999). 
Using protein microarray screening, hPTTG was found to have protein-protein 
interactions with approximately 80 proteins.  Interaction with S10 was confirmed and 
associations with transcription factors such as TATA box-binding protein-like protein 1 
(TBPL1) and activator of basal transcription 1 (ABT1) were identified, providing further 
evidence that hPTTG is important in transcriptional regulation (Tong et al. 2008; Tong and 
Eigler 2009).  A specific interaction with Aurora-A kinase was identified and validated using 
His-tag pull-down assays and co-immunoprecipitation assays in HCT116 cells.  hPTTG over-
expression resulted in inhibition of Aurora-A kinase activity and abnormally condensed 
chromatin.  hPTTG-null cell proliferation was more sensitive to Aurora-A knock down and to 
Aurora kinase Inhibitor III treatment compared to WT cells, indicating that hPTTG 
knockdown could be a potential approach to improve the efficacy of Aurora kinase inhibitors 
(Tong et al. 2008).   
Overall, hPTTG seems to exert its transcriptional effects either by direct DNA binding 
or by interacting with proteins at both the N- and C-terminal regions to facilitate or inhibit 
transcriptional processes.  However, the effects observed following mutations in the C-
terminal transactivation domain suggest that this region is particularly important in hPTTG’s 
transactivational and transforming capabilities.   
 




1.4 hPTTG promotes tumour progression 
 
Aside from the role of hPTTG in initiating thyroid cancer through the pathways 
described above, hPTTG has been shown to interact with growth factors and cytokines that 
are implicated in further dysregulation thereby driving disease progression. The relationships 
between hPTTG, FGF-2 and VEGF are the most clearly established and appear to be of 
critical importance in tumour progression through promotion of growth and angiogenesis.  
Angiogenesis is the normally quiescent process of blood vessel development that is thought to 
become highly activated during tumourigenesis and is necessary for tumour growth and 
invasion (Folkman 1992; Folkman and Shing 1992; Risau 1997; Hanahan and Folkman 1996; 
Folkman 1972; Folkman 1990).  Endocrine organs are typically highly vascular, but thyroid 
tumours acquire an even greater blood supply (Goldenberg et al. 1998; Akslen and LiVolsi 
2000; Turner et al. 2003), driven by altered levels of pro-angiogenic growth factors such as 
FGF-2 (Bikfalvi et al. 1997; Powers et al. 2000; Turner et al. 2003) and VEGF (Ferrara and 
DavisSmyth 1997) and inhibitors, as well as extracellular matrix changes that allow 
endothelial migration (Folkman 1992; Folkman and Shing 1992; Hanahan and Folkman 1996; 
Turner et al. 2003).  The critical roles of FGF-2 and VEGF are well established where both 
molecules act synergistically to modulate tumour angiogenesis and invasion (Gospodarowicz 




FGF-2 belongs to a family of small poly-peptide growth factors, comprising 23 
members, which share common certain structural characteristics, are expressed by almost all 
tissues and are mitogenic to many cell types.  FGFs are secreted into the extracellular 
environment where they form a reservoir by binding the heparin-like glycosaminoglycans 




(HLGAGs) or the extracellular matrix (ECM).  Subsequently, their activity is mediated 
through digestion of the ECM or by secreted FGF binding proteins (Powers et al. 2000).  
Though four FGF-receptors (FGFR 1-4) sharing common structures including an intracellular 
tyrosine kinase domain have been identified, FGF-2 preferentially interacts with FGFR1 
(Powers et al. 2000; Maher 1996).  FGFR1 is expressed in the nuclear fraction of various cell 
types (Maher 1996), including thyroid follicular cells (Patel et al. 1996), and nuclear FGFR1 
is associated with proliferation (Maher 1996; Stachowiak et al. 1997).  The binding of FGF-2 
to FGFR1 results in receptor dimerisation, autophosphorylation of tyrosine kinase residues 
and the subsequent activation of various signal transduction pathways (Lemmon and 
Schlessinger 1994; Bikfalvi et al. 1997; Pawson 1995).  The major pathways with reported 
involvement in FGF signalling are the Phospholipase C-γ (PLC-γ), v-crk sarcoma virus CT10 
oncogene homolog (CRK) and RAS/MAPK signalling pathways (Bikfalvi et al. 1997; 
Kouhara et al. 1997; LaVallee et al. 1998; Powers et al. 2000).  FGF-2 has important 
physiological roles in embryonic development where it is involved in the regulation of 
growth, differentiation and function of various systems (Bikfalvi et al. 1997; Powers et al. 
2000; Logan et al. 1991; McAvoy et al. 1991; Unsicker et al. 1992; Baird 1994).  In addition, 
FGF-2 is a potent angiogenic molecule which stimulates smooth muscle cell growth, wound 
healing and tissue repair in vivo and in vitro (Folkman and Shing 1992; Bikfalvi et al. 1997; 
Powers et al. 2000) and through these mitogenic and angiogenic capabilities can contribute to 




Similarly to FGF-2, VEGF is a potent mitogen but acts in a highly specific manner on 
micro- and macrovascular endothelial cells (Leung et al. 1989; Plouet et al. 1989) and 




activates serine proteases urokinase-type and tissue-type plasminogen activators known to be 
involved in cellular invasion and tissue remodelling (Pepper and Montesano 1990).  
Furthermore it affects vascular permeability, promotes the expression of adhesion molecules 
on endothelial cells, induces vasodilatation and influences monocyte chemotaxis (Senger et al. 
1983; Roberts and Palade 1995; Ferrara and DavisSmyth 1997).  Alternative splicing of a 
single VEGF gene results in the synthesis of four different isoforms (VEGF121, VEGF165, 
VEGF189, VEGF206) that have different tissue expression.  However, VEGF165 is the 
predominant isoform and thus commonly referred to as VEGF (Ferrara and DavisSmyth 
1997; Ramsden 2000).  The actions of VEGF are facilitated by binding to either VEGFR-1 
(FLT-1) or VEGFR-2 (KDR), which both have consensus tyrosine kinase sequences that are 
autophosphorylated following formation of multimeric VEGF receptor complexes (Vaisman 
et al. 1990; Ferrara and DavisSmyth 1997; Ramsden 2000; Guo et al. 1995).  Subsequently, 
SH2- containing proteins are recruited to the complex and activate intracellular transduction 
pathways involving PLC-γ and the ras GTP-ase activating protein (Ferrara and Davis-Smyth, 
1997).  The importance of VEGF in tumour development is evidenced by a correlation 
between VEGF mRNA expression and tumour vascularity (Brown et al. 1995; Viglietto et al. 
1997; Kerbel et al. 1998) and increased levels of circulating VEGF in cancer patients (Kondo 
et al. 1994).  Furthermore, upregulation of FLT-1 and KDR mRNA has been found in the 
endothelial cells associated with tumours (Plate et al. 1994; Brown et al. 1995).  Specifically 
in thyroid malignancies VEGF represents an important bio-marker as there is a strong 
correlation between its expression and tumour aggressiveness and metastasis (Soh et al. 1997; 
Bunone et al. 1999; Klein et al. 2001).   
 
 




1.4.3 hPTTG, FGF-2, VEGF and angiogenesis 
 
Various studies have described the induction of FGF-2 by hPTTG.  Stable over-
expression of hPTTG in NIH3T3 cells resulted in increased FGF-2 mRNA expression and 
secretion as determined by ELISA.  Mutation within the SH3-interacting domain of hPTTG 
resulted in abrogation of these effects and also prevented in vitro transformation and in vivo 
tumourigenesis, indicating that enhanced FGF-2 signalling is an important event in these 
processes (Zhang et al. 1999b).  Subsequently, it was demonstrated that FGF-2 in turn induces 
hPTTG mRNA expression in NIH3T3 cells, suggesting the existence of autocrine pathways 
of regulation between hPTTG and FGF-2.  This effect was blocked by antiserum against 
FGF-2, which also reduced basal hPTTG expression providing further evidence for an auto-
regulatory feedback mechanism (Heaney et al. 1999).  Our group’s own studies demonstrated 
that expression of FGF-2 was induced following hPTTG over-expression in human primary 
follicular thyroid cells.  This effect was unaltered by mutation of the hPTTG phosphorylation 
site (S165A) but was significantly reduced by mutation of the SH3-interacting domain 
(Boelaert et al. 2003a).  Furthermore, a positive correlation between high levels of hPTTG 
and FGF-2 expression was observed in differentiated thyroid cancers.  Both can be considered 
important prognostic indicators, as hPTTG over-expression was associated with tumour 
recurrence and the expression of FGF-2 mRNA was independently associated with lymph 
node invasion and distant metastases (Boelaert et al. 2003a).  Further, use of luciferase 
reporter assays in COS-7 cells demonstrated that hPTTG regulation of FGF-2 was a direct and 
promoter-specific effect (Chien and Pei 2000).   
 





Figure 1-11: hPTTG and FGF-2 as potential prognostic indicators.  A  Fold changes in hPTTG 
mRNA in recurrent and non-recurrent thyroid cancers.  B  Fold changes in FGF-2 mRNA in thyroid 
cancers with and without nodal involvement.  Gene expression is relative to a value of 1.0 in normal 
thyroid tissue. ***, p < 0.001.   Also displayed are the results of multiple linear regression analysis 
relating hPTTG mRNA to recurrence (A) and relating FGF-2 mRNA to nodal metastases (B).  Results 
shown are mean ΔCt ± SEM.  Adapted from (Boelaert et al. 2003a).   
 
Our group has also performed studies that have elucidated an additional auto-
regulatory mechanism involving hPTTG and VEGF.  Having reported increased hPTTG 
levels in 111 pituitary adenomas examined (McCabe et al, 2003), we also examined the 
expression of VEGF and KDR in these tumours (n = 103) (McCabe et al, 2002). Non-
functioning pituitary tumours (n = 81) demonstrated markedly raised VEGF mRNA (3.2-fold, 
p < 0.05) and protein concentrations compared with samples of normal pituitary (n = 10).  
Moreover a significant positive correlation between VEGF and hPTTG mRNA was noted (R
2
 
= 0.22, p < 0.001).  The expression of KDR mRNA was also highly induced in non-
functioning tumours (14-fold, p < 0.001) as well as in the whole cohort of pituitary tumours 
(14-fold, p < 0.0001) and again a positive correlation with hPTTG mRNA was demonstrated 
(R
2
 = 0.14, p < 0.001). Western blotting confirmed higher KDR expression at protein level 
(McCabe et al, 2002).  hPTTG over-expression resulted in upregulation of both FGF-2 and 
VEGF expression in NT-2, MCF-7 and JEG-3 cells.  Once again the phosphorylation status 
did not alter hPTTG upregulation of FGF-2 and VEGF, whereas mutation of the SH3 domain 


































































Mean Δ Ct 6.30 8.27
SEM ±0.14 ±0.28
N 6 18















modulate VEGF expression in endothelial cells (Seghezzi et al. 1998; Saadeh et al. 2000).  
However, in this study, depletion of secreted FGF-2 in the cell media failed to influence the 
effect of hPTTG on VEGF expression suggesting that hPTTG affects VEGF expression via a 
mechanism that is independent of hPTTG-mediated transactivation of FGF-2 (McCabe et al. 
2002).  In a further study by our group, cDNA PCR array analyses revealed that mRNA 
expression of VEGF and the pro-angiogenic gene DNA-binding 3 (ID3) were induced 
following over-expression of hPTTG in human primary thyroid follicular cells.  Induction of 
ID3 was subsequently demonstrated to be via the SH3-interacting domain, further evidencing 
the importance of this region in the transactivational capabilities of hPTTG (Kim et al. 
2006b).  Subsequent studies in follicular thyroid cancer FTC-133 cells demonstrated that 
hPTTG induces expression of ID3 following upregulation of VEGF and its receptor KDR 
revealing another potentially important autocrine feedback mechanism involving VEGF in 
thyroid cancer.  Thyroid epithelial cells were shown to express a functional KDR receptor 
through which VEGF could promote proliferation via the KDR-dependant MAPK pathway.  
Crucially, in FTC133 thyroid cells, over-expression of hPTTG resulted in an increase in 
VEGF mRNA expression and secretion (see Figure 1-12).  There was also an increase in 
KDR expression, which is consistent with the finding that KDR expression is elevated in 
thyroid cancer (Kim et al. 2006a).  Together, these data suggest that autocrine pathways of 
interaction exist between growth factors and hPTTG in thyroid cells, and that dysregulation of 
these pathways in thyroid cancer can contribute to tumour proliferation and angiogenesis. 





Figure 1-12: hPTTG regulates expression and secretion of VEGF in thyroid follicular carcinoma 
FTC-133 cells.  A  Fold change in VEGF mRNA expression in FTC133 cells transfected with hPTTG 
compared with and normalized to VO-transfected controls.  B  VEGF secretion from hPTTG-
transfected cells compared with VO-transfected control cells measured using ELISA. Results shown 
are mean ΔCt ± SEM.  *** p <  0.001.  Adapted from (Kim et al. 2006a).   
 
The evidence that hPTTG regulates expression of growth factors such as FGF-2 and 
VEGF provides possible mechanisms by which hPTTG mediates angiogenesis and overall 
disease progression.  One study directly investigated the effects of hPTTG on angiogenesis.  
Consistent with previous findings (Zhang et al. 1999b), hPTTG over-expression induced 
FGF-2 secretion in NIH3T3 cells (Ishikawa et al. 2001).  Subsequently, the conditioned 
medium from NIH3T3 cells stably over-expressing WT-hPTTG induced proliferation, 
migration and tube formation of human umbilical vein endothelial cells (HUVEC cells) in 
vitro.  In vivo, concentrated media from WT-hPTTG transfected NIH3T3 cells induced chick 
chorio-allantoic membrane (CAM) spoke-wheel-like appearances (see Figure 1-13).  
Moreover, conditioned medium derived from hPTTG transfectants harbouring the same C-
terminal mutation which abrogated FGF-2 induction (Zhang et al. 1999b), induced weaker 






































































Figure 1-13: hPTTG induces angiogenesis in vivo.  A  Chrorio-allantoic membrane (CAM) assays 
demonstrating enhanced vascularisation following incubation with concentrated medium from WT-
hPTTG transfected (WT-hPTTG-CM) NIH3T3 cells (right) compared with those treated with serum 
free DMEM (left).  B  Quantification of induced vessels counted under stereomicroscopy.  * p < 0.01.  
Adapted from (Ishikawa et al. 2001). 
 
 
A number of investigations in animal models have provided further in vivo evidence of 
the role of Pttg and growth factors in tumour progression.  Notably, in the rat model of 
oestrogen-induced pituitary lactotroph tumour formation, increased expression of Pttg is an 
early event, thereby supporting a role for Pttg in the earlier stages of tumourigenesis (Heaney 
et al. 1999).  However, the same study makes observations that support the hypothesis that 
Pttg’s relationship with growth factors could similarly promote tumour progression by driving 
proliferation and angiogenesis.  In this model, an increase in Fgf-2 and Vegf expression 
correlated with the peak in Pttg expression at the hypertrophic to hyperplastic transition of 
pituitary lactotroph tumour formation (Heaney et al. 1999).  A subsequent study in rats 






























rat oestrus cycle, further highlighting the interplay between Pttg, hormones and growth factors 
(Heaney et al. 2002).   
TRβPV/PV mice spontaneously develop follicular thyroid cancer, and show increased 
vascularisation, progression to metastasis and high levels of Pttg in the primary thyroid 
tumours, as well as in the secondary and distant lung metastases (Ying et al. 2006).  A double 
mutant transgenic line, TRβPV/PV/Pttg–/–, with deletion of Pttg, provided important insights 
into the effects of Pttg on tumour development (Kim et al. 2007a).  In the absence of Pttg, 
mice developed thyroid tumours, but vascular invasion and metastases were reduced, in line 
with a reduction in expression of Fgf-2, Fgfr1 and Vegf (Kim et al. 2007a), providing strong 
support for a role of Pttg in thyroid tumour progression through interactions with growth 
factors.  Similarly, a recent study indicated reduced FGF-2 and VEGF mRNA and protein 
expression in thyroid cancer cell lines treated with drugs that reduce hPTTG expression 
(Chintharlapalli et al. 2011).   
Additionally, there is evidence in various types of human tumours that links hPTTG 
with angiogenesis adding to our own study described above (McCabe et al. 2002).  Higher 
hPTTG mRNA expression was observed in highly vascular colorectal cancers compared with 
less vascular specimens (Heaney et al. 2000).  High hPTTG expression was associated with 
poor prognosis in hepatocellular carcinoma (HCC).  hPTTG, FGF-2 and VEGF expression 
were all positively correlated and associated with intratumoural microvessel density, 
indicating transactivation of FGF-2 and VEGF by hPTTG as a key event in HCC progression 
(Fujii et al. 2006). Similar results were obtained in studies of hPTTG and FGF-2 in 
endometrial carcinoma (Wang et al. 2004) and hPTTG and VEGF in pituitary adenomas 
(Minematsu et al. 2006). 
 




1.4.4 hPTTG and other growth factors and cytokines involved in tumour progression 
 
Despite a significant body of evidence demonstrating the relationship between 
hPTTG, FGF-2 and VEGF, there is evidence for regulation of other factors by hPTTG.  This 
was highlighted by our own studies identifying ID3 as a pro-angiogenic gene regulated by 
hPTTG in human primary thyroid follicular cells.  In the same array, IGF-1, which stimulates 
proliferation, survival and anti-apoptotic pathways, was induced 3.1-fold.  Further, anti-
angiogenic genes such as thrombo-spondin 1 (TSP-1) were downregulated (Kim et al. 2006b).  
In addition to FGF-2, IGF-1 mRNA expression was positively correlated with hPTTG in 
pituitary adenomas, providing further evidence that hPTTG-mediated IGF-1 transcription may 
be involved in tumourigenesis (Chamaon et al. 2010).  Further, in thyroids from mutant 
TRβPV/PV mice, which spontaneously develop follicular thyroid cancers, Pttg and Tgf-α 
expression was elevated at the time of metastatic spread (Ying et al. 2003).  Together these 
results indicate that interactions between hPTTG and multiple growth factors is of importance 
in tumour development.   
hPTTG over-expression in HEK293 cells upregulated interleukin-8 (IL-8) expression 
in vitro and in vivo, in tumours developed in nude mice following injection of these cells 
(Hamid et al. 2005).  The expression and secretion of matrix metalloproteinase 2 (MMP-2) 
was also elevated in these models and subsequent treatments of HUVECs with the 
conditioned medium taken from hPTTG-transfected HEK293 cells induced proliferation, 
migration and tube formation in vitro.  The addition of an MMP-2 antibody significantly 
decreased these effects (Malik and Kakar 2006).   
Together, these findings suggest that hPTTG regulates multiple downstream targets 
that are involved in proliferative and angiogenic pathways.  The described autocrine 
mechanisms of interaction between hPTTG, FGF-2 and VEGF are well established and 




clearly important but further investigation is required in thyroid models to determine whether 
hPTTG is a key mediator of other autocrine mechanisms involving growth factors that drive 
tumour progression when aberrantly controlled.   
 
1.5 PTTG Binding Factor 
 
1.5.1 PBF characterisation and structure 
 
The PTTG-Binding Factor (PBF) was isolated and identified as a novel protein that 
interacts with hPTTG using a two yeast hybrid screening system.  PBF, also known as 
PTTG1-interacting protein (PTTG1IP), is located on chromosome 21q22.3 and contains an 
open reading frame of 179 amino-acids with a predicted molecular mass of 22 kDa (Chien 
and Pei 2000).  It has since become clear that PBF had previously been cloned, when it was 
termed C21orf3 (also known as C21orf1).  C21orf3 was thought to have a role in cell 
trafficking mechanisms as a Type 1a integral membrane cell surface glycoprotein, following 
initial protein prediction studies identifying a potential N-terminal signal peptide, 
transmembrane domain, endocytosis motif and two putative N-glycosylation sites (Yaspo et 
al. 1998).  Further analysis identified potential sites for post-translational modifications such 
as phosphorylation sites for cAMP- and cGMP-dependent kinase, PKC and casein kinase II 
and five glycosylation sites for N-linked and O-linked oligosaccharides (Chien and Pei 2000). 
Additionally, an extracellular N-terminal cysteine-rich putative protein-binding domain, 
common to plexins, semaphorins and integrins and thereby referred to as a PSI domain, is 
also found in PBF (Bork et al. 1999).  However, PBF was demonstrated to contain a C-
terminal bipartite NLS suggesting that it may also have nuclear functions (Chien and Pei 
2000).  The direct and specific interaction between hPTTG and PBF was confirmed in vitro 
and in vivo, using glutathione S-transferase pull-down and co-immunoprecipitation assays in 




COS-7 cells.  Furthermore, deletion analysis identified the hPTTG binding domain in PBF to 
be located within the C-terminal 30 amino acids and the corresponding domain in hPTTG to 
be between amino acids 123 and 154 within the transactivating domain (Chien and Pei 2000). 
 
Figure 1-14: Schematic representation of the putative domains of the PBF protein.  A cleavable 
signal peptide is located at the N-terminus between amino acids 1 - 32.  The PSI domain forms the 
remaining extracellular region between amino acids 39 - 92, next to the transmembrane domain 
located between amino acids 95 - 122.  An NLS and endocytosis motif are found at the C-terminus 
from amino acids 149 and 174 respectively. The site of interaction with hPTTG, within the C-terminal 
30 amino acids, is highlighted in red (Figure adapted from (Smith et al. 2010)). 
 
 
1.5.2 PBF expression and regulation   
 
Northen blot analysis in a variety of human tissues demonstrated that PBF is 
ubiquitously expressed in normal tissue (Chien and Pei 2000; Yaspo et al. 1998).  
Subsequently, studies within our own group demonstrated a 5.7-fold over-expression of PBF 
mRNA in 111 pituitary tumours (described in section 1.4.3) compared with normal pituitary 
tissue.  Interestingly, a significant positive correlation between the expression of hPTTG and 
that of PBF mRNA was observed in pituitary adenomas but not in normal pituitaries (McCabe 
et al. 2003).  Furthermore, we found significant over-expression of PBF mRNA and protein in 
the same thyroid cancer specimens in which hPTTG was over-expressed (see section 1.2.1.3), 
indicating an important relationship between hPTTG and PBF in thyroid cancer (Stratford et 


















recurrence.  The coding region of PBF was sequenced in 24 thyroid carcinomas but no 
mutations were detected (Stratford et al. 2005). 
 
Figure 1-15: PBF is over-expressed in thyroid cancer.  A  TaqMan RT-PCR data demonstrating 
over-expression of PBF mRNA in thyroid cancer.  B  Representative Western blot analysis of four 
normal and matched thyroid tumour specimens, demonstrating over-expression of PBF protein in 
thyroid cancer (Figure adapted from (Stratford et al. 2005)).   
 
Interestingly, over-expression of hPTTG in human primary thyroid cells or hPTTG-null 
HCT116 cells induced PBF mRNA expression, an effect that was dependent on the SH3-
interacting domain.  Similarly, stable over-expression of hPTTG in NIH3T3 cells resulted in 
elevated PBF mRNA expression and conversely, stable PBF over-expression had no effect on 
hPTTG transcription (Stratford et al. 2005). 
Studies comparing C3H10T1/2 mouse embryonic fibroblasts constitutively over-
expressing Runx2 with WT cells, identified Pbf as a transcriptional target gene for the Runx2 
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and Runx2 over-expression increased activity of a 1.8 kb Pbf promoter fragment in reporter 
assays (Stock et al. 2004).   
Treatment with the growh factors, EGF and TGF-α, had no effect on PBF mRNA 
expression in folliculostellate TtT-GF cells, indicating alternative mechanisms of PBF 
regulation compared with that for hPTTG (Vlotides et al. 2006).  However, treatment of ER-
α-positive MCF-7 cells with diethylstilbestrol (DES) and 17β-estradiol (EST) induced 
significant PBF mRNA and protein expression, following direct binding of the estrogen 
receptor α (ERα) to the PBF promoter (Watkins et al. 2010).   
 
1.5.3 PBF localisation and function 
 
PBF demonstrates no sequence homology with other human proteins, indicating that it 
is functionally unique.  It is however, highly conserved across other species (77 % homology 
to rat, 75 % mouse, 60 % chicken), suggesting that it is functionally important, though its 
primary function remains to be determined.   
Identification of the interaction between PBF and hPTTG prompted further 
characterisation studies to investigate the functional significance of this relationship (Chien 
and Pei 2000).  Immunofluorescence and subcellular fractionation techniques were used to 
investigate the subcellular localisation of hPTTG and PBF following their transfection into 
COS-7 cells (see Figure 1-16).  GFP-tagged hPTTG demonstrated mainly cytoplasmic 
localisation, but its expression in the nucleus was greatly enhanced following co-transfection 
with PBF-HA, suggesting PBF facilitates translocation of hPTTG to the nucleus.  When the 
NLS site was deleted in PBF, GFP-hPTTG expression was confined to the cytoplasm, 
demonstrating a specific dependency on PBF for nuclear translocation.  Functionally, PBF 
translocation of hPTTG to the nucleus resulted in a more than 3-fold induction in FGF-2 




promoter activity, whereas in the absence of PBF little FGF-2 transcription occurred.  It 
therefore appears that PBF may be required for some of hPTTG’s transactivational 
capabilities (Chien and Pei 2000). 
 
Figure 1-16: Nuclear translocation of hPTTG by PBF. COS-7 cells were transfected with A. 
hPTTG-GFP; B. hPTTG-GFP + PBF-HA or C. hPTTG-GFP and HA-tagged mutant PBF with a 
deleted NLS (mPBFNLS). 24 hours after transfection, cells were fixed and stained. GFP-hPTTG was 
detected by green fluorescence (figure adapted from(Chien and Pei 2000)). 
   
The original prediction that PBF is a cell-surface glycoprotein (Yaspo et al. 1998) was 
further supported by immunofluorescent studies within our own group, demonstrating a 
strong presence of PBF in intracellular vesicles where it colocalised with the late endosomal 
marker CD63, following internalisation (Smith et al. 2009).  Deletion of the C-terminal 30 
amino acids results in PBF accumulation at the plasma membrane suggesting the tyrosine-
based sorting signal within this region is functional (Smith et al. 2009).   
 
1.5.4 PBF as a proto-oncogene 
 
Crucially, clones selected from NIH3T3 cells with stable over-expression of either 
hPTTG (see section 1.2.1) or PBF led to significant colony formation in soft agar assays, thus 
demonstrating the transforming capabilities of both in vitro.  hPTTG mutants lacking a 
functional SH3-interacting domain, as described previously, cannot induce PBF mRNA 
expression or interact with the PBF protein.  In this study, the hPTTG SH3-mutant did not 
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induce transformation, indicating that PBF could be an effector of hPTTG-induced 
transformation and tumourigenesis.  To this effect, PBF was identified as an independent 
proto-oncogene following injection of NIH3T3 cells stably expressing PBF into nude mice.  
This induced tumour formation, thereby demonstrating the tumourigenic ability of PBF in 
vivo (Stratford et al. 2005).   
 
Figure 1-17: PBF has transforming capabilities independent of hPTTG.  A total of 5 x10
6
 cells from 
vector-only or PBF-expressing stable NIH3T3 lines were injected into athymic nude mice.  Examples 
of tumour formation in PBF injected mice are indicated by the black arrows, where the PBF mouse on 
the right developed a tumour weighing 1.4g (inset) (Figure adapted from (Stratford et al. 2005)). 
 
 
To further investigate the oncogenic potential of PBF in vivo, our group recently 
generated a murine transgenic model with thyroid targeted over-expression of PBF.  This 
model was the subject of some of the investigations reported within this thesis, which led to 
publication of these data.  hPBF-Tg transgenic mice exhibited a striking enlargement of the 
thyroid gland associated with hyperplastic and macrofollicular lesions, mediated by activation 












Figure 1-18: Mice with thyroid targeted over-expression of PBF develop enlarged thyroid glands.  
A  Representative images of thyroid glands from 52-week-old PBF-Tg and WT mice. Dotted line 
indicates margin of thyroid lobes.  B  Composite image of an entire thyroid lobe from a 78-week-old 
PBF-Tg mouse with diffuse goitre (DG) and hyperplastic regions (HP). Scale bars, 100 mm. 
 
1.6 Sodium Iodide Symporter (NIS) 
 
1.6.1 Characterisation of NIS 
 
The ability of thyroid cells to accumulate iodide has been known for a long time, 
being reported as early as 1915 (Marine and Feiss 1915).  Though the existence of an iodide 
transporter was inferred from studies elucidating some of the properties of this phenomenon 
throughout the 20
th
 century, NIS was only cloned in 1996 and marked a major advance in the 
field of thyroid biology (Dai et al. 1996; Smanik et al. 1996; Dohan et al. 2003).  NIS 
mediates the active transport of I
- 
into thyroid follicular cells, which is the critical and rate-
limiting step of thyroid hormone biosynthesis, where I
- 








triiodothyronine (T3) and thyroxine (T4).  NIS is an integral plasma membrane glycoprotein 
located at the basolateral membrane of thyroid follicular cells and co-transports 2 Na
+
 and 1 I
-
 
ion into the cytoplasm of these cells.  This occurs against the I
- 
electrochemical gradient, but 
is driven by the Na
+ 




 ATPase (Spitzweg et 
al. 2001; Boelaert and Franklyn 2003; Dohan et al. 2003; Riesco-Eizaguirre and Santisteban 
2006).  Cell polarisation is important in I
- 
transport and cytoplasmic I
- 
is driven across the 




transporter, pendrin (Scott et al. 1999), 
or the apical I
-
 transporter (AIT) (Rodriguez et al. 2002) in a process called I
-
 efflux.  At this 
stage, free I
- 
is organified at the cell-colloid interface.  In a complex reaction catalysed by 
thyroid peroxidase (TPO), I
- 
is oxidised and incorporated onto tyrosyl residues of 
thyroglobulin (Tg), leading to the coupling of iodotyrosine residues to form T3 and T4.  
Iodinated Tg is stored in the colloid until it is endocytosed back into thyroid follicular cells 
and T3 and T4 are secreted into the blood stream in response to a biological demand for 
thyroid hormones.  This entire process is primarily regulated by activation of the adenylate 
cyclase-cAMP pathway following binding of TSH to the TSH-receptor (TSHR) located in the 
basolateral membrane of thyroid follicular cells (Spitzweg et al. 2001; Dohan et al. 2003; 
Riesco-Eizaguirre and Santisteban 2006; Weiss et al. 1984; Nissim et al. 1987).   





Figure 1-19: Schematic illustration of the key aspects of iodine transport and organification in the 
thyroid gland. TSHR, TSH receptor, TPO thyroid peroxidase, Tg, thyroglobulin, AIT, apical iodide 
transporter (Figure adapted from (Spitzweg et al. 2001; Dohan et al. 2003).   
 
 
Importantly, our knowledge of the thyroid’s ability to take up iodide has allowed us to 
exploit this mechanism to provide diagnostic and therapeutic tools in benign and malignant 
thyroid disease.  Scintigraphic imaging is used diganostically to visualise the thyroid and 
thyroid function, as well as to detect thyroid cancer metastases.  In addition, therapeutic doses 
of 
131I are administered to patients with Graves’ disease, multinodular goitre, functional 
differentiated thyroid cancers and their metastases in order to ablate pathological tissue in a 
highly targeted manner (Spitzweg et al. 2001; Boelaert and Franklyn 2003; Dohan et al. 2003; 
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1.6.2 NIS in thyroid disease 
 
Immunohistochemical studies of normal thyroid tissue have demonstrated that NIS 
protein is heterogeneously expressed at the basolateral membrane of a minority of thyroid 
follicular cells (Caillou et al. 1998; Castro et al. 1999a).  However, thyroidal NIS expression 
is often altered in diseased states.  Immunohistochemical analysis of thyroid specimens from 
Graves’ disease patients revealed strong over-expression of NIS protein in the basolateral 
membrane of most thyroid follicular cell, consistent with the clinically observed increase in 
radioiodine uptake in acute Graves’ thyrotoxicosis (Saito et al. 1997; Caillou et al. 1998; Joba 
et al. 1999; Castro et al. 1999a).  Further, there is evidence that NIS is a novel thyroid 
autoantigen, where NIS autoantibodies have been detected in the sera of patients with auto-
immune thyroid disease (AITD).  The results of these studies are detailed in two reviews, 
which both conclude that the biological function of anti-NIS autoantibodies remains 
undetermined (Spitzweg and Morris 2002; Dohan et al. 2003).  Expression of NIS protein in 
AITD is similar to normal thyroid tissue with strongest expression near to lymphocytic 
infiltrates (Caillou et al. 1998).  Toxic multinodular goitres demonstrate stronger 
heterogeneous expression of NIS protein than normal thyroid (Caillou et al. 1998), whereas 
levels are low in non-toxic MNG and diffuse iodine deficiency goitres (Joba et al. 1999).  
Similarly, NIS levels are increased in autonomously functioning thyroid nodules (hot nodules) 
with increased radio-iodine uptake and are decreased in cold nodules with low or absent 
uptake of radio-iodine (Joba et al. 1999).  
Critically, I
- 
uptake is reduced in many thyroid cancers and their metastases compared 
with normal thyroid, thereby limiting the efficacy of radio-iodine therapies (Maxon and Smith 
1990).  Even after TSH stimulation, 10-20 % of tumours with reduced I
- 
uptake remain 
incapable of sufficient I
- 
concentration for effective radio-ablation therapy (Kogai et al. 2006; 




Robbins et al. 1991; Schmutzler and Koehrle 2000).  A correlation between NIS expression 
and I
- 
uptake in thyroid tumours has been confirmed (Caillou et al. 1998; Castro et al. 1999a) 
and tumours with reduced NIS activity are associated with a poor prognosis (Ward et al. 
2003).   
Various mRNA (Smanik et al. 1997; Lazar et al. 1999; Ringel et al. 2001; Arturi et al. 
2003; Park et al. 2000; Ryu et al. 1999; Ward et al. 2003) and protein studies using specific 
poly- and monoclonal antibodies (Jhiang et al. 1998b; Caillou et al. 1998; Castro et al. 1999a; 
Castro et al. 1999b; Faggiano et al. 2007; Gerard et al. 2003; Trouttet-Masson et al. 2004) 
have demonstrated reduced NIS expression in thyroid cancer tissue, suggesting repression of 
I
- 
uptake is caused by a transcriptional effect.  However, contrasting studies observed normal 
or even increased levels of NIS expression in as many as 70 % of thyroid cancers at the level 
of mRNA (Arturi et al. 1998; Luciani et al. 2003; Saito et al. 1998; Tanaka et al. 2000) or 
protein (Dohan et al. 2001; Saito et al. 1998; Wapnir et al. 2003).  Immunohistochemical 
analysis of NIS over-expression in these thyroid cancers, revealed that NIS was primarily 
localised to the cytoplasm and not at the basolateral membrane where it is required to be in 
order to be functional (Castro et al. 1999b; Dohan et al. 2001; Wapnir et al. 2003).  This 
indicates that reduced I
- 
uptake is at least in part attributable to mislocalisation of NIS 
following interference with intracellular trafficking or plasma membrane retention 
mechanisms.  Together these results suggest that an understanding of the mechanisms of both 
NIS induction and NIS localisation are required to develop therapeutic strategies to improve 
radioiodide treatment in thyroid cancer (Spitzweg and Morris 2002; Dohan et al. 2003). 





Figure 1-20: Functional levels of NIS are regulated by factors affecting expression (A) and 
subcellular localisation of NIS (B).    
   
1.6.3 Regulation of NIS expression and function 
 
Regulation of NIS expression and function is characteristically intricate, with multiple 
factors effecting NIS transcription, translation, post-translational modification and cellular 
trafficking mechanisms controlling its localisation.  As mentioned previously, TSH is the 
major regulator of thyroid function and has been shown to induce NIS transcription and 
translation, resulting in enhanced I
-
 uptake by rat thyroid FRTL-5 cells (Kogai et al. 1997; 
Ohno et al. 1999; Riedel et al. 2001) and human primary thyroid follicular cells (Saito et al. 
1997; Kogai et al. 2000).   Further, TSH regulation of NIS has been demonstrated in vivo, 
including studies in rat (Levy et al. 1997) and human (Martino et al. 2000) systems.  In a 
secondary mechanism of NIS regulation, TSH levels have also been shown to effect the 
localisation or retention of NIS to the basolateral membrane where it is functional (Riedel et 
al. 2001; Kogai et al. 1997).  NIS is a phospho-protein with phosphorylation patterns 
governed by TSH in FRTL-5 cells (Riedel et al. 2001).  Targeting of NIS to the basolateral 
membrane was proposed to be mediated by phosphorylation of the C-terminal, but despite the 
presence of various phosphorylation residues, none have been confirmed to play a role in NIS 
trafficking (Vadysirisack et al. 2007).  However, activation of the PI3K pathway in MCF-7 
cells interfered with cell-surface trafficking and induction of endogenous and exogenous NIS 
NIS NIS
NIS
REDUCED EXPRESSION ALTERED LOCALISATIONA. B.
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function (Knostman et al. 2007b).  Furthermore, two recent studies have described regulation 
of NIS expression by the PI3K pathway (Zaballos et al. 2008; Kogai et al. 2008).   
Aside from TSH, high levels of I
-
 itself have long been known to reduce thyroid 
function.  The Wolff-Chaikoff effect describes a highly specialised intrinsic autoregulatory 
system, whereby I
-
 organification by TPO is acutely blocked upon receipt of high doses of I
-
, 
resulting in reduced NIS activity.  However, an adaptation of the system occurs as early as 2 
days after, restoring I
- 
uptake to allow normal biosynthesis of thyroid hormones (Wolff and 
Chaikoff 1948; Wolff et al. 1949).  Despite extensive investigation, the precise mechanisms 
underlying the inhibition of iodide organification by high levels of I
- 
remain poorly 
understood, though studies in FRTL-5 cells have reported transcriptional (Spitzweg et al. 
1999) and post-translational (Eng et al. 2001) regulation of NIS following treatment with I
-
. 
Other regulators of NIS include various cytokines and growth factors that repress NIS 
expression and function in a time- and dose-dependent manner.  Transforming growth factor 
beta (TGF-β), IGF-1, tumor necrosis factor alpha (TNF-α) and beta (TNF-β), interferon 
gamma (IFN-γ), interleukin alpha (IL-1α), beta (IL-1β) and 6 (IL-6) have been proven to 
inhibit NIS mRNA expression and iodide uptake activity in FRTL-5 and human thyroid cells 
(Ajjan et al. 1998; Pekary et al. 1997; Pekary et al. 1998; Garcia and Santisteban 2002).  IFN-
γ repression of NIS has also been demonstrated in vivo (Caturegli et al. 2000).  Thyroglobulin 
also acts as a potent suppressor of NIS transcription and subsequently I
-
 uptake (Suzuki et al. 
1999; Ulianich et al. 1999; Kohn et al. 2001).  Though the mechanism is poorly understood, it 
is thought that this may represent a negative feedback autoregulatory mechanism that 
counterbalances TSH stimulation of follicular function.  Furthermore, oestradiol promotes 
proliferation and inhibits NIS expression and I
-
 uptake in FRTL-5 cells, providing a 




mechanism that potentially contributes to higher incidence of thyroid disease in women 
(Furlanetto et al. 1999; Furlanetto et al. 2001).   
 
1.6.4 hPTTG, PBF and NIS 
 
Of particular importance to our own research interests, both hPTTG and PBF have 
been implicated in the regulation of NIS and I
-
 uptake.  hPTTG regulation of NIS was 
originally observed in rat FRTL-5 cells over-expressing hPTTG (Heaney et al. 2001).  I
-
 
uptake was strongly repressed in cells over-expressing hPTTG and subsequent Northern blot 
analysis demonstrated that this was due to reduced NIS mRNA expression.  Further, hPTTG 
over-expression induced transcription and secretion of FGF-2.  Treatment of FRTL-5 cells 
with FGF-2 also caused reduced NIS mRNA expression and I
-
 uptake, at similar levels to 
those observed following hPTTG over-expression (Heaney et al. 2001).  FGF-2 mediated 
repression of I
-
 uptake has also been demonstrated in human primary thyrocytes (Cocks et al. 
2003).  Together these results suggest that hPTTG effects on NIS are mediated at least in part 
through induction of FGF-2 as part of autocrine feedback mechanisms involving hPTTG and 
FGF-2 (Heaney et al. 2001).  Subsequently, in a study confirming hPTTG expression as a 
prognostic indicator for persistent disease, immunohistochemical analysis of 16 human 
differentiated thyroid tumours demonstrated strong hPTTG over-expression that was 
associated with reduced  I
-
 uptake in patients (Saez et al. 2006).  Studies within our own 
group demonstrated that both hPTTG and its binding factor PBF repress expression of NIS 
mRNA and inhibit I
-
 uptake in FRTL-5 cells and human primary thyroid follicular cells 
(Boelaert et al. 2007).  Promoter studies in FRTL-5 cell and human primary thyroid cells 
demonstrated that repression of NIS by hPTTG and PBF was via specific binding to a PAX8-
upstream stimulating factor 1 (USF1) response element within a 1 kb element in the NIS 
promoter known as the human upstream enhancer element (hNUE).  Depletion of secreted 




FGF-2 partially inhibited NIS repression by hPTTG, providing further support for the 
existence and importance of autocrine pathways involving hPTTG and growth factors.  FGF-2 
depletion had no effect on NIS repression by PBF in human primary thyroid cells, implying 
that PBF acts independently of FGF-2.  Increased hPTTG, PBF and FGF-2 expression were 
significantly correlated with reduced NIS expression in human thyroid cancers demonstrating 
the importance of these interactions in vivo (Boelaert et al. 2007).  Furthermore, our group 
have demonstrated a further mechanism of NIS regulation by PBF, whereby PBF modulates 
the internalisation of NIS from the basolateral membrane of thyroid follicular cells (Smith et 
al. 2009).  Subcellular localisation studies in COS-7 cells, demonstrated the redistribution of 
NIS from the plasma membrane into intracellular vesicles following over-expression of PBF.  
Reduced expression of NIS in the plasma membrane was confirmed in cell-surface 
biotinylation assays and coimmunoprecipitation and GST-pull-down experiments 
demonstrated a direct interaction between NIS and PBF.  I
-
 uptake studies were performed in 
FRTL-5 cells to demonstrate the functional consequence of this interaction.  Over-expression 
of WT PBF repressed iodide uptake by FRTL-5 cells by 39.4 ± 5 % (P<0.001) compared with 
VO control.  In contrast, over-expression of three deletion mutants of PBF, which do not 
localise within intracellular vesicles in COS-7 or FRTL-5 cells, lost the ability to inhibit NIS 
activity (Smith et al. 2009). 
 





Figure 1-21: PBF and hPTTG repress expression and activity of the sodium iodide 
symporter in human primary thyroid cultures.  A  TaqMan RT-PCR data demonstrating 
repression of NIS mRNA following over-expression of either PBF or hPTTG.  B    Iodide 
uptake assays were performed in 24-well plates, 48 h after transient transfection and 
demonstrate reduced uptake following PBF or hPTTG over-expression.  Data were adjusted 
for transfection efficiency, as assessed by β-gal staining (Figures A and B adapted from 
(Boelaert et al. 2007)).  C  In an alternative mechanism, PBF alters the subcellular 
localisation of NIS into intracellular vesicles. (i) Immunofluorescent detection of NIS-HA and 
endogenous PBF in cells transfected with NIS-HA and VO control. (ii) PBF over-expression 
is associated with an increase in NIS staining within intracellular vesicles. Scale bars: 20 
µM.  (Figure adapted from (Smith et al. 2009)).   
 
 Together, these findings suggest that over-expression of hPTTG and PBF in thyroid 
cancer (see sections 1.2.1.3 and 1.5.2) has serious implications for expression and activity of 
















therapy.  We have conducted further studies of these relationships reported in CHAPTER  and 
some of these results were recently published (Read et al. 2011).   
 
1.7 Hypothesis and aims 
The hypothesis that is paramount to the investigations described in this thesis is that 
hPTTG has a dual role in thyroid tumourigenesis.  In the first instance, hPTTG initiates 
tumourigenesis by causing aneuploidy and genetic instability through its role as a securin.  
Secondly, hPTTG promotes mitogenic and angiogenic mechanisms of tumour expansion 
through auto- and paracrine interactions with growth factors.  In addition, hPTTG negatively 
impacts upon efficacy of radiodine treatment through repression of NIS expression and 
function (see Figure 1-22). 
 Following on from previous studies demonstrating that hPTTG is a transforming gene 
over-expressed in thyroid tumours and is involved in the regulation of growth factors and 
NIS, we further explored this hypothesis under the following broad aims: 
 
1.  Work described in this thesis has sought to establish whether hPTTG is involved in 
autocrine mechanisms of interaction with the growth factors EGF, TGF-α and IGF-1, 
in thyroid cells in vitro.  Transient transfection studies and growth factor treatments 
were performed in thyroid cancer cell lines and human primary thyroid follicular cells. 
 
2. In order to directly test our dual hypothesis, we set out to generate a murine transgenic 
model with thyroid-targeted hPTTG over-expression (hPTTG-Tg mice).  Transgenic 
colonies were obtained following pronuclear injection of a DNA construct containing 
hPTTG under control of the bovine thyroglobulin promoter.   




3. Having obtained a transgenic colony of hPTTG-Tg mice, we sought to determine the 
effects of thyroidal hPTTG over-expression on thyroid cell growth and function 
through extensive characterisation studies including histological and thyroid function 
analysis, as well as primary murine thyroid cell cultures.     
 
4. In parallel studies, we aimed to determine gene expression alterations in hPTTG-Tg 
mice, including effects on growth factor induction by hPTTG in vivo, using gene-
specific TaqMan RT-PCR assays and ELISAs.  Angiogenesis-specific PCR cDNA 
arrays were performed to assess gene expression in hPTTG-Tg thyroid glands. 
 
5. Finally, we sought to challenge our group’s in vitro observations of NIS repression by 
hPTTG and PBF, through conducting in vivo studies in hPTTG-Tg and PBF-Tg mice.  
Importantly, we aimed to determine whether hPTTG and PBF represent novel 
therapeutic targets for enhancing treatment with radioiodine in thyroid disease.  
 





Figure 1-22: Schematic diagram illustrating the proposed model of thyroid tumourigenesis, 
including the major hypotheses investigated within this thesis.  hPTTG initiates tumourigenesis 
through induction of aneuploidy and genetic instability.  hPTTG contributes to tumour development 
through autocrine interactions with growth factors that promote proliferation and angiogenesis.  
hPTTG impairs 131I radioiodine ablation therapy through downregulation of NIS expression and 




















2 CHAPTER TWO 
 






















2.1 Cell lines 
Thyroid papillary carcinoma TPC-1 and anaplastic thyroid carcinoma SW1736 cells 
were kindly provided by Dr Rebecca Schweppe (Division of Endocrinology, Metabolism, & 
Diabetes, University of Colorado Denver, Aurora, Colorado), and thyroid papillary 
carcinoma K1 cells were obtained from the Health Protection Agency Culture Collections, 
UK.  All thyroid carcinoma cell lines were routinely cultured in RPMI 1640 (Life 
Technologies, Grand Island, NY, USA) supplemented with 10 % fetal bovine serum 
(Invitrogen; EU approved, South American origin), penicillin (10
5
 U/l) and streptomycin 
(100 mg/l) [Invitrogen].  Cells were passaged twice weekly.  
 
2.2 Thyroid samples and human primary thyroid culture 
Collection of thyroid specimens was with approval of the Local Research Ethics 
committee and following informed written consent from patients.  All tissues were surplus to 
pathological requirement. Human thyroid follicular cells were prepared from surgical 
specimens, and consisted mainly of multinodular goitres and normal thyroid tissue from the 
contralateral lobe, as previously described (Eggo et al. 1996; Eggo 1998; Ramsden et al. 
2001).  Thyroid tissue was digested by 0.2 % type II collagenase (Worthington 
Biochemicals).  Follicles were plated in 12-well plates in medium described previously by 
Ambesi-Impiombato et al. (Ambesiimpiombato et al. 1980), supplemented with thyrotrophin 
(300 mU/l) [Sigma], insulin (100 μg/l) [Sigma], penicillin (105 U/l), streptomycin (100 mg/l) 
and 5 % fetal calf serum. Serum was omitted after 72 hours of culture, and experiments were 
performed between days 7-11 of the culture.  Generally, these cultures survive and maintain 
function for more than 4 weeks and fibroblast as well as endothelial cell contamination is 
negligible under these conditions (Eggo 1998). 
 
 




2.3 Murine primary thyrocyte culture 
A method for mouse primary thyrocyte culture was adapted from a previously 
described approach (Jeker et al. 1999).  Thyroids from mice of different genotypes were 
aseptically dissected before being disrupted mechanically in PBS and digested in 0.2 % 
collagenase for 45 minutes at 37 ºC on a rotator.  Collagenase was inactivated by addition of 
culture medium and cells were centrifuged for 10 minutes at 700 g to obtain a pellet 
containing mainly single thyroid follicles.  After discarding the supernatant, the pellet was 
resuspended in 1 ml of culture medium and pipetted up and down until no fragments were 
macroscopically visible.  Cells from each thyroid (2 wells for each hPTTG-Tg or WT 
thyroid; 4 wells for each hPBF-Tg thyroid) were seeded into 12-well plates in medium 
described by Ambesi-Impiombato et al. (Ambesiimpiombato et al. 1980), supplemented with 
thyrotrophin (300 mU/l), insulin (10 mg/ml), transferrin (5 mg/ml) [Sigma], hydrocortisone 
(3.5 ng/ml) [Sigma], somatostatin (10 ng/ml) [Sigma], glycyl-L-histidyl-L-lysine acetate (2 
ng/ml) [Sigma],  penicillin (105 U/l), streptomycin (100 mg/l) and 5 % fetal calf serum.  
After 72 hours, serum was omitted and experiments were performed between days 7-14 of 
the culture.   
 
2.4 RNA extraction and reverse transcription 
 
 Total RNA was extracted from cells, utilising a single step acid guanidinium phenol-
chloroform extraction method [Tri-reagent (250 µl per well of a 12-well plate), Ambion, 
Austin, TX, USA] (Chomczynski and Sacchi 1987). Following manufacturer’s guidelines, 
chloroform (99+ %, 50 µl; Sigma-Aldrich, St. Louis, MO, USA) was added to each reaction, 
mixed thoroughly and left to stand at room temperature for 15 minutes before centrifugation 
at 12,000 g for 15 minutes at 4 ºC, which separates the mixture into 3 phases. The uppermost 
colourless aqueous phase containing RNA was transferred into a fresh tube and isopropanol 
(99+ %, 125 µl; Sigma-Aldrich, St. Louis, MO, USA) was added. After mixing, the sample 




was left to stand at room temperature for 5-10 minutes before centrifugation at 12,000 g for 
10 minutes at 4 ºC, which results in the formation of an RNA pellet at the bottom of the tube. 
The supernatant was discarded and the pellet washed in 75 % ethanol (250 µl) then 
centrifuged at 7500 g for 5 minutes at 4 ºC. The ethanol was discarded and the pellet dried at 
room temperature before elution in 30 µl of nuclease-free water and storage at -80 ºC. 
 Tissue samples from mouse organs excised for RNA studies were stored at -20 ºC in 
RNAlater RNA stabilisation reagent (Qiagen, UK).  Total RNA was extracted from up to 5 
mg of tissue using the RNeasy Microkit (Qiagen, UK), as per the manufacturer’s instructions.   
 500 nanograms of RNA (determined by spectroscopy at λ260 nm using a NanoDrop 
spectrometer (NanoDrop Products, Wilmington, DE, USA)) was reverse transcribed (RT) 
with avian myeloblastosis virus (AMV) reverse transcriptase in a total reaction volume of 10 
μl, with 5 pmol random hexamer primers, 1 μl 10 AMV reverse transcriptase buffer, 1 μl 
deoxynucleotide triphosphate (dNTP) mix (200 μM each), 10 units ribonuclease inhibitor 
(RNasin
™
) and 7.5 units AMV reverse transcriptase (All reagents from Promega, Madison, 
WI, USA). 
 
2.5  Quantitative polymerase chain reaction PCR (QT-PCR) 
Relative fold changes in expression of mRNAs encoding various proteins were 
calculated with control samples as a reference (given an arbitrary value of 1).  These 
experiments were performed using the ABI 7500 Sequence Detection System, which employs 
TaqMan
TM 
chemistry for highly accurate quantitation of mRNA levels (Wang and Brown 
1999). 
A fluorogenic TaqMan probe consists of an oligonucleotide with a 5’ reporter dye 
(FAM 6-carboxy-fluorescein or VIC) and a 3’ quencher dye (TAMRA 6-carboxy-
tetramethyl-rhodamine).  Fluorescent quenching of the reporter depends on the spatial 




proximity of its quencher.  PCR amplification releases the reporter into solution, away from 
its quencher, yielding a signal that can be read by a LASER and CCD camera.  One such 
event occurs for each PCR product generated, enabling real time detection of cDNA 
amplification.  Quantitative primers and probe were designed (Primer Express
TM
 software, 
PE Biosystems, USA) for a unique sequence of each gene ensuring that the PCR product 
spanned at least one exon boundary, and hence avoiding genomic DNA amplification.  
Alternatively, pre-optimised specific gene-expression assays for QT-PCR were purchased 
(Applied Biosystems, Warrington, UK).   
PCR was carried out in 25 µl volumes on 96 well plates, in a reaction buffer 
containing 1x TaqMan Universal PCR Master Mix (Applied Biosystems, Warrington, UK) [3 
mM Mg(OAc)2, 200 µM dNTPs, 1.25 units Ampli-Taq Gold polymerase, 1.25 units 
AmpErase UNG], 175 nM TaqMan probe and 900 nM primers with 1 µl of the RT reaction.  
All target gene probes were labelled with FAM, and the housekeeping genes, 18S and DS-
CAM, with VIC.  All reactions were multiplexed where possible.  For specific gene-
expression assays that were not validated for multiplexing, reactions were singleplexed.  The 
18S primers and probe are provided as a pre-optimised control system (Applied Biosystems, 
Warrington, UK), enabling data to be expressed in relation to an internal reference, to allow 
for differences in RT efficiency.  Reactions were as follows: 50 °C for 2 minutes, 95 °C for 
10 minutes; then 44 cycles of 95 °C for 15 seconds and 60 °C for 1 minute.   
As per the manufacturer’s guidelines, data were expressed as Ct values (the cycle 
number at which logarithmic PCR plots cross a calculated threshold line) and used to 
determine ΔCt values (ΔCt = Ct of the target gene minus Ct of the housekeeping gene 18S).  
Measurements were carried out in duplicate for each sample.  The fold change of mRNA in 
an experimental group compared to the control group is calculated using the equation fold 
change = 2








2.6 Western blot analysis 
 
Proteins were prepared from thyroid tissues in lysis buffer (100 mmol/L sodium 
chloride, 0.1 % Triton X-100, and 50 mmol/L Tris, pH 8.3) containing enzyme inhibitors (1 
mmol/L phenylmethylsulphonylfluoride, 0·3 µmol/L aprotinin, and 0·4 mmol/L leupeptin).  
Protein concentration was determined using the BCA Protein Assay kit (Thermo-Fisher 
Scientific, Rockford, IL, USA) with bovine serum albumin standards.  10-60 µg of protein 
was denatured in 4 x laemlli buffer (Bio-Rad, Hertfordshire, UK) for 5 minutes at 95 ºC.    
Western blot analyses were performed as we have described previously (Boelaert et 
al. 2003a; Kim et al. 2005; Smith et al. 2009).  Soluble proteins (10-60 µg) were separated by 
electrophoresis in 12.5 % sodium dodedecyl sulphate polyacrylamide gels, transferred to 
polyvinylidene fluoride membranes, incubated in 5 % non-fat milk in tris-buffered saline 
with 0.1 % Tween, followed by incubation with appropriate primary antibodies for 16 hours 
at 4 °C.  After washing in tris-buffered saline plus 0·1 % Tween, blots were incubated with 
appropriate secondary antibodies conjugated to horseradish peroxidase for 1 hour at room 
temperature.  After further washes, antigen-antibody complexes were visualised by the ECL 
plus and ECl advance chemiluminescence detection systems (GE Healthcare, UK) on x-ray 
film (Kodak, UK).  Actin expression was determined in all Western blot analyses 
(monoclonal anti-β-Actin Clone AC-15 (Sigma-Aldrich), used at 1:10 000) to assess potential 
differences in protein loading.  Scanning densitometry studies were performed to quantify 




Formalin-fixed, paraffin-embedded sections of wild-type and PTTG-Tg mouse thyroid 
specimens were immunostained using an avidin-biotin peroxidise technique (Vectastain Elite; 




Vector Laboratories, Peterborough,UK). All reagents were prepared according to the kit 
instructions. 
Briefly, the slides were dewaxed in Histoclear and rehydrated in an ethanol 
concentration gradient. After washing in 20 mm Tris/0.15 m sodium chloride with 0.3 % 
Tween 20 (pH 7.4) (TBS-T), slides were incubated in 1 mg/ml hyaluronidase in 0.1 m 
sodium acetate (pH 5.5) at 37 ºC for 30 minutes, washed, and then incubated in 0.03 % 
hydrogen peroxide in 20 mM Tris/0.15 M sodium chloride (pH 7.4) to block endogenous 
peroxidase activity. Slides were then blocked in 5 % normal goat serum (NGS) in TBS-T for 
30 minutes in a humidity chamber before being incubated with primary antibody in blocking 
buffer for 16 hours at 4 ºC in a humidity chamber. For negative controls, the primary 
antibody was replaced by 10 % normal goat serum. After three 5-minute washes in TBS-T, 
the sections were incubated in biotinylated anti-rabbit antibody for 30 minutes at room 
temperature, followed, after additional TBS-T washes, by addition of the avidin-biotin-
peroxidase complex. The reaction was developed using the DAB peroxidise substrate kit for 
5-10 minutes and then counterstained in Mayer’s hematoxylin. Slides were dehydrated, 
cleared, and mounted.  Immunostained thyroid tissue sections were viewed under a light-
microscope (Zeiss) and images captured using Axiovision software (Version 4).   
 
2.8 Statistical analysis 
 
Data were analysed using Sigma Stat and SPSS version 11.5 software (SPSS Science 
Software UK Ltd, Birmingham UK).  Distributions of data were determined using the 
Kolmogorov-Smirnov test.  Student’s t-test and the Mann Whitney U test were used for 
comparison between two groups of parametric and non-parametric data respectively.  
Analysis of Variance (ANOVA) and Kruskal-Wallis tests were used for between-group 
comparisons of multiple groups of parametric and non-parametric data respectively.  The 




combined effects of mouse genotypes and time on body weight changes were analyzed using 
a two-way ANOVA with repeated measurements over time.  Correlations between pairs of 
mRNA results were examined using Spearman rank correlation.  Scanning densitometry data 
with fewer than five data points were assumed to be Gaussian following use of the Anderson-
Darling test, and subsequently subject to analysis by student’s t-test or ANOVA for 
comparison between two groups or multiple groups of data respectively.    Kaplan-Meier 
mouse survival analysis was performed using the XLSTAT add-on to Microsoft Excel.  The 
log-rank (Mantel-Cox) test was used to compare the survival distribution of two sample sets 













3 CHAPTER THREE 
 

























hPTTG is expressed at low levels in most normal adult tissues but over-expression of 
hPTTG has been described in numerous primary tumours and neoplasms (see section 
1.2.1.2). 
hPTTG over-expression in thyroid disease was first described in a relatively small 
study, where Northern blot analysis revealed an abundance of hPTTG in a subset of 
specimens of thyroid hyperplasia, follicular adenomas and follicular carcinomas, with no 
increased expression evident in papillary cancers (Heaney et al. 2001).  Furthermore, TSH 
treatment of rat FRTL5 thyroid cells and human thyroid cells in primary culture, was reported 
to induce hPTTG expression in vitro, consistent with a role for hPTTG in controlling thyroid 
cell growth (Heaney et al. 2001).  A further study conducted by our own group used highly 
accurate quantitative RT-PCR to demonstrate an approximately 2-fold increase in hPTTG 
mRNA expression in hyperplastic thyroid conditions (n = 38) and a striking 9.5-fold 
induction in pretranslational hPTTG expression in differentiated thyroid cancers (n = 27).  In 
contrast to the study by Heaney et al., no difference in hPTTG expression was detected when 
comparing follicular and papillary carcinomas (Boelaert et al. 2003a).   
hPTTG over-expression is associated with inappropriate cell divison, cell 
transformation and transactivation of other genes that have critical roles in tumourigenesis 
(see sections 1.3 and 1.4).  Furthermore, hPTTG represses NIS mRNA expression in thyroid 
cells leading to reduced iodide uptake (Boelaert et al. 2007), an effect which has significant 
consequences for the treatment of thyroid cancer with radioiodine.  Based on the current 
evidence, hPTTG over-expression may have significant implications in the progression and 
treatment of thyroid cancer.  Thus far, no mutations have been discovered in either the coding 
or non-coding regions of hPTTG (Zhang et al. 1999b; Kanakis et al. 2003) and there is 
insufficient explanation for hPTTG over-expression in tumour tissues.  Whilst the regulation 




of hPTTG has not been clarified completely, hormones such as oestrogen (Heaney et al. 
1999; Kakar and Jennes 1999; Heaney et al. 2002), TSH (Heaney et al. 2001) and insulin 
(Chamaon et al. 2005; Thompson and Kakar 2005) have been implicated (see section 
1.2.1.4).  Furthermore, there is increasing evidence that hPTTG expression is regulated by a 
number of growth factors.   
 One study described over-expression of hPTTG in astrocytomas and subsequently 
demonstrated hPTTG induction by the EGFR ligands, EGF and TGF-α, in xenotransplantable 
U87 human glioma cells.  This effect was abrogated by treatment with the specific EGFR 
inhibitor, AG1478.  The c-met ligand, HGF, also induced hPTTG expression but to a lesser 
extent (Tfelt-Hansen et al. 2004).   
 A subsequent study demonstrated similar regulation of hPTTG by EGF and TGF-α in 
pituitary folliculostellate TtT-GF cells.  Once again, these effects were blocked following 
inhibition of EGFR, by treatment with either AG1478 or gefitinib.  Rapid phosphorylation of 
EGFR and subsequent activation of the MAP-Kinase and PI3-Kinase pathways were 
demonstrated following treatment with EGF and TGF-α, suggesting that these pathways are 
important in hPTTG regulation.  EGF induction of hPTTG was cell-cycle dependent where 
its expression peaked at the S-G2 transition and the effect was absent following early S-phase 
blockade (Vlotides et al. 2006).   
 IGF-1 has been shown to regulate hPTTG expression in human breast cancer MCF-7 
cells (Thompson and Kakar 2005) and in malignant and non-malignant astrocytes (Chamaon 
et al. 2005).  In both studies, hPTTG induction by IGF-1 was partially or completely blocked 
by treatment with either of the specific PI3-Kinase inhibitors, LY294002 and Wortmannin, or 
the specific MAP-Kinase inhibitor PD98059.  Interestingly, the latter study demonstrated a 
direct interaction between both kinases and endogenous hPTTG in both malignant astrocytes 
and non-tumourous cells.  In addition to enhancement of hPTTG transcription following 




treatment with IGF-1, it was suggested that a second and more direct route of hPTTG 
regulation may be mediated via direct binding of either kinase (Chamaon et al. 2005).   
 The induction of hPTTG expression by FGF-2 (see section 1.2.1.4.2) has been 
demonstrated in NIH3T3 cells (Heaney et al. 1999) and in primary cultures of uterine 
leiomyomas, benign tumours of myometrial smooth muscle tissue (Tsai et al. 2005).  
The transcription factor SP1 is well established as a critical regulator of hPTTG 
expression (Pei 1998; Kakar and Jennes 1999; Wang and Melmed 2000b; Clem et al. 2003; 
Zhou et al. 2003), where mutation of the SP1 binding site in the hPTTG promoter resulted in 
70 % reduced overall promoter activity (Clem et al. 2003).  A recent study described reduced 
hPTTG, FGF-2 and VEGF expression in various thyroid cancer cell lines treated with drugs 
inhibiting SP1 (Chintharlapalli et al. 2011) and VEGF expression was upregulated following 
phosphorylation of SP1 by MAP-Kinase and PI3-Kinase (Milanini-Mongiat et al. 2002; Pore 
et al. 2004).   
hPTTG expression is cell-cycle dependent and it is most abundant during G2/M-phase 
where it is reportedly phosphorylated by the kinase CDC2 at the Ser-165 residue (Zou et al. 
1999; Yu et al. 2000b; Ramos-Morales et al. 2000).  While hPTTG expression is upregulated 
during mitosis, the observation that over-expression of hPTTG in differentiated thyroid 
cancer did not correlate with expression of the proliferation marker, PCNA, suggests that 
hPTTG over-expression is at least partly independent of increased mitotic rates (Boelaert et 
al. 2003a). 
   Collectively, these studies suggest that hPTTG is induced by a number of mitogenic 
factors via complex pathways involving activation of multiple kinases, transcription factors 
and cell-cycle regulators.  The aim of this study was to assess whether hPTTG expression is 
regulated by growth factors in thyroid cells as part of the investigation of our hypothesis that 
hPTTG and growth factors are involved in autocrine and paracrine mechanisms of regulation 




that may be aberrantly controlled in thyroid tumours.  Malignant thyroid cell lines and human 
primary thyrocytes were treated with various growth factors and potential mechanisms of 
hPTTG regulation were investigated through use of specific inhibitors and siRNA 
knockdown studies.   
 
3.2 Materials and Methods 
 
3.2.1 Cell lines and treatment with growth factors and inhibitors 
 
Human thyroid papillary carcinoma TPC-1 and K1 cells, and human anaplastic thyroid 
carcinoma SW1736 cell lines, were routinely cultured as described in section 2.1.  For 
treatment experiments with growth factors, TPC-1, K1 and SW1736 cells were seeded in six-
well plates at a density of 9 x 10
4
, 1.3 x 10
5
 and 1.2 x 10
5 
cells/well respectively.  After 24 
hours, media was replaced with serum free media for a further 24 hours to obtain 
synchronised cells.  In the first instance, preliminary dose-response and timecourse 
experiments were performed in synchronised K1 cells as described in section 3.3.3.1.  
Subsequently, synchronised TPC-1, K1 and SW1736 cells were incubated with EGF (5 nM), 
TGF-α (5 nM) [Sigma-Aldrich, UK], IGF-1 (10 ng/ml) or FGF-2 (5 nM) [Peprotech, UK] 
with or without PD98059 (30 µM), Wortmannin (50 nM) or LY294002 (50 µM) 
[Calbiochem, La Jolla, CA].  Concentrations of inhibitors were determined from the literature 
(Thompson and Kakar 2005; Chamaon et al. 2005).  Cells were harvested in protein lysis 
buffer at the times indicated.  
 
3.2.2 siRNA transfection studies 
 
TPC-1 cells were transfected with siRNAs targeting SP1 (60 nM # S13318) or CDC2 
(30 nM # S464) transcripts and controlled for by equivalent scrambled (# AM4635) siRNA 
transfections (Life Technologies, Grand Island, NY, USA).  All siRNA transfections were 




performed using the siPORT™ NeoFX™ Transfection Agent (Life Technologies, Grand 
Island, NY, USA) according to the manufacturer’s instructions.  24 hours post-transfection, 
cells were synchronised and treated with growth factors as described above (see section 
3.2.1), or with anisomycin (100 µM) for 8 hours (Sigma-Aldrich, UK).  Cells were harvested 
in protein lysis buffer or 0.5 ml Tri Reagent (Life Technologies, Grand Island, NY, USA).   
 
3.2.3 Thyroid samples, human primary thyroid culture and transfections 
 
Collection of thyroid samples was with approval of the Local Research Ethics 
committee and thyroid cells were cultured as described in section 2.2.  All serum, insulin and 
TSH was removed from human primary thyrocytes for at least 24 hours before treatment with 
growth factors or inhibitors, which were performed as described above in section 3.2.1. 
Human primary thyrocytes were transfected with 1 µg DNA/well using FuGENE-6 
Transfection Reagent (Roche, Indianapolis, IN, USA), with an optimised ratio of 6 µl per 1 
µg plasmid DNA using either pCI-neo-hPTTG or equal amounts of blank plasmid (vector-
only, VO, control).  In siRNA studies, human primary thyrocytes were transfected with a 
specific CDC2 siRNA (60 nM) and controlled for by equivalent scrambled siRNA 
transfections (see section 3.2.2) using the lipofectamine-2000 transfection agent (Invitrogen, 
UK) according to the manufacturer’s instructions.   
 
3.2.4 RNA extraction, reverse transcription, QT-PCR 
 
Total RNA was extracted from TPC-1, K1, SW1736 cells and human primary 
thyrocytes as described in section 2.4.  Reverse transcription and QT-PCR techniques were as 
described above (see sections 2.4 and 2.5).  Primers and probes for hPTTG mRNA detection 
were designed as described above (see section 2.5) and the sequences are given in Table 3-1.  




Gene-specific expression assays for EGFR (Hs01076078_m1), IGF1R (Hs00609566_m1) 
and FGFR1 (Hs00915142_m1) were purchased from Applied Biosystems (Warrington, UK).  
 
Table 3-1:  Oligonuleotide sequences of PCR primers and TaqMan probe used to detect hPTTG 
mRNA expression. All TaqMan primers run at 59°C and yield amplicons of 70-150bp.   
 
 
3.2.5 Western blot analysis 
 
Protein extraction, quantification and subsequent Western blotting methods were as 
described previously (see section 2.6).  Blocked membranes were subsequently incubated 
with primary antibodies against hPTTG (2 µg/ml) [Invitrogen, UK], CDC-2 (1:1000), SP1 
(1:500), phospho-P44/42 ERK1/2 (1:1000) and phospho-AKT (1:1000) [Cell Signalling 
Technology, Boston, MA, USA].  After washing in TBS-T, blots were incubated with 
appropriate secondary antibodies conjugated to horseradish peroxidise (Dakocytomation, 
UK) for 1 hour at room temperature before being visualised by techniques described in 
section 2.6.   
 
3.2.6 MTT cell viability assays 
 
The rate of cellular proliferation of synchronised TPC-1 cells treated with growth 
factors was assessed by internalisation and reduction of 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT).  Cells were seeded in 96-well plates, synchronised and 
treated with growth factors as described above (see sections 3.2.1 and 3.2.2).  Cells were 
incubated with 0.8 mg/ml MTT (Sigma-Aldrich, UK) for the last 3 hours of culture 
incubation.  Cells were then washed with cold PBS before formazan crystals were solubilised 
Sequence Name Sequence 
hPTTG Probe CGTCTTGCCACCGGCTTCCCT 
hPTTG Forward Primer GAGAGAGCTTGAAAAGCTGTTTCAG 
hPTTG Reverse Primer TCCAGGGTCGACAGAATGCT 




by addition of 100 µl dimethyl sulfoxide for 15 minutes.  The absorbance at 540 nm was 
measured using a Wallac 1420 Victor plate-reader (Perkin-Elmer, Massachusetts, USA).   
 
3.2.7 Statistical analysis 
 




3.3.1 Endogenous hPTTG expression in thyroid cells 
 
To predict whether hPTTG is regulated by growth factors in thyroid cells, we first 
analysed the endogenous expression levels of hPTTG and growth factor receptors (see 
section 3.3.2) in human primary thyrocytes, TPC-1 and K1 thyroid papillary carcinoma cells 
and in SW-1736 anaplastic thyroid carcinoma cells.  Real-Time PCR analysis revealed a 8.1-, 
11.9- and 25.5-fold increased expression of hPTTG mRNA in TPC-1 (n = 4, p < 0.001), K1 
(n = 4, p < 0.001) and SW1736 (n = 4, p < 0.001) cells respectively, compared with normal 
human primary thyrocytes (n = 12).  SW1736 cells had significantly higher expression of 
hPTTG mRNA compared with TPC-1 (p < 0.01) but not K1 cells.  Western blot analysis 
confirmed hPTTG protein over-expression in transformed cell lines compared with normal 
human primary thyrocytes, where expression was heterogeneous but at generally low levels.  
Further Western blot analysis using a lower length of exposure was performed to determine 
the relative levels of hPTTG protein in thyroid cancer cell lines.  TPC-1 cells had the lowest 
levels of over-expression of hPTTG protein; K1 cells had moderate over-expression of 
hPTTG protein; and SW1736 cells had very strong over-expression of hPTTG protein.  These 
results are indicative of higher levels of hPTTG expression in cells derived from a more 
aggressive tumour type (see Figure 3-1).   





Figure 3-1: Endogenous expression of hPTTG in human primary thyrocytes, TPC-1, K1 
and SW1736 cell lines. A  Endogenous hPTTG mRNA expression levels in thyroid cells, 
determined by TaqMan RT-PCR using hPTTG-specific primers and probes.  In this and 
following histograms, gene expression is displayed relative to a value of 1.0 for human 
primary thyrocytes (normal thyroid cells). The number of samples used for each group are 
given in the corresponding columns in the table underneath the graph.  Error bars represent 
the standard error of the mean (SEM) (** p < 0.01, *** p < 0.001, NS = non-significant).  B  
Endogenous hPTTG protein expression levels in thyroid cells, determined by Western blot 
analysis, demonstrating strong over-expression of hPTTG in thyroid cancer cell lines 
compared to low heterogeneous expression in normal human primary thyrocytes.  C  Lower 
exposure Western blot analysis demonstrating relative hPTTG expression levels in thyroid 
cancer cell lines.   
 
 
3.3.2 Growth factor receptor expression in thyroid cells 
 
EGFR, IGF1R and FGFR1 are growth factor receptors that have been implicated in 
thyroid malignancies and in facilitating signalling by growth factors that regulate hPTTG 
(Chamaon et al. 2005; Tfelt-Hansen et al. 2004; Thompson and Kakar 2005; Heaney et al. 
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al. 1999; St Bernard et al. 2005; Cocks et al. 2003).  The mRNA expression of these growth 
factor receptors was analysed in thyroid cell lines and compared to expression levels in 
normal human primary thyrocytes (n = 12) to determine responsiveness of these cell types to 
treatment with growth factors.  EGFR mRNA was over-expressed 1.75-, 2.38- and 3.08-fold 
in TPC-1 (n = 4, p = NS), K1 (n = 4, p = 0.05) and SW1736 (n = 4, p < 0.01) cells 
respectively.  IGF1R was expressed in transformed thyroid cell lines but showed a 0.45-, 
0.23- and 0.45-fold reduction of mRNA expression in TPC-1 (n = 4, p < 0.05), K1 (n = 4, p < 
0.001) and SW1736 (n = 4, p < 0.05) cells respectively, when compared with primary cells.  
FGFR1 mRNA was over-expressed 5.86-, 6.53- and 5.24-fold in TPC-1 (n = 4, p < 0.05), K1 
(n = 4, p < 0.05) and SW1736 (n = 4, p < 0.05) cells respectively, compared to normal human 
primary thyrocytes (n = 12) (see Figure 3-2). 





Figure 3-2: Histograms displaying endogenous mRNA expression of growth factor receptors in 
human primary thyrocytes, TPC-1, K1 and SW1736 cell lines, determined by TaqMan RT-PCR. A  
EGF-R mRNA expression in thyroid cells, showing significant over-expression in K1 and SW1736 
thyroid cancer cell lines.  B  IGF1R mRNA expression in thyroid cells, showing significantly reduced 
expression in thyroid cancer lines. C FGF-R1 mRNA expression in thyroid cells, showing significant 
over-expression in thyroid cancer cell lines.  Error bars represent the SEM (* p < 0.05, ** p < 0.01, 
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3.3.3 hPTTG regulation by growth factors in thyroid cells 
Having determined expression levels of hPTTG and growth factor receptors in those 
thyroid cells being tested, we investigated the regulation of hPTTG protein expression 
following treatment with either EGF, TGF-α (EGFR ligands), IGF-1 (IGF1R ligand) or FGF-
2 (FGFR1 ligand).  
 
3.3.3.1 Preliminary time-course and dose-response experiments  
  In the first instance, time-course and dose-response experiments were performed in 
K1 cells to determine the optimal duration of treatment time and growth factor concentration.  
For dose-response experiments, synchronised K1 cells were incubated with varying growth 
factor concentrations for 24 hours.  hPTTG protein was induced in a dose-dependent manner 
by EGF and TGF-α (0.5, 5 and 50 nM) peaking with a dose of 5 nM, and no further induction 
was observed following treatment with 50 nM doses.  Similarly, IGF-1 (1, 10 and 100 
ng/mL) induced hPTTG protein in a dose-dependent manner but hPTTG protein expression 
was only marginally increased with the higher 100 ng/mL dose compared to treatment with 
10ng/mL.  All concentrations of FGF-2 (0.5, 5 and 50 nM) caused a mild induction of 
hPTTG protein.  Subsequently, the most relevant doses for each growth factor were decided 
to be 5 nM EGF, 5 nM TGF-α, 10 ng/mL IGF-1 and 5 nM FGF-2, based on the responses 
observed (see Figure 3-3 A). 
 In timecourse experiments, treatment of K1 cells with the doses of growth factor 
decided above caused no response at 0-12 hours, but there was evidence of hPTTG protein 
induction at 24-36 hours, with maximal growth factor induced hPTTG expression observed at 
24 hours (see Figure 3-3 B).   
 





Figure 3-3: Preliminary dose-response and timecourse treatments of K1 cells with growth 
factors.  A  Western blot analyses demonstrating hPTTG regulation by different doses of EGF [0.5, 
5.0, 50 nM] (i), TGF- α [0.5, 5.0, 50.0 nM] (ii), IGF-1 [1.0, 10.0, 100.0 ng/mL] (iii) and FGF-
2 [0.5, 5.0, 50.0 nM](iv).  B  Western blot analyses demonstrating regulation of hPTTG by 5 
nM EGF, 5 nM TGF-α, 10 ng/mL IGF-1 and 5 nM FGF-2 at 0 (i), 12 (ii), 24 (iii) and 36 
hours (iv).  UT = untreated, V = vehicle treated.   
 
 
3.3.3.2 hPTTG regulation by growth factors in presence and absence of inhibitors 
 
Having determined appropriate treatment times and doses, synchronised thyroid cells 
(TPC-1, K1, SW1736, human primary thyrocytes) were incubated with either 5 nM EGF, 5 
nM TGF-α, 10 ng/ml IGF-1 or 5 nM FGF-2 for the duration of 24 hours.  Western blot 
analysis and scanning densitometry studies were performed to determine hPTTG protein 
expression in GF-treated cells compared to vehicle-only treated cells.  Treatment with 5 nM 
EGF induced hPTTG protein expression in human primary thyrocytes (3.2-fold, n = 3, p ˂ 
0.05), TPC-1 cells (6.4-fold, n = 5, p ˂ 0.001), K1 cells (3.2-fold, n = 5, p ˂ 0.001) and in 
SW1736 cells (1.7-fold, n = 3, p = NS).  Similarly, 5 nM TGF-α treatments induced 3.5-, 6.9-
, 3.8- and 1.5-fold elevation of hPTTG protein expression in human primary thyrocytes (n = 
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= 3, p = NS), respectively.  For all cell types except SW1736 cells (where hPTTG was not 
significantly induced by EGFR ligands) these effects were abrogated upon addition of the 
MAP-Kinase-specific inhibitor PD98059 (30 µM) (see Figure 3-4). 
 
Figure 3-4:   Induction of hPTTG protein expression following treatment of thyroid cells with growth 
factors ± inhibitors.  A Representative Western blot analyses demonstrating hPTTG protein 
expression following treatment with EGF (5 nM) and TGF-α (5 nM) ± PD98059 (30 µM), for 24 
hours, in synchronised human primary thyrocytes (i), TPC-1 (ii), K1 (iii)  and SW1736 cell lines (iv).  
B  Scanning densitometry studies demonstrate hPTTG protein expression levels given as a value 
relative to 1.0 for vehicle only control treatments, ± SEM.  Results are based on ≥ 3 separate 
experiments.  (* p < 0.05, ** p < 0.01, *** p < 0.001, NS = non-significant).    
 
Treatment with 10 ng/ml IGF-1 caused a 1.9-, 4.2-, 2.2- and 1.7-fold upregulation of 
hPTTG protein expression in human primary thyrocytes (n = 3, p < 0.05), TPC-1 cells (n = 4, 
p < 0.01), K1 cells (n = 4, p < 0.01) and SW1736 cells (n = 3, p = NS) respectively.  In all 
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cell types except SW1736 cells, hPTTG induction by IGF-1 was abrogated by treatment with 
either of two PI3-Kinase specific inhibitors, Wortmannin (50 nM) or LY294002 (50 µM).  
Treatment with 5 nM FGF-2 had no effect on hPTTG protein expression in human primary 
thyrocytes (1.2-fold, n = 3, p = NS), K1 cells (1.4-fold, n = 3, p = NS) or SW1736 cells (1.5-
fold, n = 3, p = NS), but resulted in a striking 8.8-fold induction in TPC-1 cells (n = 3, p < 
0.001).  This effect was not investigated further due to the inconsistent responses 
demonstrated between different thyroid cell types (see Figure 3-5). 
 
Figure 3-5: Induction of hPTTG protein expression following treatment of thyroid cells with 
growth factors ± inhibitors.  A  Representative Western blot analyses demonstrating hPTTG protein 
expression following treatment with IGF-1 (10 ng/mL) ± LY294002 (50 µM) or Wortmannin (50 nM) 
and FGF-2 (5 nM), for 24 hours, in synchronised human primary thyrocytes (i), TPC-1 (ii), K1 (iii) 
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levels given as a value relative to 1.0 for vehicle only control treatments, ± SEM.  Results are based 
on ≥ 3 separate experiments.  (* p < 0.05, ** p < 0.01, *** p < 0.001, NS = non-significant). 
 
Notably, treatment with growth factors resulted in increased expression of both 
unphosphorylated and phosphorylated hPTTG, where the heavier upper band of the doublet 
represents phosphorylated hPTTG (Ramos-Morales et al. 2000).  Together these results 
provide evidence that hPTTG protein expression and phosphorylation is upregulated in 
thyroid cells via the MAP-Kinase and PI3-Kinase pathways, following activation of the EGF-
Receptor and the IGF1-Receptor respectively.   
 
3.3.4 Confirmation of MAP-kinase and PI3-kinase activation by treatment with 
growth factors 
 
To confirm activation of the MAP-kinase and PI3-kinase pathways in response to 
growth factor treatment, we analysed phospho-P44/42 ERK1/2 and phospho-AKT expression 
10, 30 and 90 minutes following treatment in TPC-1, K1 and SW1736 cells (Vlotides et al. 
2006).  Treatment with EGF (5 nM) or TGF-α (5 nM) stimulated ERK-phosphorylation from 
10 minutes post-treatment and was sustained throughout the timecourse.  Furthermore, there 
was significant activation of the PI3-kinase pathway as evidenced by increased p-AKT 
expression.  These effects were partially or completely abrogated following pre-incubation 
with PD98059 (30 µM).  Similarly, treatment with IGF-1 (10 ng/mL) resulted in the AKT-
phosphorylation after 10 minutes that was sustained throughout the experiment.  Once again, 
increased p-ERK expression was indicative of MAP-kinase pathway activation following 
IGF-1 treatment.  These effects were partially or completely abrogated following pre-
incubation with LY294002 (50 µM) (see Figure 3-6). 





Figure 3-6: Western blot analyses confirming MAP-kinase and PI3-kinase activation in thyroid 
cell lines following treatment with EGF, TGF-α and IGF-1.  A-C, Western blot analyses of timecourse 
experiment showing detection of phospho-P44/42 ERK1/2 and phospho-AKT in TPC-1 (A), K1 (B) 
and SW1736(C) cells following treatment with EGF (5 nM) and TGF-α (5 nM) ± PD98059 (30 µM) 
(i) or IGF-1 (10 ng/mL) ± LY249002 (50 µM) (ii) at early time-points of 10, 30 and 90 minutes.  V = 
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3.3.5 Regulation of hPTTG by growth factors is independent of SP1 and CDC2 
 
Given the reported roles of the transcription factor SP1 and the kinase CDC2 (CDK1) 
in the regulation of hPTTG expression and phosphorylation respectively (Clem et al. 2003; 
Ramos-Morales et al. 2000), we set out to investigate the potential involvement of these 
proteins in the mechanism of hPTTG regulation by growth factors in thyroid cells.  TPC-1 
cells were chosen for these studies as they were the most responsive to treatment with growth 
factors and were consistently amenable to transfection.  Growth factor treatments of TPC-1 
cells were repeated following knockdown of SP1 and CDC2 transcripts.  hPTTG protein 
expression was determined following successful SP1 and CDC2 knockdown through Western 
blotting and scanning densitometry.  As expected, we observed a strong induction of hPTTG 
protein expression by either EGF (2.7-fold, n = 4, p < 0.05) or TGF-α (3.1-fold, n = 4, p < 
0.01) following transfection with scrambled siRNA.  Basal levels of hPTTG protein in 
vehicle treated cells showed a marked 0.27-fold reduction in expression following SP1 
knockdown (n = 4, p < 0.05) compared to scrambled controls (n = 4), consistent with a role 
for SP1 in regulating basal hPTTG expression.  Nonetheless, even with depleted SP1 levels, 
hPTTG protein expression was induced following treatment with EGF (4.6-fold, n = 4, p < 
0.01) and TGF-α (5.2-fold, n = 4, p < 0.01) compared with vehicle treated controls (n = 4) 
(see Figure 3-7). 





Figure 3-7: hPTTG regulation by growth factors is independent of SP1. A  Western blot analysis 
demonstrating persistent regulation of hPTTG by growth factors when SP1 levels are depleted in 
TPC-1 cells.  B  Scanning densitometry studies demonstrating hPTTG protein expression levels 
relative to a value of 1.0 for vehicle treated scrambled only controls, ± SEM.  Results are based on n 
= 4 repeats of the described experiment.  (* p < 0.05, ** p < 0.01).  V = vehicle.   
 
CDC2 siRNA transfections resulted in successful knockdown of CDC2 expression, 
determined by Western blot analysis at the time of treatment and the time of termination.  As 
expected, there was a strong induction of both unphosphorylated and phosphorylated hPTTG 
by growth factors in cells transfected with a scrambled siRNA control and treated with 5nM 
EGF (3.7-fold, n = 3, p < 0.05).  Interestingly, when CDC2 expression was repressed, basal 
levels of hPTTG expression in vehicle treated cells were strikingly induced in comparison to 
scrambled controls (9.9-fold, n = 4, p < 0.05).  However, treatment with EGF resulted in 
further induction of hPTTG expression (13.8-fold, n = 3, p = NS), compared with vehicle 
























































Figure 3-8: hPTTG regulation by growth factors is independent of CDC2.  A  Western blot 
analysis demonstrating successful knockdown of CDC2 protein throughout the duration of the 
experiment.  B  Representative Western blot analysis demonstrating successful knockdown of CDC2, 
causing a generic increase in hPTTG expression and phosphorylation that is further enhanced upon 
addition of EGF in TPC-1 cells.  C  Scanning densitometry studies demonstrating hPTTG protein 
expression levels relative to a value of 1.0 for vehicle treated scrambled only controls, ± SEM.  
Results are based on n = 3 repeats of the described experiment.  (* p < 0.05, NS = non-significant).  
V = vehicle.     
 
 
3.3.6 CDC2 regulates expression and phosphorylation of hPTTG 
 
The observation that repression of CDC2 results in increased levels of hPTTG implies 
that CDC2 is a key regulator of hPTTG expression and we investigated this further.  Firstly, 
we confirmed that knockdown of CDC2 results in increased hPTTG expression in both TPC-
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(see Figure 3-9).  To clearly demonstrate that CDC2 depletion results in upregulation of both 
phosphorylated and unphosphorylated hPTTG we used primary thyrocytes transfected with 
WT or Phos- hPTTG (which cannot be phosphorylated) as controls.  The lack of the heavier 
band following transfection with Phos- hPTTG clearly illustrates that this band represents a 
phosphorylated form of hPTTG.  This band migrates more slowly due to the increased 
molecular mass caused by an additional phosphate group (PSO43-), where the additional 
negative charge is negated by use of SDS (see Figure 3-9 A.i.).   
 
Figure 3-9: CDC2 regulates expression and phosphorylation of hPTTG.  A+B  Representative 
Western blot analyses and scanning densitometry confirming an increase in hPTTG expression and 
phosphorylation following repression of CDC2 in TPC-1 cells (A i-ii) and human primary thyrocytes 
(B i-ii).  Scanning densitometry studies demonstrate hPTTG protein expression levels relative to a 
value of 1.0 for scrambled only transfection controls, ± SEM.  Results are based on n ≥ 3 repeats of 
the described experiment.  (* p < 0.05, ** p < 0.01).  P+ hPTTG = Phosphorylated hPTTG, P- 
hPTTG = Unphosphorylated hPTTG.   
 
We employed two approaches to investigate whether the regulation of hPTTG by 
CDC2 is due to transcriptional or post-translational events.  Firstly, we performed CDC2 
knockdown experiments in TPC-1 cells followed by treatment with anisomycin (100 µM) to 
inhibit translation 36 hours post-transfection.  Western blot analysis demonstrated that the 
upregulation of hPTTG caused by repression of CDC2 is abrogated upon the addition of 




























































































Real-Time PCR analysis revealed that hPTTG mRNA expression was significantly 
upregulated (1.7-fold, n = 8, p < 0.01) when CDC2 was depleted, providing further evidence 
that CDC2 is a criticial mediator of hPTTG transcription (see Figure 3-10).   
 
Figure 3-10: CDC2 regulates transcription of hPTTG.  A  Representative Western blot analysis 
demonstrating that hPTTG upregulation following CDC2 repression is inhibited by treatment with 
anisomycin (100 µM), implicating this as a transcriptional effect.  B  Consistent with this, TaqMan 
RT-PCR analysis confirmed that hPTTG mRNA expression was induced following CDC2 repression.  
hPTTG mRNA expression is given as value relative to 1.0 for scrambled only transfection controls.  N 
= 3 experiments.  Error bars represent the SEM (** p < 0.01).   
 
 
3.3.7 Upregulation of hPTTG by growth factors is not associated with increased 
proliferation; CDC2 repression causes reduced cell proliferation 
 
Given hPTTG’s crucial role in mitosis as the human securin, we investigated if the 
increased hPTTG expression in response to growth factors was due to increased cellular 
proliferation.  To test this we performed MTT cell viability assays and simultaneously 
investigated proliferative effects following CDC2 depletion in the absence or presence of 
growth factors.  There was no significant difference in the cell viability of TPC-1 cells 
following treatment with growth factors (n = 3) compared to vehicle treated controls.  
















































vehicle treated cells (n = 3, p < 0.001) compared to scrambled siRNA controls, suggesting 
that the observed increase in hPTTG expression following CDC2 knockdown results in 
reduced cell proliferation.  When CDC2 expression was repressed, there was no significant 
difference in cell viability following treatment with growth factors (n = 3) compared to 
vehicle treated controls (see Figure 3-11). 
 
Figure 3-11: MTT cell viability assays demonstrating that hPTTG induction by growth factors is 
not as a result of increased proliferation, but that CDC2 repression results in a significantly reduced 
proliferation rate in TPC-1 cells.  N = 3 experiments.  Error bars represent the SEM (*** p < 0.001, 




The precise mechanisms of hPTTG over-expression in thyroid cancer have not been 
fully elucidated.  Since hPTTG is induced by EGF, TGF-α, IGF-1 and FGF-2 in non-thyroid 
human cell types (Tfelt-Hansen et al. 2004; Vlotides et al. 2006; Chamaon et al. 2005; 
Thompson and Kakar 2005; Heaney et al. 1999; Tsai et al. 2005), we investigated if similar 
effects were observed in human thyroid cells.  This study demonstrated that hPTTG 
expression and phosphorylation is regulated by EGF, TGF-α and IGF-1 in both malignant 




































investigated.  Interestingly, these effects were independent of the known regulators of hPTTG 
expression (SP1) and phosphorylation (CDC2).  Furthermore, CDC2 was identified as a 
novel regulator of hPTTG expression in thyroid cells.   
3.4.1 Expression of hPTTG and growth factor receptors in thyroid cells 
 
Endogenous hPTTG mRNA and protein were over-expressed in transformed thyroid 
papillary carcinoma cell lines compared to normal human primary thyrocytes, consistent with 
hPTTG over-expression in thyroid malignancies, where its expression correlates with 
aggressiveness of tumour subtypes (Boelaert et al. 2003a; Heaney et al. 1999).  Indeed, 
hPTTG over-expression was greater in SW1736 cells derived from an anaplastic thyroid 
carcinoma, compared with TPC-1 and K1 cells derived from papillary thyroid cancers.   
EGFR, IGF1R and FGFR1 are tyrosine kinase receptors that facilitate the signalling 
capabilities of EGF and TGF-α, IGF-1 and FGF-2, respectively.  The MAPK and PI3K 
signalling cascades are the major pro-survival, anti-apoptotic pathways activated by EGFR, 
IGF1R and FGFR1 following ligand binding, receptor dimerisation and tyrosine auto-
phosphorylation (Oda et al. 2005; Riedemann and Macaulay 2006).  High expression of 
EGFR in TPC-1 (albeit statistically non-significant), K1 and SW1736 cell lines was 
consistent with previous studies demonstrating its over-expression in six thyroid cancer cell 
lines (Yeh et al. 2006) and in thyroid tumours where elevated EGFR expression was 
associated with disease progression (Landriscina et al. 2011; Lee et al. 2007; Lam et al. 
2011).  Taken together with observations that the thyroid is an EGF-rich environment 
(Kajikawa et al. 1991) and that TGF-α is over-expressed in thyroid tumours (Lam et al. 
2011), enhanced EGFR signalling appears to be an important process in thyroid cancer 
progression.   
Similarly, our findings of elevated levels of FGFR1 in TPC-1, K1 and SW1736 cells 
compared to normal human primary thyrocytes is consistent with other observations of 




enhanced FGFR1 expression in ex vivo human specimens of thyroid hyperplasia (Thompson 
et al. 1998) and cancer (St Bernard et al. 2005).  In addition, expression of the FGFR1 ligands 
FGF-1 and FGF-2 is increased in thyroid hyperplasia and cancer (Thompson et al. 1998; 
Eggo et al. 1995), suggesting FGF signalling is involved in thyroid disease progression.  
Moreover, FGF-2 expression positively correlated with elevated hPTTG expression in 
thyroid cancer specimens, where it was identified as an independent prognostic indicator of 
metastasis (Boelaert et al. 2003a).  Subsequently, FGF-2 induction by hPTTG was 
demonstrated in thyroid cells (Boelaert et al. 2004).  Together, these observations suggest that 
hPTTG could have an important role in mediating increased autocrine FGF-2 signalling to 
drive thyroid tumour progression.   
Under-expression of IGF1R mRNA in TPC-1, K1 and SW1736 cells compared with 
human primary thyrocytes is contradictory to reports of increased IGF1R protein expression 
in TPC-1 and three other thyroid carcinoma cell lines (Belfiore et al. 1999).  Further, both 
IGF-1 (mRNA and protein) and IGF1R (protein) upregulation has been reported in ex vivo 
human thyroid adenomas and carcinomas, supporting a role for enhanced IGF1R signalling in 
disease progression where their expression positively correlated with tumour aggression 
(Maiorano et al. 2000).  However, our results were consistent, statistically significant and 
obtained using a robust technique in TaqMan RT-PCR.    
3.4.2 Regulation of hPTTG expression and phosphorylation by growth factors 
 
Despite varying levels of growth factor receptor expression, all thyroid cells tested 
were responsive to treatments with EGF, TGF-α and IGF-1, resulting in induction of hPTTG 
protein expression and phosphorylation.  However, induction of hPTTG by growth factors in 
SW1736 cells was less clear than in TPC-1, K1 and human primary thyroid cells and 
scanning densitometry studies revealed non-significant hPTTG induction.  It is plausible that 




since endogenous hPTTG expression levels are high in SW1736 cells, the effects of growth 
factor treatment on further hPTTG induction are attenuated.  
hPTTG expression and phosphorylation were strikingly enhanced  following treatment 
with FGF-2 in TPC-1 cells, whereas no significant effects were observed in other cell types.  
It is possible that normal human primary thyrocytes were not responsive due to low FGFR1 
expression compared with increased expression in thyroid cancer cells as observed in this and 
previous studies (St Bernard et al. 2005).  Effects of growth factors on hPTTG expression 
were generally less striking in SW1736 cells and further dose-response and time-course 
studies may clarify hPTTG regulation by FGF-2 in K1 cells, since preliminary dose-response 
and timecourse experiments indicated FGF-2 induction of hPTTG expression.  FGF-2 effects 
were not investigated further due to the inconsistent responses demonstrated between 
different thyroid cell types.   
Given the role of hPTTG as the human securin (Zou et al. 1999; Zur and Brandeis 
2001; Yu et al. 2000b), it may be difficult to discern direct effects on hPTTG and those 
secondary to stimulation of cellular proliferation.  MTT assays in TPC-1 cells revealed no 
change in proliferation following addition of growth factors, implying direct effects on 
hPTTG regulation, consistent with the observation that hPTTG over-expression did not 
correlate with PCNA expression in human thyroid tumours (Boelaert et al. 2003a). 
The effects of EGFR ligands and IGF-1 were abrogated following additional 
treatments with specific MAPK (PD98059) or PI3K (LY294002 and Wortmannin) inhibitors 
respectively, consistent with observations in non-thyroid cells (Chamaon et al. 2005; Tfelt-
Hansen et al. 2004).  Analysis of phospho-P44/42 ERK1/2 and phospho-AKT expression 
confirmed rapid activation of the MAPK and PI3K cascades respectively, by both EGFR 
ligands and IGF-1.  Notably, these pathways were also activated in SW1736 cells suggesting 
high levels of endogenous hPTTG in this cell type is driven by alternative pathways.  Our  




findings add to increasing evidence of significant levels of crosstalk between these signalling 
pathways (Castellano and Downward 2011; Vlotides et al. 2006), and therapeutic targeting of 
both pathways has been proposed in the management of thyroid cancer (Miller et al. 2009).   
3.4.3 Mechanisms of hPTTG regulation by growth factors 
 
Subsequent investigations were performed in TPC-1 cells since these were the most 
responsive to growth factors and highly amenable to siRNA transfection.  Given the 
established role of SP1 as a regulator of hPTTG transcription (Chintharlapalli et al. 2011; 
Clem et al. 2003) and its reported activation by MAPK and PI3K (Milanini-Mongiat et al. 
2002; Pore et al. 2004), we investigated whether SP1 mediates hPTTG induction by growth 
factors.  Observation of reduced hPTTG in vehicle treated cells following SP1 depletion 
confirmed its role in hPTTG transcription, consistent with siRNA studies in hepatocellular 
carcinoma cells (Chen et al. 2008).  Following SP1 knockdown, hPTTG was nonetheless 
inducible by growth factors suggesting the effect is independent of SP1, concurrent with 
studies of hPTTG regulation by EGF in pituitary folliculostellate TtT/GF cells (Vlotides et al. 
2006).   
CDC2 is the sole-confirmed phosphorylator of hPTTG (Ramos-Morales et al. 2000) 
and we assessed its importance in growth factor mediated phosphorylation of hPTTG.  
Unexpectedly, CDC2 depletion caused a striking upregulation of unphosphorylated and 
phosphorylated hPTTG protein in vehicle-only treated cells.  This finding is in contrast to a 
study demonstrating direct phosphorylation at Ser165 of hPTTG by CDC2 during mitosis in 
HeLa cells  (Ramos-Morales et al. 2000).  Induction of hPTTG was further enhanced, albeit 
non-significantly, upon addition of EGF, and so it is conceivable that growth factor effects on 
hPTTG expression and phosphorylation are independent of CDC2 and that alternative 
mechanisms of hPTTG phosphorylation exist.  MAPK directly phosphorylates Ser162 on rat 
Pttg, which is the analogous site to Ser165 in hPTTG (Pei 2000).  Moreover, a direct 




interaction between hPTTG and both MAPK and PI3K was observed in malignant and non-
neoplastic astrocytes, as well as human testis (Chamaon et al. 2005).  It is tempting to 
speculate that activation of these kinases by growth factors leads to the direct 
phosphorylation of hPTTG, though this requires further investigation.  
3.4.4 Regulation of hPTTG by CDC2 
 
Induction of hPTTG protein expression and phosphorylation following CDC2 
depletion was confirmed in TPC-1 cells and human primary thyrocytes.  This effect was 
abrogated by treatment with the translation inhibitor, anisomycin, suggesting the effect is not 
post-translational.  Subsequently, TaqMan RT-PCR studies revealed upregulation of hPTTG 
mRNA expression following knockdown of CDC2, suggesting a transcriptionally driven 
effect.  Thus we have identified CDC2 as a novel regulator of hPTTG expression.  
Proliferation of TPC-1 cells was significantly reduced following CDC2 depletion, potentially 
as a result of TPC-1 induced hPTTG expression with high levels of hPTTG resulting in 
mitotic inhibition through its role as a securin (Boelaert et al. 2003b).   
3.4.5 Conclusion 
 
This study confirmed that EGF, TGF-α and IGF-1 activate MAPK and PI3K 
pathways via the EGFR and IGF1R respectively to induce hPTTG expression and 
phosphorylation in thyroid cells.  Enhanced expression of growth factors and their receptors 
in thyroid cancer could provide an explanation for hPTTG over-expression in thyroid 
malignancies.  SP1 and CDC2 are not involved in regulating growth factor mediated hPTTG 
expression and phosphorylation, though CDC2 was identified as an independent regulator of 
hPTTG expression.  Further investigations of the exact mechanisms by which growth factors 
regulate hPTTG expression and phosphorylation may elucidate novel potential targets to 













4 CHAPTER FOUR 
 






























As demonstrated and discussed in Chapter 3, hPTTG expression and phosphorylation is 
induced by growth factors.  In addition, several studies have demonstrated that hPTTG in turn 
transactivates growth factors. 
hPTTG induction of the angiogenic growth factors, FGF-2 and VEGF, has been 
described in various studies.  Initially, an increase in FGF-2 expression was observed 
following hPTTG over-expression in NIH3T3 fibroblasts.  Further, increased FGF-2 
secretion was detected in the conditioned media of cells, and both of these effects were 
dependent on the SH3-interacting domain of hPTTG (Zhang et al. 1999b).  A subsequent 
study made similar observations through investigating the effect of hPTTG over-expression 
in angiogenesis.  Increased proliferation, migration and tube formation were observed in 
human umbilical vein endothelial cells (HUVECs), following treatment with the conditioned 
media from hPTTG-transfected NIH3T3 cells.  The pro-angiogenic effects of hPTTG over-
expression were  significantly reduced by mutation of the SH3-interacting domain or by 
addition of a neutralising FGF-2 antibody (Ishikawa et al. 2001).  Luciferase reporter assays 
performed in COS-7 cells indicated that hPTTG regulation of FGF-2 expression is as a result 
of direct effects on the FGF-2 promoter (Chien and Pei 2000).  Two studies from our own 
group have provided strong evidence for FGF-2 upregulation by hPTTG in thyroid cancer.  In 
the first instance, over-expression of both hPTTG and FGF-2 was demonstrated in 
differentiated thyroid cancer, where there was a strong positive correlation of the expression 
of hPTTG and FGF-2 transcripts.  Importantly, this study identified hPTTG and FGF-2 as 
potential prognostic indicators of tumour recurrence and metastasis, respectively (Boelaert et 
al. 2003a).  Subsequently, hPTTG induction of FGF-2 in thyroid cells was demonstrated 
more directly following over-expression of hPTTG in primary human thyrocytes, where the 




SH3-interacting domain of hPTTG was once again critical to regulation of FGF-2 (Boelaert 
et al. 2004).   
A further study from our laboratory indicated there was increased expression of VEGF 
and its receptor, KDR, in pituitary tumours with high hPTTG expression.  In addition, 
hPTTG over-expression induced both FGF-2 and VEGF expression in NT-2, MCF-7 and 
JEG-3 cells via its SH3-interacting domain.  hPTTG regulation of VEGF was shown to be 
independent of FGF-2 induction through depletion of secreted FGF-2 in the cell media 
(McCabe et al. 2002). 
Our group used an angiogenesis-specific cDNA PCR array to investigate the regulation 
of other angiogenic genes by hPTTG in thyroid cells.  Notably, cells over-expressing hPTTG 
induced the pro-angiogenic genes VEGF, ID3 and IGF-1, and downregulated the anti-
angiogenic gene thrombospondin-1 (TSP-1), suggesting hPTTG may be a critical regulator of 
multiple genes that are important in angiogenesis and tumour progression in thyroid cancer 
(Kim et al. 2006b).  The SH3-interacting domain was necessary for regulation of ID3, which 
was later shown to be mediated by the stimulation of VEGF and KDR (Kim et al. 2006a).   
A recent study revealed positive correlations between expression of hPTTG, FGF-2 
and IGF-1 transcripts in pituitary adenomas, providing further evidence of hPTTG’s 
interaction with these growth factors in tumours (Chamaon et al. 2010).  It is possible that 
other growth factors are also regulated by hPTTG and thyroids from mutant TRβPV/PV mice 
which spontaneously develop follicular thyroid cancers demonstrated elevated Pttg and TGF-
α expression at the time of metastatic spread (Ying et al. 2003). 
The growing body of research that describes a correlation between increased hPTTG 
and growth factor expression in a variety of tumours strongly suggests that their relationship 
is important in angiogenesis and disease progression.  We have demonstrated that hPTTG is 
regulated by growth factors in thyroid cells (Chapter 3) and in turn, hPTTG has been shown 




in previous studies to induce expression of some growth factors in both thyroid (Boelaert et 
al. 2003a; Kim et al. 2006a; Kim et al. 2006b) and non-thyroid cell types (Zhang et al. 1999b; 
Heaney et al. 1999; Chien and Pei 2000; Ishikawa et al. 2001; McCabe et al. 2002).  In 
addition, human thyroid follicular and endothelial cells express growth factors as well as their 
receptors, mediating cross talk between these cell types and thus facilitating mitogenesis and 
angiogenesis (Fagin 2005b; Patel et al. 2003).  Based on these observations we performed 
studies to test the hypothesis that hPTTG and growth factors may regulate each other through 
auto/paracrine feedback mechanisms that are aberrantly controlled in thyroid cancer.   
Following on from studies in Chapter 3, which confirmed that hPTTG expression is 
induced by EGF, TGF-α and IGF-1, the aim of this study was to investigate whether hPTTG 
itself transactivates these growth factors.  Thyroid cells were transiently transfected with 
hPTTG and growth factor expression was determined through quantitative TaqMan RT-PCR.  
Thyroid cells were treated with conditioned media taken from vector only control or 
WT/mutant hPTTG-transfected cells in order to investigate autocrine and paracrine induction 
of hPTTG and to infer a mechanism of growth factor regulation.  Specific neutralising 
antibodies and growth factor receptor inhibitors were used to determine the significance of 
each signalling pathway implicated in the auto-regulation of hPTTG and growth factors in 
thyroid cells.   
4.2 Materials and methods 
 
4.2.1 Cell culture and transfections 
 
Human thyroid papillary carcinoma TPC-1 and K1 cell lines were routinely cultured 
as described in section 2.1.  For transfection experiments, TPC-1 and K1 cells were seeded in 
12-well plates at a density of 4.5 x 10
4
 and 6.5 x 10
4 
cells, respectively.  Cells were left 24 
hours before transfection. 




Collection of thyroid samples was with approval of the Local Research Ethics 
committee and samples were cultured as described in section 2.2.  All serum, insulin and 
TSH was removed from human primary thyrocytes for at least 24 hours before transfection.   
For hPTTG over-expression studies, we utilised a collection of constructs consisting 
of the pCI-neo vector housing either wild-type hPTTG, hPTTG with a Ser165 mutation 
(termed Phos-), or hPTTG with PXXP motif mutations (termed SH3-), all as previously 
described (Boelaert et al. 2004).  Cells were transfected with 1 µg DNA/well using FuGENE-
6 Transfection Reagent (Roche, Indianapolis, IN, USA), with an optimised ratio of 6 µl per 1 
µg plasmid DNA.  Control transfections utilised equal amounts of blank plasmid (vector-
only, VO, control).  Transfection efficiency of human primary thyrocytes was predicted by 
Western blotting, parallel transfections of β-galactosidase (β-gal staining) or GFP 
(fluorescence microscopy).  Cells were harvested 48 hours post-transfection in protein lysis 
buffer or 250 µl Tri Reagent.  Growth factor expression was determined in experiments 
where a minimum of 30 % transfection efficiency had been achieved.   
4.2.2 Conditioned media treatments 
 
Conditioned media from transfected human primary thyrocytes were collected and 
centrifuged at 600 g for 10 minutes at room temperature to remove particulates.  Cell culture 
supernatant was then used to treat primary thyrocytes derived from the same specimen, with 
or without the addition of neutralising antibodies against EGF (20 µg/ml), IGF-1 (20 µg/ml) 
[R&D SYSTEMS, UK] and TGF-α (1 : 40) [Biovision Inc., California, USA], or gefitinib 
(Iressa, 100 µM) and picropodophyllin (PPP, 20 µM) [Tocris Bisoscience, Missouri, USA].  
Gefitinib and picropodophyllin are highly specific inhibitors of phosphorylation of the 
tyrosine kinase domains of EGFR and IGFR respectively.  Inhibitors were added to cells 30 
minutes prior to treatment with conditioned media in order to block growth factor receptor 
activity.  Further inhibitor was added at the same time as conditioned media in order to 




sustain inhibition of growth factor receptor activity.  Cells were harvested 24 hours later in 
protein lysis buffer.   
4.2.3 RNA extraction, reverse transcription, QT-PCR 
 
Total RNA was extracted from TPC-1, K1 cells and from human primary thyrocytes 
as described in section 2.4.  Reverse transcription and QT-PCR techniques were as described 
above (see sections 2.4 and 2.5).  hPTTG mRNA was detected using the primers and probe 
described above (see Table 3-1).  Gene-specific expression assays for EGF 
(Hs01099999_m1), TGF-α (Hs_00608187_m1) and IGF-1 (Hs01547656_m1) were 
purchased from Applied Biosystems (Warrington, UK).   
4.2.4 Western blot analysis 
 
Protein extraction, quantification and subsequent Western blotting methods were as 
described previously (see section 2.6).  Blocked membranes were subsequently incubated 
with primary antibodies against hPTTG (2 µg/ml) [Invitrogen, UK].  After washing in TBS-
T, blots were incubated with appropriate secondary antibodies conjugated to horseradish 
peroxidise (Dakocytomation, UK) for 1 hour at room temperature before being visualised by 
techniques described in section 2.6.   
4.2.5 Enzyme-linked immunosorbent assays (ELISAs) 
 
Conditioned medium from primary thyrocytes was collected 48 hours following 
transfection with VO and WT-hPTTG plasmids. The medium was then centrifuged at 12000 g 
for 15 minutes at 4 ºC to remove particulates.  EGF and IGF-1 concentration were assayed in 
200 µl and 50 µl of the supernatant respectively, using the Quantikine HS human EGF and 
human IGF-1 enzyme-linked immunosorbent assays (R&D Systems, Inc.) as per the 
manufacturer’s instructions.  Following the preparation of reagents and standards, cell culture 
or standard (200 µl EGF; 50 µl IGF-1) was added to assay diluent (50 µl EGF; 150 µl IGF-1) 




in each well of a 96 well plate.  After 3 hours incubation at room temperature (18-23 °C), 
plates were washed and 200 µl of either EGF or IGF-1 basic conjugate was added to each 
well.  After a further 2 hour incubation period at room temperature, plates were washed and 
200 µl of substrate solution was added to each well.  Following a further 30 minute 
incubation period, the reaction was terminated by the addition of 50 µl stop solution to the 
wells.  The optical density of each well was determined within 30 minutes using a microplate 
reader set to 450 nm.  Readings were also taken at 570 nm wavelength and these were 
subtracted from the readings at 450 nm to correct for optical imperfections in the plate.    
4.2.6 Statistical analysis 
 




4.3.1 Effects of hPTTG expression on growth factor expression in thyroid cells 
 
hPTTG has been shown to induce expression of proangiogenic growth factors 
including VEGF and FGF-2 (Kim et al. 2006a; Boelaert et al. 2004).  We set out to 
investigate whether hPTTG is capable of upregulating expression of mitogenic growth factors 
implicated in thyroid tumour progression, including EGF, TGF-α and IGF-1 (Hoelting et al. 
1994; Holting et al. 1995; Lam et al. 2011; Maiorano et al. 2000).  We explored this through 
transient transfection studies in thyroid cells where either vector only controls or wild-type 
hPTTG were over-expressed in thyroid cells.   
4.3.1.1 Growth factor expression following hPTTG over-expression in transformed 
thyroid cell lines 
 
In the first instance, we performed transient transfection experiments in TPC-1 and 
K1 papillary thyroid carcinoma cells since they were most consistently amenable to 
transfection.  Successful hPTTG over-expression was confirmed by Western blot analysis.  




Forty eight hours post-transfection, TaqMan RT-PCR revealed that there was no significant 
induction of EGF or TGF-α mRNA expression by hPTTG in either TPC-1 or K1 cells.  IGF-
1 mRNA expression was completely undetectable in both cell lines (see Figure 4-1).   
 
Figure 4-1: hPTTG does not induce growth factor expression in TPC-1 and K1 transformed cell 
lines.  A  Representative Western blot anlalysis demonstrating successful transfection of TPC-1 and 
K1 cells with wild-type hPTTG.  B  TaqMan RT-PCR data showing relative mRNA expression levels 
of EGF, TGF-α and IGF-1 following transient hPTTG over-expression compared to vector only 
transfection controls.  N = 3 experiments.  Error bars represent the SEM (NS = non-significant).   
 
4.3.1.2 hPTTG over-expression induces growth factor expression in human primary 
thyrocytes 
 
  Given the above findings, we performed further transient transfection experiments in 
human primary thyrocytes in which endogenous hPTTG expression is low (see Figure 3-1) 
and which express all three growth factors being investigated.  Transfection efficiency was 
determined by Western blot analysis or by detection of beta-galactosidase and GFP control 
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%, growth factor expression was analysed.  At 48 hours post-transfection TaqMan RT-PCR 
revealed that hPTTG over-expression induced EGF (1.7-fold, n = 6, p < 0.001), TGF-α (1.5-
fold, n = 5, p < 0.001) and IGF-1 (1.6-fold, n = 7, p < 0.001) mRNA expression compared to 
vector only transfected cells (see Figure 4-2). 
 
Figure 4-2: Over-expression of hPTTG in human primary thyrocytes induces growth factor 
mRNA expression.  A  Representative Western blot analyses (i) demonstrating successful transient 
over-expression of hPTTG in human primary thyrocytes derived from different specimens.  β-
galactosidase staining (ii) and GFP fluorescence microscopy (iii) demonstrating 30-50 % transfection 
efficiency of human primary thyrocytes.  B  TaqMan RT-PCR data showing relative mRNA expression 
levels of EGF, TGF-α and IGF-1 following transient hPTTG over-expression compared to vector only 
transfection controls.  N indicates number of repeat experiments.  Error bars represent the SEM (*** 








VO hPTTG VO hPTTG VO hPTTG VO hPTTG














































N 6 5 7




4.3.2 hPTTG and growth factors are involved in paracrine and autocrine feedback 
mechanisms 
 
To investigate whether the increase in growth factor mRNA expression results in 
enhanced translation and secretion of these growth factors and subsequent paracrine 
upregulation of hPTTG by these growth factors, we performed treatments of human primary 
thyrocytes with the conditioned media of transfected cells from the same thyroid specimen.  
We also transfected hPTTG mutants to infer the mechanism involved in growth factor 
regulation by hPTTG.  Western blot analysis demonstrated that cells treated with the 
conditioned media from wild-type hPTTG transfectants showed a 7-fold induction of 
endogenous hPTTG (n = 4, p < 0.001) compared to vector only controls (n = 4).  This effect 
was dependent upon the SH3-interacting domain of hPTTG, since cells treated with 
conditioned media following transfection with SH3- hPTTG showed a non-significant 
upregulation of endogenous hPTTG (1.9-fold, n = 4, p = NS).  However, transfection with 
Phos- hPTTG resulted in a 7.3-fold induction of hPTTG protein (n = 4, p < 0.001), similar to 
effects following wild-type hPTTG transfection, indicating that these effects are independent 
of hPTTG phosphorylation (see Figure 4-3). 





Figure 4-3: Over-expression of hPTTG in vitro induces further autocrine and paracrine 
upregulation of hPTTG.  A  Representative Western blot analysis and scanning densitometry data (B) 
demonstrating hPTTG expression following treatment of human primary thyrocytes with conditioned 
media from wild-type or mutant hPTTG-transfected cells from the same specimen.  Results are based 
on n = 4 repeats of the described experiment (*** p < 0.001, NS = non-significant).    
 
4.3.3 Detection of growth factor secretion by ELISA 
 
In order to identify the specific growth factors involved in autoregulation of hPTTG 
expression, and to determine whether increased transcription of growth factors (see section 
4.3.1.2) results in increased translation and secretion, we used ELISAs to analyse EGF and 
IGF-1 concentrations in cell culture supernatants from human primary thyrocytes following 
transient transfection with hPTTG.  Although technical success of the assays was 
demonstrated, both EGF and IGF-1 were undetectable, suggesting that the levels of EGF and 
IGF-1 in the cell culture medium of human primary thyrocytes are beyond the limits of 



















































Figure 4-4: EGF and IGF-1 levels in human primary thyrocyte cell culture supernatants were 
undetectable by ELISA.  A-B  Concentration standard curves and exemplary calculations of growth 
factor concentrations for EGF (A) and IGF-1 (B).  
 
 
4.3.4  Inhibition of hPTTG auto-regulation 
 
Having failed to confirm increased growth factor secretion by ELISA, we performed 
further investigations into hPTTG auto-regulation to establish the importance of specific 
growth factors.  Treatments of human primary thyrocytes with conditioned media were 
repeated (see section 4.3.2) and neutralising antibodies against growth factors or specific 
inhibitors of growth factor receptor tyrosine kinase activity were introduced.  Western blot 
analysis revealed that addition of neutralising antibodies, against either TGF-α or EGF, to 
conditioned media treatments abolished the upregulation of hPTTG observed in untreated 
controls.  Addition of an antibody that neutralises IGF-1 only partially abrogated the hPTTG 
response.  Gefitinib and picropodophyllin (PPP) are currently used therapeutically as highly 
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specific inhibitors of phosphorylation of the tyrosine kinase domains of EGFR and IGF1R 
respectively.  Western blot analysis demonstrated that additional treatment of cells with 100 
µM gefitinib completely prevented upregulation of hPTTG following treatment with 
conditioned media.  Additional treatments with 20 µM PPP only partially abrogated the 
hPTTG response.  Thus, autocrine upregulation of hPTTG expression could be attenuated by 
preventing EGF, TGF-α and IGF-1 signalling via their respective receptors (see Figure 4-5).   
 
 
Figure 4-5: Intervention of hPTTG auto-regulation with neutralising antibodies against growth 
factors and selective inhibitors of growth factor receptor tyrosine kinase activity.  A+B  
Representative Western blot  analyses showing effects on hPTTG induction following treatment with 
conditioned media, by addition of neutralising antibodies against EGF, TGF-α, IGF-1(A), the EGFR 
inhibitor gefitinib (100 µM) or the IGFR inhibitor picropodophyllin (20 µM) (B).  Western blots are 
representative of n ≥ 2 separate experiments.    
 
 
4.3.5 Positive correlation between hPTTG and growth factor expression in human 
thyroid specimens 
 
To further characterise the relationship between hPTTG and growth factors in the 
thyroid, we investigated the correlation between expression of hPTTG and growth factor 
transcripts in 34 human thyroid specimens from either normal thyroid tissue or multinodular 
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hPTTG and that of both EGF (Rs = 0.2177, p < 0.01) and IGF-1 (Rs = 0.2104, p < 0.01).  
There was a weak correlation between hPTTG and TGF-α mRNA expression (Rs = 0.0793, p 
= 0.101) that was not statistically significant (see Figure 4-6).   
 
Figure 4-6: Correlation between mRNA expression for hPTTG and growth factors in normal 
thyroids and multinodular goitres. Significant associations are illustrated between hPTTG and EGF 
(A) and IGF-1 (B), but not with TGF-α (C). Data are given as ΔCT values and the R2 and p values 




Increased hPTTG expression causes transactivation of growth factors such as VEGF 
and FGF-2 that contribute to sustained tumour growth and angiogenesis (Ishikawa et al. 
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hPTTG is regulated by EGF, TGF-α and IGF-1 in thyroid cells, we investigated whether 
hPTTG in turn regulates these growth factors.  To this effect, we demonstrated that hPTTG 
regulated expression and secretion of EGF, TGF-α and IGF-1 as part of autocrine feedback 
mechanisms in vitro, which led to further upregulation of hPTTG.  Treatments with specific 
neutralising antibodies or tyrosine kinase inhibitors resulted in abrogation of autocrine 
hPTTG induction.  Thus, intervention of these autocrine pathways represents a potential 
therapeutic strategy to reduce hPTTG over-expression in thyroid cancer.   
4.4.1 Induction of growth factors by hPTTG in thyroid cells 
 
In the first instance, studies were performed in TPC-1 and K1 papillary thyroid 
carcinoma cells due to our ability to consistently over-express hPTTG in these cell types.  
However, TaqMan RT-PCR revealed no significant alterations in EGF and TGFα mRNA 
expression following hPTTG over-expression.  IGF-1 mRNA was not expressed in either cell 
type, consistent with studies demonstrating lack of IGF-1 expression in thyroid cancer cell 
lines (Belfiore et al. 1999).  We considered the possibility that pathways driving expression 
of EGF and TGFα may already be strongly activated in these cells where endogenous hPTTG 
expression is already very high (see section 3.3.1).  To test this, we performed further 
transient transfection studies in human primary thyrocytes, which have low levels of 
endogenous hPTTG (see section 3.3.1) and which express all three growth factors being 
investigated.  Achieving a consistent level of transfection was challenging, but we were able 
to verify or refute successful transfection through Western blot analysis, β-gal staining and 
GFP microscopy.  All cells examined had 30-50 % transfection efficiency and TaqMan RT-
PCR analysis revealed that EGF, TGF-α and IGF-1 mRNA expression was induced 
following hPTTG over-expression.  EGFR (Landriscina et al. 2011; Lee et al. 2007; Lam et 
al. 2011) and IGF1R (Belfiore et al. 1999; Maiorano et al. 2000) upregulation in thyroid 
cancer is associated with disease progression.  Moreover, the thyroid is an EGF-rich 




environment (Kajikawa et al. 1991) and TGF-α (Lam et al. 2011) and IGF-1 (Maiorano et al. 
2000) are over-expressed in thyroid tumours.  Together these findings suggest that enhanced 
EGFR and IGF1R signalling appears to be critical in thyroid cancer progression.   Our 
findings suggest that over-expression of growth factors in thyroid cancer may be partly 
mediated by hPTTG over-expression and that pathways of growth factor regulation by 
hPTTG could provide novel therapeutic targets to reduce growth factor expression and 
prevent disease progression.   
 
4.4.2 Secretion of growth factors and autocrine regulation of hPTTG 
 
Given the induction of hPTTG by growth factors (see section 3.3.3) and having 
determined upregulation of EGF, TGF-α and IGF-1 mRNAs by hPTTG in thyroid cells, we 
sought to establish whether growth factor secretion is enhanced and leads to autocrine 
upregulation of hPTTG.  Treatments with the conditioned media of transfected cells induced 
hPTTG protein expression in cell cultures derived from the same specimen, suggesting 
increased secretion of growth factors.  Transfections with hPTTG mutants revealed that this 
effect was dependent on the SH3-interacting domain but independent of hPTTG 
phosphorylation, concurrent with various studies demonstrating transactivational capabilities 
of hPTTG owing to its SH3-interacting domain.  Induction of FGF-2 by hPTTG is well 
established and this effect was dependent on an intact SH3-interacting domain in NIH3T3 
mouse fibroblasts (Zhang et al. 1999b) and human primary thyrocytes (Boelaert et al. 2004).  
Furthermore, FGF-2 mediated angiogenesis following hPTTG over-expression in HUVEC 
cells was diminished  following introduction of a point mutation in the region coding for the 
SH3-interacting domain (Ishikawa et al. 2001).  Similarly, hPTTG induction of VEGF in 
NT2, MCF-7 and JEG-3 cells (McCabe et al. 2002) and of ID3 in human primary thyrocytes 
(Kim et al. 2006b) was mediated via the SH3-interacting domain.  These findings, together 




with the observations of the current study, emphasise the importance of hPTTG’s C-terminal 
SH3-interacting domain in the transactivation of growth factors involved in tumour growth 
and vascularisation.   
We used ELISAs to try and confirm the specific growth factors involved and their 
relative contribution to autocrine regulation of hPTTG.  However, failure to detect EGF or 
IGF-1 in this approach suggested that concentration levels were beyond the limits of 
detection of the assays used.  Alternatively, there could have been a technical issue with 
growth factor degradation as a result of long term storage of samples. 
As a result, an alternative strategy was adopted that allowed us to confirm the specific 
pathways involved in hPTTG autoregulation and provide insight into possible therapeutic 
approaches.  In repeats of conditioned media treatments, additional treatments with 
neutralising antibodies against EGFR ligands or the specific EGFR tyrosine kinase inhibitor 
gefitinib prevented autocrine regulation of hPTTG, strongly supporting a relationship 
between hPTTG, EGFR ligands and EGFR in thyroid cells.  Addition of an IGF-1 
neutralising antibody or the specific IGF1R inhibitor PPP only partially abrogated the effect, 
suggesting this pathway may be less important.  Alternatively, hPTTG may be involved in 
interactions with IGF-2, which also binds IGF1R and is implicated in neoplasia (Riedemann 
and Macaulay 2006; Pollak et al. 2004).  In addition, other receptor types may be involved 
since IGF signalling is complicated by the ability of the IGF1R to dimerise with the insulin 
receptor [IR] (Riedemann and Macaulay 2006).  Some IGF1R inhibitors including PPP only 
inactivate IGF1R and not IR (Vasilcanu et al. 2008) and thus IGF1R inhibition may not 
completely prevent IGF-1/IGF-2 activity.  Indeed, IGF1R/IR dimers are over-expressed in 
thyroid cancer (Belfiore et al. 1999) and this may be important in terms of specificity and 
toxicity when employing treatments targeting the IGF system. 




This section of work provokes discussion regarding the benefits of targeting EGFR 
and IGF1R in thyroid cancer.  Gefitinib (Iressa, AstraZeneca) selectively binds the ATP site 
of the EGFR tyrosine kinase enzyme and has been shown to slow or block growth of thyroid 
cancer cell lines (Schiff et al. 2004; Nobuhara et al. 2005).  It is currently used in the 
treatment of non-small cell lung cancer where the clinical response correlates with mutational 
activation of EGFR (Brown et al. 2010).  An early phase II clinical trial using gefitinib to 
treat 27 patients with advanced differentiated thyroid cancer reported mild tumour volume 
reduction and prolonged stable disease in some patients, although this did not meet ‘partial 
response criteria’ (Pennell et al. 2008).  Erlotinib (Tarceva, OSI/Genentech) and Lapatanib 
(Tykerb, GlaxoSmithKline) are alternative EGFR tyrosine kinase inhibitors that are FDA 
approved for lung/pancreatic and breast cancer respectively, while cetuximab (Erbitux, 
ImClone/Bristol-Myers Squib) and panitumumab (Vectibix, Amgen) are FDA approved 
monoclonal antibodies that block the EGFR ligand binding site.   
PPP is a cyclolignan that inhibits tyrosine phosphorylation of Y1136 in the activation 
loop of IGF1R (Girnita et al. 2004; Vasilcanu et al. 2004), and treatment with this agent has 
been shown to induce significant tumour regression and to inhibit metastasis in various cell 
systems and xenografted mice (Girnita et al. 2006; Vasilcanu et al. 2006; Stromberg et al. 
2006).  In order to assess its suitability as a drug for targeting IGF1R, ongoing research 
continues to investigate mechanisms of tumour cell resistance to PPP following long-term 
exposure (Hashemi et al. 2011) and PPP remains a highly promising drug for future cancer 
treatments.  Many other drugs targeting IGF1R are in phase I clinical trials (Lopez-Calderero 
et al. 2010), including monoclonal antibodies that bind IGF1R and induce internalisation of 
the receptor by endocytosis.  αIR3 was the first monoclonal antibody targeting IGF1R to 
demonstrate anti-cancer effects in vivo (Arteaga et al. 1989), and more recently developed 
antibodies such as CP-751,871 [figitumumab, Pfizer] (Cohen et al. 2005) and IMC-A12 




[cixutumumab, Imclone] (Wu et al. 2005) are showing promise in trials in a wide range of 
malignancies including multiple myeloma, Ewing’s sarcoma, neuroendocrine tumours, 
colorectal, prostate, breast, pancreatic, liver, and head and neck cancers (Lopez-Calderero et 
al. 2010).  Moreover, trials of newly developed tyrosine kinase inhibitors targeting IGF1R 
such as INSM-18 [Insmed] (Ryan et al. 2008) and OSI-906 [OSI Pharmaceuticals] (Carden et 
al. 2009; Lindsay et al. 2009) have demonstrated significant potential for future use in clinical 
practice.   
Further trials in patients with thyroid cancer are required to determine the overall 
benefits of treatments targeting EGFR and IGF1R signalling but the studies described in this 
chapter demonstrate that one advantage of this approach could be the desirable intervention 
in the autocrine feedback mechanisms involving hPTTG and growth factors.   
4.4.3 hPTTG and growth factor correlation studies in human thyroid samples 
 
Several studies have investigated the correlation between hPTTG and growth factors 
in endocrine malignancies.  Our group’s own study demonstrated a positive correlation of 
hPTTG and FGF-2 expression in 27 differentiated thyroid cancers compared with 11 normal 
thyroids, where hPTTG and FGF-2 were identified as independent markers of tumour 
recurrence and metastasis, respectively (Boelaert et al. 2003a).  There was also strong 
positive correlation between hPTTG and FGF-2, as well as IGF-1 mRNA expression in 103 
pituitary adenomas (Chamaon et al. 2010).  Another study in pituitary adenomas, conducted 
by our own group, observed positive correlation between hPTTG and VEGF, as well as the 
VEGF receptor, KDR (McCabe et al. 2002).  Further, in mutant TRβPV/PV mice which 
spontaneously develop follicular thyroid cancers, Pttg and Tgf-α were both strongly 
upregulated at the metastatic stage (Ying et al. 2003).  Given these findings and the 
observations of the current study that hPTTG induces expression of EGF, TGF-α and IGF-1, 
we performed studies to correlate mRNA expression in 37 human thyroid specimens taken 




from normal thyroid tissue or multinodular goitre.  Moderate positive correlations were 
observed between hPTTG and all three growth factor transcripts investigated, though the 
relationship between hPTTG and TGF-α was not significant.  These observations further 
support the existence of important relationships between hPTTG and growth factors in 
normal and hyperplastic thyroid cells.  In this setting, only a weak to moderate correlation 
was evident, potentially since growth factor expression is influenced by activation of multiple 
pathways.  It would be of great interest to investigate whether this relationship is maintained 
or enhanced in a malignant setting, by performing further correlation studies in thyroid cancer 
samples.   
4.4.4 Conclusion 
 
This study confirmed that hPTTG over-expression causes upregulation of EGF, TGF-
α and IGF-1 expression and secretion in human thyroid cells via its SH3-interacting domain.  
Moreover, treatments with conditioned media demonstrated that hPTTG induced growth 
factor secretion is capable of autocrine upregulation of hPTTG.  The work in this and the 
previous chapter collectively establish the existence of autocrine pathways of interaction 
between hPTTG and growth factors, which may be aberrantly controlled in thyroid tumours.  
Specific depletion of growth factors with neutralising antibodies or treatments with growth 
factor receptor tyrosine kinase inhibitors revealed that EGFR signalling may be of particular 
importance in hPTTG autoregulation, while IGF1R signalling may also be significant.  
Treatments with gefitinib and PPP, already used in some clinical settings, may be used to 
disrupt autocrine growth factor signalling at the site of the EGFR and IGF1R respectively, 
thereby reducing hPTTG expression.  Further investigations of the exact mechanisms by 
which hPTTG regulates growth factors and vice versa, may elucidate novel potential targets 












5 CHAPTER FIVE 
 
Generation of a Murine Model with Thyroid Targeted hPTTG 
Expression 
  






Following the discovery of rat Pttg (Pei and Melmed 1997) and the subsequent cloning of 
hPTTG in several contemporaneous studies (Zhang et al. 1999b; Dominguez et al. 1998; 
Kakar and Jennes 1999), it was demonstrated that both rat and hPTTG are potent 
transforming genes in vitro and in vivo.  Stable transfection of hPTTG in NIH3T3 mouse 
fibroblast cells caused an increase in cellular proliferation, augmented anchorage-independent 
growth in soft agar and induced tumour formation after subcutaneous injection into athymic 
nude mice (Pei and Melmed 1997; Zhang et al. 1999b; Kakar and Jennes 1999).   
 Subsequently,  hPTTG was found to be over-expressed in various human tumours 
including those of the pituitary (Zhang et al. 1999a; McCabe et al. 2003), breast (Puri et al. 
2001), colon (Heaney et al. 2000), ovary (Puri et al. 2001), oesophagus (Shibata et al. 2002), 
lung (Kakar and Jennes 1999) and liver (Jung et al. 2006).  Other studies reported hPTTG 
over-expression in haematopoietic neoplasms (Dominguez et al. 1998; Saez et al. 2002), 
astrocytomas (Tfelt-Hansen et al. 2004) and in metastatic gastric carcinomas (Wen et al. 
2004).  Furthermore, studies have elucidated critical tumour-promoting mechanisms of 
hPTTG, including induction of aneuploidy and genetic instability through its role as a securin 
(see sections 1.3.1 and 1.3.2) and stimulation of growth factors and angiogenesis (see section 
1.4 and Chapter 5).   
Together, these findings suggest that hPTTG over-expression may have crucial roles 
in both the initiation and progression of many tumour types.   However, the precise function 
of hPTTG in vivo, and the oncogenic potential of hPTTG in a specific organ has not been 
widely tested.  Further insight has been provided by two studies that investigated the effects 
of targeted hPTTG over-expression in the pituitary glands (Abbud et al. 2005) and ovaries 
(El-Naggar et al. 2007) of transgenic mice.  These studies reported hPTTG-induced pituitary 
hyperplasia and cystic glandular hyperplasia of the endometrium respectively (see section 




1.3.3 and Chapter 6).  Studies by our own group and those of others have demonstrated that 
hPTTG is over-expressed in thyroid tumours (Heaney et al. 2001; Boelaert et al. 2003a).  
Furthermore, our group’s own in vitro studies have demonstrated specific interactions 
between hPTTG and growth factors in thyroid cells (Boelaert et al. 2003a; Kim et al. 2006a), 
as well as an inhibitory effect on NIS expression and function, with implications for 
radioiodide therapies in thyroid disease (Boelaert et al. 2007).  At this stage, it was therefore 
of significant interest to generate a transgenic mouse model with thyroid targeted hPTTG 
expression in order to perform in vivo investigations of the precise role of hPTTG in thyroid 
tumourigenesis.   
A major approach for the generation of transgenic mice was first described in 1980, 
where exogenous DNA becomes randomly integrated into the mouse genome following 
microinjection into the male pronuclei of fertilised oocytes, which are subsequently 
implanted into pseudopregnant foster mothers (Gordon et al. 1980).  Typically, thyroid-
targeted transgene expression has been achieved using this technique to introduce DNA 
constructs with transgene expression under control of the thyroid-specific bovine 
thyroglobulin promoter.  For example, this technique has been employed successfully to 
demonstrate that transgenic mice with thyroid targeted BRAF
V600E 
expression develop goitre 
and papillary thyroid cancers (Knauf et al. 2005).  More recently, out group has also 
successfully generated a murine transgenic model with thyroid-specific over-expression of 
PBF, using a DNA construct containing the bovine thyroglobulin promoter  and demonstrated 
significant goitrogenesis and hyperplasia (Read et al. 2011).  Given the success of these and 
numerous other studies, the same methodology was chosen to investigate the in vivo effects 
of thyroid-specific over-expression of hPTTG.   
The aims of the work reported in this chapter were therefore to generate a murine 
transgenic model with thyroid-targeted hPTTG over-expression, to investigate the hypothesis 




that increased hPTTG expression in thyroid follicular epithelial cells promotes thyroid 
growth and neoplasia.  Moreover, we sought to perform studies to determine whether several 
important in vitro observations, including increased growth factor expression and repression 
of NIS in response to hPTTG over-expression, could be validated in an in vivo model.   
 
5.2 Materials and methods 
 
5.2.1 Generation of transgene construct: TG-hPTTG-FLAG 
 
5.2.1.1 PCR amplification of 3'-FLAG tagged hPTTG cDNA 
 
PCR primers were designed to amplify hPTTG cDNA with the addition of a sequence 
encoding a FLAG epitope (N-DYKDDDDK-C) at the 3' end, from the vector pCI-neo-
hPTTG (Zhang et al. 1999b; Boelaert et al. 2004).  The forward primer contained an EcoRI 
restriction enzyme site and the reverse primer contained a BamH1 restriction enzyme site 
following the stop codon (see Figure 5-1).   
 
Figure 5-1: Sequence and features of the PCR primers designed to amplify and tag the hPTTG 
cDNA on the 3' end with the FLAG epitope. 
 
 The PCR reaction consisted of 500 ng pCI-neo-hPTTG plasmid DNA template, 600 
nM each of forward and reverse primers (Alta Bioscience), 250 µM dNTPs, 1.5 mM MgCl2 
(Bioline, London, UK), 0.5x NH2 reaction buffer (Bioline), 2.5 U Biotaq™ DNA polymerase 
(Bioline), which was made up to a total volume of 50 µl with nuclease-free water.  
The PCR cycling conditions used were 95 ºC for 5 min for the initial denaturation of 
DNA template before holding at 78 ºC at which stage the DNA polymerase in NH2 reaction 
5’ – GCC GAA TTC ATG GCT ACT CTG ATC TAT GTT GAT AAG GAA – 3’









buffer was added.  Subsequently, there were 40 cycles of 94 ºC for 30 sec (denaturation), 65 
ºC for 30 sec (primer annealing) and 72 ºC for 1 min 30 sec (extension), followed by a final 
extension step of 72 ºC for 7 min.  This was performed on a Mastercycler gradient 
(Eppendorf, Hamburg, Germany).  The PCR product was subsequently electrophoresed on a 
1.5 % agarose (Bioline) gel in 1x TAE (Tris-Acetate-EDTA) buffer (Eppendorf) (see Figure 
5-2).   
 
Figure 5-2:  Agarose gel illustrating the hPTTG-FLAG PCR product (~600 bp).  PCR1 and 2 
show PCR products for two separate PCR reactions.  Plasmid = undigested/unamplified pCI-neo-
hPTTG plasmid.  DNA Hyperladder IV was used to indicate band sizes (Bioline).   
 
 
5.2.1.2 Gel extraction of PCR product 
 
The PCR product (~600 bp in size) was excised from the gel using a scalpel and 
extracted from the agarose using the QIAquick gel extraction kit (Qiagen, Hilden, Germany), 
according to the manufacturer’s instructions.  Briefly, the gel fragment was dissolved in 3 
volumes of Buffer QG to 1 volume of gel (100 mg ~ 100 ml) at 50 ºC.  One gel volume of 
isopropanol was added and the solution centrifuged through a QIAquick column.  After 
discarding the flow-through, the column was washed with Buffer QG and then twice with 
Buffer PE, which contained ethanol.  A final centrifugation step minus wash solution ensured 
maximal removal of ethanol before elution in 30 µl nuclease-free water.   
~600bp 
plasmidPCR 2PCR 1




5.2.1.3 Restriction digestion and ligation of pSG5 and PCR product 
 
The next step was to subclone the FLAG-tagged hPTTG gene into the pSG5 plasmid 
downstream of the beta-globin intron II and a T7 promoter, and upstream of an SV40 
polyadenylation (poly-A) tail, between the EcoR1 and BamH1 restriction enzyme sites (see 
Figure 5-4).   
In a total volume of 25 µl, 1 µg pSG5 and 14 µl gel extracted PCR product were 
digested using 15 U EcoRI (Promega), 15 U BamH1 (Promega), 10x acetylated BSA and 10x 
Buffer H (Promega) for 2 hours at 37 ºC.  Digested vector and PCR product were 
electrophoresed on a 1.5 % agarose gel and gel extracted using the QIAquick gel extraction 
kit as described in section 5.2.1.2.  The ligation reaction was carried out at 6 ºC overnight and 
consisted of digested vector and PCR product in a 1:3 Molar ratio, 10x T4 DNA ligase buffer 
(Promega) and 3 U T4 DNA ligase (Promega) in a total volume of 20 µl.   
5.2.1.4 Transformation into DH5α cells 
 
According to the manufacturer’s instructions, 2 µl of the ligation reaction were 
transformed into Subcloning Efficiency™ DH5™ Competent Cells (Invitrogen).  The 
ligation reaction was added to 50 µl bacterial cells and incubated on ice for 30 minutes.  The 
cells were heat-shocked for 20 seconds at 42 ºC and returned to ice for a further 2 minutes.  
Lysogeny broth (LB) was added to a total volume of 1 ml and the cells incubated at 37 ºC for 
1 hour with shaking at 200 rpm.  The cells were subsequently pelleted by centrifugation at 
13,000 rpm for 3 minutes and, after the supernatant was decanted off, resuspended in the 
~50-100 µl remaining LB.   The cell suspension was then spread on an LB-agar (1 % agar) 
plate with 100 µg/ml carbenicillin (Sigma-Aldrich) and incubated at 37 ºC for 16 hours. 
Colonies were screened for plasmid containing hPTTG-FLAG cDNA by PCR using 
the primers described in Figure 5-1.  Each bacterial colony was boiled for 10 minutes at 95 ºC 
in 10 µl water to release the plasmid DNA.  The PCR reaction comprised of 10 µl plasmid 




DNA, 600 nM forward and reverse primers (Alta Bioscience), 500 µM dNTPs, 1.5 mM 
MgCl2 (Bioline), 1x NH2 reaction buffer (Bioline) and 2.5 Units Biotaq™ DNA polymerase 
(Bioline), which was made up to a total volume of 50 µl with nuclease-free water.  The PCR 
cycling conditions used were 95 ºC for 5 minutes, 40 cycles of 94 ºC for 30 seconds, 60 ºC 
for 30 seconds and 72 ºC for 45 seconds, followed by 72 ºC for 7 minutes.  The 600 bp PCR 
products were subsequently electrophoresed on a 1.5 % agarose gel. 
5.2.1.5 Plasmid DNA purification 
 
Bacterial colonies in which the hPTTG-FLAG cDNA was successfully ligated into the 
plasmid vector were used to inoculate 5 ml LB containing carbenicillin (100 µg/ml) and 
incubated at 37 ºC for 1 hour with shaking at 200 rpm.  Plasmid DNA was purified from 
these cultures using the Wizard
®
 Plus SV Minipreps DNA Purification System (Promega) 
according to the manufacturer’s instructions.  Briefly, the cells were pelleted by 
centrifugation and supernatant discarded.  The pellet was resuspended and cells lysed.  The 
addition of alkaline protease solution was followed by incubation at room temperature for 5 
minutes to inactivate endonucleases.  Cell lysis was terminated with neutralisation solution 
and centrifugation produced a cleared lysate, which was transferred to a spin column.  The 
DNA bound to the column was washed twice with an ethanol-based wash solution and then 
centrifuged without wash solution present to ensure maximal removal of ethanol.  Finally, 
plasmid DNA was eluted from the column with 50 µl nuclease-free water. 
 
5.2.1.6 DNA sequencing of pSG5-hPTTG-FLAG minipreps 
 
10 µl DNA sequencing reactions containing 500 ng miniprep DNA, 2 µl sequencing 
primer (5 pmol/µl) and water were analysed by the Genomics Laboratory (University of 
Birmingham) using an ABI 3730 DNA analyser.  DNA sequence analyses were viewed using 




Chromas Lite Version 2.0 (Technelysium Pty Ltd, Australia) and compared with template 
sequences using BLAST software (http://blast.ncbi.nlm.nih.gov/Blast.cgi).  The sequencing 
primers used at this step were a T7 primer (5’ TAA TAC GAC TCA CTA TAG GG ‘3) and 
primers E, F, G and K (see Figure 5-6 B) [All provided by Alta Biosciences, UK]. 
 
5.2.1.7 Maxiprep of pSG5-hPTTG-FLAG 
 
Once the cDNA sequences had been confirmed, larger quantities of DNA were 
purified by maxiprep.  Originating from the same colonies that were selected initially for 
plasmid DNA purification and sequencing, 150 ml bacterial cultures were incubated at 37 ºC 
for 16 hours.  Plasmid DNA was subsequently isolated using the GenElute™ HP Plasmid 
Maxi-Prep Kit (Sigma) following the manufacturer’s instructions.  To pellet the bacterial 
cells, 100 ml culture was centrifuged at 7500 g for 10 minutes at 4 ºC.  Following 
resuspension, the cells were lysed with an alkaline-SDS solution, in which chromosomal 
DNA was denatured.  When the lysate was neutralised by acidic sodium acetate, 
chromosomal DNA renatured and formed aggregates, which were co-precipitated along with 
protein-SDS complexes and high molecular weight RNA.  This material was removed by 
passing through a filter syringe.  The filtered lysate was centrifuged at 3000 g for 2 minutes 
to bind the plasmid DNA to a column and again to wash the DNA with an ethanol-based 
solution.  Another 5 minute wash step was performed before the DNA was eluted in 3 ml 
nuclease-free water by centrifugation at 3000 g for 7 minutes.  The quantity of plasmid DNA 
obtained was determined by measuring absorbance at a wavelength of 260 nm using a 
NanoDrop spectrometer (NanoDrop Products, Wilmington, DE, USA).   
5.2.1.8 Introduction of XhoI restriction enzyme site to pSG5-hPTTG-FLAG 
 
PCR primers were designed to introduce a XhoI restriction enzyme site to pSG5-
hPTTG-FLAG at the 3’ end downstream of the poly-A tail (see Figure 5-3). 





Figure 5-3: Sequence and features of the PCR primers designed to introduce a Xho1 restriction 
enzyme site to pSG5-hPTTG-FLAG at the 3’ end downstream of the poly-A tail.   
 
 PCR amplification of pSG5-hPTTG-FLAG was carried out as per reactions and 
thermo-cycling protocols described in section 5.2.1.1.  The PCR product (~1500 bp in size) 
was excised from the gel using a scalpel and extracted from the agarose using the QIAquick 
gel extraction kit (Qiagen) as described in section 5.2.1.2.   
5.2.1.9 Restriction digestion and ligation of pBSK plasmid and PCR product 
 
The pBSK plasmid containing the bovine thyroglobulin promoter was kindly provided 
by Dr. Jeffrey Knauf and Prof. James Fagin (Memorial Sloan-Kettering Cancer Centre, New 
York, USA).  This pBSK plasmid and the PCR product with a region of cDNA containing the 
beta-globin intron II, hPTTG-FLAG and the poly-A tail, were digested using Xho1 and Cla1 
restriction enzymes.  Reactions were identical to those described in section 5.2.1.3.  Digested 
vector and PCR product were electrophoresed on a 1.5 % agarose gel and gel extracted using 
the QIAquick gel extraction kit as described in section 5.2.1.2.  The ligation reaction was 
carried out as described in section 5.2.1.3. Transformation of the ligation product into 
DH5α cells and subsequent PCR screening of colonies was performed as decribed in section 
5.2.1.4.  The PCR primers used were those described in Figure 5-3.   
5.2.1.10 Plasmid DNA purification and sequence verification  
 
Bacterial colonies in which the cDNA was successfully ligated into the plasmid vector 
were cultured overnight as described in section 5.2.1.5.  Plasmid DNA was purified from 
5’ – GCC ATC GAT CCT GAG AAC TTC AGG GTG A – 3’
5’ – GCC CTC GAG CAG ACA TGA TAA GAT ACA – 3’
FWD
REV
B-globin intron II cDNA
POLY-A Tail cDNAXho1




these cultures using the Wizard
®
 Plus SV Minipreps DNA Purification System (Promega) as 
described in section 5.2.1.5.  
The correct nucleotide sequence was confirmed using the primers described in the 
table in Figure 5-6 B and by DNA sequencing analysis as described in 5.2.1.6.  Once cDNA 
sequences had been confirmed, larger quantities of DNA were purified by maxiprep using the 
Qiagen EndoFree Plasmid Maxi Kit (Qiagen).  The protocol is similar to that described in 
section 5.2.1.7, except for the inclusion of an extra step that removes all endotoxins released 
during the lysis step of plasmid purification.  This extra step was essential to obtain the high 
levels of DNA purity for transgenic animal work.   
5.2.1.11 Isolation and microinjection of the transgene 
 
The final linearised transgene construct was isolated using restriction enzyme digest 
reactions and diagnostic agarose gels.  Restriction enzyme digest of pBSK-TG-hPTTG-FLAG 
was performed in reactions similar to those described in 5.2.1.3  using Xho 1, Spe 1 and Pvu 
1.  The reaction product following digestion with Xho 1, Spe 1 and Pvu 1 was 
electrophoresed on a 1.5 % agarose gel and the presence of a DNA fragment for the predicted 
size of ~3500 bp was gel extracted and purified as described in 5.2.1.2.  Following further 
purification steps carried out by Andrea Bacon  (Biomedical Services Unit, University of 
Birmingham), the generation of the hPTTG-Tg transgenic line was performed by 
microinjection of fertilized mouse oocytes with the TG-hPTTG-FLAG transgene and 
subsequent transfer into pseudopregnant females, as per standard protocols (Bacon et al. 
2007; Hogan et al. 1994; Read et al. 2011).  WT and transgenic PTTG-Tg mice were bred at 
the University of Birmingham and all experiments performed in accordance with U.K. Home 
Office regulations.  




5.2.2 Cell culture 
 
Normal rat thyroid FRTL5 cells (purchased from the Health Protection Agency 
Culture Collections, UK) were maintained in identical media to that described for human 
primary thyrocytes (see section 2.2).  Human non-small cell lung carcinoma H1299 cells 
were kindly provided by Dr. Andy Turnell (School of Cancer Sciences, University of 
Birmingham), were grown in RPMI 1640 medium, supplemented with 10 % fetal bovine 
serum, 1 % L-glutamine and 1 % pen/strep (Life Technologies, Inc., Grand Island, NY, 
USA).  Human colorectal cancer HCT116 cells (kindly provided by Prof. Vogelstein, MD, 
USA) were grown in McCoy’s 5A modified medium, supplemented with 10 % fetal bovine 
serum, 1 % L-glutamine and 1 % pen/strep (Life Technologies, Inc., Grand Island, NY, 
USA). 
5.2.3  Transfections 
 
FRTL5, H1299 and HCT116 cells were seeded at 5.0 x 10
4
 and 1.0 x 10
5
 cells/well in 
12 and 6-well plates respectively.  Cells were transfected with 1 µg (12-well plate) and 2 µg 
(6-well plate) of plasmid DNA/well using FuGENE-6 Transfection Reagent (Roche, 
Indianapolis, IN, USA), with an optimised ratio of 3 µl per 1 µg plasmid DNA.  Control 
transfections utilised equal amounts of blank plasmid (vector-only, VO, control).  Cells were 
harvested 48 hours post-transfection in protein or RNA lysis buffer.   
5.2.4 Tissue DNA extraction 
 
Genomic DNA of potential founder mice was extracted from mouse ear clippings 
using the DNeasy Blood and Tissue kit (Qiagen), as per the manufacturer’s instructions.  In 
brief, tissue samples were first lysed using proteinase K for 3 hours at 56 ºC.  RNase A was 
added for 2 minutes to ensure RNA free genomic DNA was yielded.  Subsequently, buffering 
conditions were adjusted to provide optimal DNA binding conditions and the lysate was 




loaded onto the DNeasy Mini spin column.  During centrifugation, DNA was selectively 
bound to the DNeasy membrane as contaminants pass through.  Remaining contaminants and 
enzyme inhibitors are removed in two efficient wash steps and DNA is then eluted in water.  
DNA concentration and purity was determined by spectroscopy at λ260 nm using a 
NanoDrop spectrometer (NanoDrop Products, Wilmington, DE, USA) where DNA routinely 
demonstrated high purity with A260/A280 ratios of 1.8–2.0. 
5.2.5 Screening by conventional PCR 
 
 Potential transgenic mice were screened by PCR using up to four different primer sets 
(Figure 5-9 B) in order to demonstrate reproducibility of genotyping results and to improve 
the reliability of this assay.  The PCR reaction consisted of 100 ng mouse genomic DNA 
template, 600 nM each of forward and reverse primers (Alta Bioscience), 200 µM dNTPs, 2.5 
mM MgCl2 (Bioline, London, UK), 1x TaqMaster PCR Enhancer (5Prime, Hamburg, 
Germany), 0.5x NH2 reaction buffer (Bioline), 2.5 U Biotaq™ DNA polymerase (Bioline), 
which was made up to a total volume of 50 µl with nuclease-free water.    
 The PCR cycling conditions used were 95 ºC for 5 minutes for the initial denaturation 
of DNA template before holding at 78 ºC at which stage the DNA polymerase in NH2 
reaction buffer was added.  Subsequently, there were 40 cycles of 94 ºC for 30 seconds 
(denaturation), 58/62 ºC for 30 seconds (primer annealing) and 72 ºC for 1 minute 30 seconds 
(extension), followed by a final extension step of 72 ºC for 7 minutes.  This was performed 
on a Mastercycler gradient (Eppendorf, Hamburg, Germany).  PCR products were 
subsequently electrophoresed on a 1.5 % agarose (Bioline) gel in 1x TAE (Tris-Acetate-
EDTA) buffer (Eppendorf) before gels were visualised to identify ~ 600 bp bands 
representative of transgenic mice.   
 




5.2.6 Screening and genotyping through QT-PCR zygosity assay 
 
The genotype of transgenic mice was determined by Real-Time RT-PCR analysis 
essentially as described previously (Ballester et al. 2004; Read et al. 2011).  Primers used to 
specifically detect the human PTTG gene were as described in Table 3-1.  Real-Time PCR 
reactions and data analysis were carried out as described in section 2.5, except that PCR 
reactions were also performed using primers and probe directed to an 89 bp sequence in the 
Dscam gene to normalise DNA levels, which is a conserved sequence in both mouse and 
human genomes (Table 5-1).  Low amounts of mouse genomic DNA (5 ng) were amplified 
and ΔΔCT values calculated from Ct values for hPTTG in human placenta and liver DNA 
controls.   
 
Table 5-1: Oligonuleotide sequences of PCR primers and TaqManTM probe used to detect an 89 
bp sequence in the DSCAM gene expression as a genomic DNA control for zygosity assays.  VIC = 5’ 
reporter dye.   
 
 
5.2.7 RNA extraction, reverse transcription, QT-PCR 
 
Total RNA was extracted from FRTL-5, HCT116 and H1299 cells using the 
Stratagene Absolutely RNA miniprep kit [Agilent Technologies UK Ltd.].  Total RNA was 
extracted from mouse thyroid glands and control tissue organs using the RNeasy microkit 
(Qiagen, UK).  In both instances, adherent cells or mouse tissue was homogenised in lysis 
buffer containing β-Mercaptoethanol before isolating RNA according the manufacturer’s 
protocols.  In both kits, RNA was isolated using an RNA-binding spin column and treated 
with DNase I to ensure an RNA yield with a high level of purity.  Extracting RNA of high 
Sequence Name Sequence
DSCAM Probe 5’ VIC-TTCAAGTGCATTATCCCCTCCTCGGTG-3’
DSCAM Forward Primer 5’-CAGAAAACCATGAGAGGCAATG-3’
DSCAM Reverse Primer 5’-TTCTCCCATGAGACGACAGTGA-3’




purity is critical because contaminating DNA present in the RNA sample can give rise to 
amplification products that mimic the amplification product expected from the RNA target. 
Subsequent reverse transcription and QT-PCR techniques were as described (see 
sections 2.4 and 2.5).  hPTTG mRNA was detected using the primers and probe described 
previously (see Table 3-1). 
5.2.8 Western blot analysis 
 
Protein extraction, quantification and subsequent Western blotting methods were as 
described previously (see section 2.6).  Blocked membranes were subsequently incubated 
with either of two primary antibodies against hPTTG; Pds1 (mouse anti-hPTTG; 1:1000) 
[Labvision, Thermofisher, UK] or hPTTG1 (rabbit anti-hPTTG; 2 µg/ml) [Invitrogen, UK].  
After washing in TBS-T, blots were incubated with appropriate secondary antibodies 
conjugated to horseradish peroxidise (Dakocytomation, UK) for 1 hour at room temperature 
before being visualised by techniques described in section 2.6.   
5.2.9 Immunohistochemistry 
 
Immunohistochemical analysis of hPTTG expression in formalin-fixed, paraffin-
embedded sections of wild-type and PTTG-Tg mouse thyroid specimens was carried out as 
described in section 2.7.  A primary antibody against hPTTG was used (2 µg/ml) [Invitrogen, 
UK].   
5.2.10 Statistical analysis 
 










5.3.1 Generation of an hPTTG-FLAG transgene construct 
 
A multi-step cloning strategy was adopted in order to generate a transgene construct 
consisting of a human PTTG-FLAG-tagged cDNA downstream of the bovine thyroglobulin 
promoter.  In the first instance, a FLAG-tagged hPTTG cDNA was cloned into the pSG5 
vector downstream of the rabbit beta-globin intron II and upstream of an SV40 
polyadenylation (poly-A) tail.  Subsequently, a DNA fragment containing the rabbit beta-
globin intron II, FLAG-tagged hPTTG and the poly-A tail was cloned into a pBSK plasmid 
containing the bovine thyroglobulin promoter, kindly provided by Professor James Fagin 
(Memorial Sloane-Kettering Cancer Centre, New York) (see Figure 5-4). 





Figure 5-4: Schematic overview of the multi-step cloning strategy for the development of the Tg-
hPTTG-FLAG transgene construct.  A  hPTTG-FLAG cDNA was ligated into the pSG5 construct 
following digestion with the EcoR1 and BamH1 restriction enzymes.  B  A DNA fragment consisting 
of the beta-globin intron II, hPTTG-FLAG and a poly-A-tail was isolated following digestion with Cla 
1 and Xho 1 restriction enzymes.  C  The fragment obtained in B was ligated into the pBSK plasmid 
containing the bovine thyroglobulin promoter (TG), following digestion with Xho 1 and Cla 1 
restriction enzymes.  D  The final transgene construct was isolated following restriction digests with 
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5.3.2 Verification of Transgene Activity and Specificity 
 
To assess the activity and specificity of the transgene construct, transient transfections 
of pBSK-VO/hPTTG or a control plasmid pSG5-VO/hPTTG, were performed in normal rat 
thyroid FRTL5, human colorectal cancer HCT116 and human lung cancer H1299 cells.  
hPTTG mRNA expression was analysed using TaqMan RT-PCR to assess transgene activity 
in each cell type.  As expected, hPTTG mRNA expression was increased in FRTL5 (5692-
fold, n = 3, p < 0.001), HCT116 (8-fold, n = 3, p < 0.001) and H1299 (128-fold, n = 3 , p < 
0.001), following transfection with pSG5-hPTTG compared with VO controls.  Importantly, 
there was a 421-fold increase of hPTTG mRNA expression in FRTL-5 cells transfected with 
pBSK-hPTTG (n = 3, p < 0.001) with no expression observed in either HCT116 or H1299 
cells (see Figure 5-5). 





Figure 5-5: TaqMan RT-PCR demonstrating relative hPTTG mRNA expression following 
transient transfection with either pSG5-PTTG or pBSK-PTTG in FRTL5 cells (A), HCT116 cells (B) 
and H1299 cells (C).  Data are given as a value relative to 1.0 for appropriate transfection controls.  
Error bars represent the SEM (*** p < 0.001, NS = non-significant).   
 
5.3.2.1 Verification of construct by DNA sequencing 
 
Having confirmed thyroid specific expression of hPTTG mRNA following 
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sequencing that verified the correct nucleotide sequence and orientation of all construct 
components (see Figure 5-6). 
 
Figure 5-6: Direct sequencing of the pBSK-TG-hPTTG-FLAG construct confirmed the correct 
nucleotide sequence and orientation of the construct.  A  The nucleotide sequence for the transgene 
construct from the Spe 1 to Xho I restriction sites (3563 bp).  B  Table of sequencing primers used 
(marked as underlined and in italics in A).   
5.3.2.2     Preparation and microinjection of transgene construct 
 
A linearised transgene construct was isolated using restriction enzyme digest reactions 
and diagnostic agarose gels.  Digestion with only Xho 1 and Spe 1 resulted in two bands of 
A.
B.
                                                                        BOVINE THYROGLOBULIN PROMOTER                 Spe I site ACTAGT 
 BETA GLOBIN INTRON II                    BamH1 site GGATCC 
                                                                        T7 PROMOTER                      Cla I site ATCGAT 
HUMAN PTTG                   EcoR1 site GAATTC 
FLAG-TAG                                         Xho 1 site CTCGAG 
POLY-A TAIL                                  Sal 1 site GTCGAC 



































PRIMER NAME SEQUENCE DIRECTION START REGION 
Primer A 5’-ATTAACCCTCACTAAAGGGA-3’ FORWARD T3 promoter (plasmid) 
Primer B 5’-CTGGAGAAGGAAATGGC-3’ FORWARD Bov. Tg. promoter 
Primer C 5’-TGAAGAGCACCAGATTGC-3’ FORWARD Bov. Tg. promoter 
Primer D 5’-CCTGGAGAAGGGAATGGCTA-3’ FORWARD Bov. Tg. Promoter 
Primer E 5’-AGAAACAACTACATCCTGGTC-3’ FORWARD Beta-globin intron II 
Primer F 5’-TGAAGAGCACCAGATTGC-3’ FORWARD hPTTG 
Primer G 5’-CTTGAGTGGAGTGCCTC-3’ FORWARD hPTTG 
Primer H 5’-TCAGTGAGGGTGAGAGC-3’ REVERSE Bov. Tg. Promoter 
Primer I 5’-GGCAGGTGTGGGAGAGC-3’ REVERSE Bov. Tg. Promoter 
Primer J 5’-GAGCCTTTATAGCACTG-3’ REVERSE Bov. Tg. Promoter 
Primer K 5’-CCATCTAAGGCTTTGAT-3’ REVERSE hPTTG 
Primer L 5’-TTACCCAACTTAATCGCCTT-3’ REVERSE pBSK plasmid 
 




DNA migrating very closely together, representing the ~3500 bp transgene and a similarly 
sized fragment from the remainder of the plasmid.  Additional digestion with Pvu 1 caused 
cuts at two further sites within the pBSK plasmid so that the transgene fragment was more 
easily isolated on an agarose gel.  The reaction product obtained following digestion with 
Xho 1, Spe 1 and Pvu 1 was migrated on an agarose gel and the presence of a DNA fragment 
for the predicted size of ~3500 bp was confirmed.  Following further restriction digests of 
pBSK-TG-hPTTG-FLAG and migration of the products on an agarose gel, the transgene 
fragment was extracted from the gel and purified (see Figure 5-7).   
 
 
Figure 5-7: Isolation of the linearised TG-hPTTG-FLAG transgene construct.  A  Diagnostic 
agarose gel illustrating the products of various restriction digest reactions.  Red circle demonstrates 

































circle highlights the identification of the transgene fragment (~3500 bp) following digestion with Xho 
1, Spe 1 and Pvu 1.  B  Agarose gel showing migration of a sample of the linearised transgene 
following excision from original agarose gels and a purification step.  The clean, sharp appearance of 
the band indicates a pure and non-denatured DNA sample.     
 
The purified transgene construct was given to Andrea Bacon at the transgenic facility 
of the Biomedical Services Unit, University of Birmingham, who performed further 
purification steps before injecting into the male pronuclei of fertilised oocytes from the 
FVB/N mouse strain.  Oocytes were then implanted into the oviducts of pseudopregnant 
foster mothers for development to term (see Figure 5-8). 
 
 
Figure 5-8: Schematic diagram illustrating pronuclear injection of the transgene construct before 
introduction to a pseudopregnant foster mother, resulting in offspring litters containing potential 
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5.3.3 Identification and propogation of transgenic lines 
 
5.3.3.1 Conventional PCR analysis to identify potential founders 
 
PCR primer sets were designed in order to amplify an approximately 600 bp fragment 
spanning the region between the beta-globin intron and hPTTG.  This design strategy was 
adopted to ensure specific detection of the transgene and avoid amplification of the 
endogenous murine Pttg gene.  PCR primer sets and reaction conditions were validated and 
optimised by performing PCR amplifications directly from the pBSK-Tg-hPTTG plasmid and 
visualising agarose gels (see Figure 5-9). 
 
Figure 5-9: Design and validation of PCR primers for screening of transgene in potential 
founders.  A  Schematic diagram illustrating PCR primer design strategy for specific detection of the 
transgene.  B  Table of primer pairs and sequences with validated optimal melting temperatures.  C  
Migration of PCR products on an agarose gel following transgene amplification directly from the 
pBSK-TG-hPTTG-FLAG plasmid using primer pairs 1, 2 and 3.  (Primer set 4 was similarly 
validated).   
PRIMER PAIR PRIMER NAME PRIMER SEQUENCE Optimal Melting  
Temp. ( ºC) 
PAIR 1 
Primer 1 FWD CTGGTCATCATCCTGCCTTTCTC 
62 
Primer 3 REV GCTTGGCTGTTTTTGTTTGAGG 
PAIR 2 
Primer 4 FWD CGTGCTGTTATTGTGCTGT 
62 
Primer 5 REV GAGAGGCACTCCACTCAAGG 
PAIR 3 
Primer 4 FWD CGTGCTGTTATTGTGCTGT 
62 
Primer 6 REV CATCATCTGGAGGCAGGAACA 
PAIR 4 
Primer 8 FWD GCCTTCTTCTTTTTCCTACAGC 
58 
Primer 9 REV CAGGCAGGTCAAAACTCTCA 












Amount of DNA (µg) 0.05 0.10 0.00 0.05 0.10 0.00 0.05 0.10 0.00 
Primer Pair 1 2 3 




Subsequently, DNA was extracted from ear tissue clippings from mice in potential 
transgenic founder litters and subject to rigorous screening by conventional PCR, using all 
four different PCR primer sets to validate results.  Positive control PCR reactions were 
routinely set up to detect mouse Notch1 in order to confirm the presence of genomic mouse 
DNA in each sample and to verify efficient PCR amplifications.  These were important 
controls to minimise the risk of false negatives whereby transgene-positive founder mice may 
have been misidentified as transgene-negative WT mice (see Figure 5-10).  
 
Figure 5-10: Screening of potential founder mice by conventional PCR.  A  Demonstration of 
Notch-1 amplification in 9 potential founder DNA samples, confirming the presence of mouse 
genomic DNA and successful PCR amplification.  B  Agarose gels demonstrating identification and 
confirmation of 3 TG-hPTTG-FLAG transgenic founder mice (# 1-3) and 1 WT mouse (# 4) through 
use of all four primer pairs.  C  Agarose gel demonstrating the identification of 9 founder mice (A-I) 
out of a total of 95 screened.  +/-  = hemizygous hPTTG founder mouse.   
 
Mouse Sample 1 2 3 4 -ve 1 2 3 4 -ve 1 2 3 4 -ve 1 2 3 4 -ve
Genotype +/- +/- +/- WT +/- +/- +/- WT +/- +/- +/- WT +/- +/- +/- WT









SAMPLE 1 2 3 4 5 6 7 8 9 -ve -ve
A.




Further confirmation of screening results was achieved by TaqMan RealTime-PCR 
using a primer and probe set that specifically amplified hPTTG and not murine Pttg.  Using 
this approach, 9 founder mice identified above were confirmed as transgene-positive (see 
Figure 5-11). 
 
Figure 5-11: Confirmation of conventional PCR screening results through quantitative TaqMan 
RealTime-PCR.  A  Table showing sequences of primers and probe that specifically amplify hPTTG 
and not murine Pttg.  B  Real-Time PCR reaction curves for the 9 founder mice (in duplicate) 
demonstrating amplification of the hPTTG transgene.  C  Table of Ct values highlighting the presence 
of the hPTTG transgene in the 9 founder mice (A-I) and complete lack of detection in potential 
founder mice considered transgene-negative.   
 
Nine mice were identified as transgenic founders from 95 mice in a total of 20 
potential founder litters.  Mice identified as positive for the transgene were set up with WT 
breeding partners to propagate transgenic lines in order to confirm transmission of the 
transgene to subsequent generations, and to obtain mouse tissue for the assessment of hPTTG 




hPTTG Forward Primer 5’-GAGAGAGCTTGAAAAGCTGTTTCAG-3’
hPTTG Reverse Primer 5’-TCCAGGGTCGACAGAATGCT-3’
SAMPLE hPttg Ct Average Ct
FOUNDER A 27.7 27.5
27.3
FOUNDER B 20.4 20.5
20.5
FOUNDER C 24.1 24.0
23.9
FOUNDER D 23.0 22.2
21.4
FOUNDER E 19.6 19.4
19.2
FOUNDER F 24.6 24.6
24.7
FOUNDER G 26.2 25.1
24.1
FOUNDER H 21.6 21.6
21.6
FOUNDER I 25.3 25.2
25.0
PF 10 Undet. Undet.
Undet.
PF 11 Undet. Undet.
Undet.
PF 12 Undet. Undet.
Undet.
PF 13 Undet. Undet.
Undet.

















5.3.3.2 Evaluation of hPTTG mRNA expression in transgenic thyroids 
 
From the original 9 founder mice, 1 was infertile while the 8 others successfully 
transmitted the transgene.  Total RNA was extracted from the thyroid glands of transgenic 
mice in each of the remaining 8 lines and hPTTG mRNA expression was evaluated by 
TaqMan RT-PCR.  Five of these lines failed to express hPTTG mRNA in the thyroid and 
were terminated (data not shown).  Hemizygous mice in the remaining 3 lines (termed lines 
A, B and C) demonstrated expression of hPTTG mRNA in excised thyroid glands.  
Hemizygous mice in line A showed a 13,076-fold increase in thyroid hPTTG mRNA 
expression (n = 3, p ˂ 0.001), whilst lines B and C demonstrated a significantly lower 22- (n 
= 3, p ˂ 0.05) and 13-fold (n = 3, p ˂ 0.05) over-expression of hPTTG mRNA respectively 
(see Figure 5-12). 
 
Figure 5-12: TaqMan RT-PCR data demonstrating strong thyroid hPTTG mRNA expression in 
Line A (A) and significantly weaker over-expression in Lines B and C (B).  Error bars represent the 
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5.3.3.3  Evaluation of hPTTG protein expression in transgenic thyroids 
  
Concomitantly to analysis of thyroid hPTTG mRNA over-expression in lines A, B 
and C, we determined hPTTG protein expression levels in excised thyroid glands of 6-week-
old transgenic mice by Western Blot analysis.  Surprisingly, FLAG-tagged hPTTG 
expression was undetectable using any of three commercial FLAG antibodies (data not 
shown).  However, using a hPTTG antibody (Cambridge Biosciences), it was confirmed that 
transgenic mice in line A had over-expression of hPTTG protein (n=4) in the thyroid gland 
but mice from lines B (n=5) and C (n=6) did not (see Figure 5-13). 
 
Figure 5-13: Western blot analyses confirming hPTTG protein expression in thyroids from 
transgenic mice in line A (A+B) but not in lines B (A) and C (B).    
Consequently, lines B and C were terminated, while line A was investigated further to 
determine whether hPTTG expression was successfully confined to the thyroid gland.   
5.3.3.4 Determination of thyroid specific hPTTG mRNA expression in Line A 
 
Having identified line A as a transgenic line with significant over-expression of 
hPTTG mRNA and protein in the the thyroid gland, we investigated the specificity of 
transgene expression.  Total RNA was extracted from the thyroid glands, heart, lungs, 
kidneys, spleen and liver of transgenic mice from line A and hPTTG mRNA expression was 
WT LINE A LINE B
LINE A LINE CWT
# 1 # 2 # 1 # 2 # 1 # 2 # 3 # 4 # 5
# 1 # 2 # 3 # 4 # 5 # 6# 3 # 4# 3
hPTTG 













evaluated by TaqMan RT-PCR.  As before, stong over-expression of hPTTG mRNA was 
demonstrated in the thyroid gland (28,143-fold, n = 4, p < 0.001).  hPTTG mRNA was 
completely undetected in liver, heart, kidney and spleen (n = 4) but was mildly over-
expressed in lung tissue (280.5-fold, n = 4, p < 0.001).  As murine Pttg is not amplified by 
our hPTTG TaqMan RT-PCR primers, fold changes were calculated by comparing to the 
average WT background signal and are therefore not representative of absolute expression 
differences (see Figure 5-14). 
 
Figure 5-14: TaqMan RT-PCR demonstrating significant over-expression of hPTTG mRNA in the 
thyroid glands compared to control organs of transgenic mice in line A.  hPTTG mRNA was 
completely undetected in liver, heart, kidney and spleen control organs but relatively mild over-
expression of hPTTG mRNA in lung tissue suggests partial activation of the transgene in the lung.  
Error bars represent the SEM (*** p < 0.001).   
  
 
5.3.3.5 Propagation and maintenance of a murine transgenic colony 
 
Following confirmation of line A as an appropriate transgenic line, this line was 
propagated by strategically inbreeding hemizygous transgenic mice in order to fully establish 
1.0
28,143.2
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a murine colony with thyroid-specific over-expression of hPTTG for subsequent 
investigations (see Figure 5-15). 
 
Figure 5-15: Schematic diagram of the inbreeding strategy employed to establish a homozygous 
murine transgenic colony with thyroid hPTTG over-expression.    
 
DNA was extracted from tissue clippings taken from the offspring of hemizygote-
hemizygote breeding pairs to determine the genotype of mice using a RealTime-PCR-based 
zygosity assay.  hPTTG DNA was detected using the primer and probe set specifically 
designed for hPTTG amplification and results were normalised to expression of the Dscam 
genomic DNA control.  From the zygosity assay it was predicted by comparison to human 
DNA controls that hemizygous mice have approximately 9 randomly inserted copies of the 
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Figure 5-16: TaqMan Real-Time PCR zygosity assay.  A  Representative image of hPTTG 
amplification reaction curves for mouse DNA samples and human DNA controls.  B  Table 
demonstrating an example of mouse genotyping calculations.  hPTTG is completely undetectable in 
WT mice, while hPTTG-Tg+/+ mice have approximately double the amount compared to hPTTG-Tg+/- 
mice.  C  Histogram presenting the predicted copy number of the randomly inserted hPTTG transgene 
in hPTTG-Tg+/- and hPTTG-Tg+/+ mice, determined by comparison to human DNA controls.      










































Mean copy number 8.80 17.14
N 16 9
SAMPLE DSCam Average Pttg Ct Average ΔCt Ave ΔCt ΔΔCt Fold Change Fold change*2 Zygosity
1 25.318 25.427 23.394 23.289 -1.924 -2.138 -2.138 4.402 8.803 hemizygote
25.536 23.184 -2.352
2 25.071 25.189 23.094 22.982 -1.977 -2.206 -2.206 4.614 9.228 hemizygote
25.306 22.871 -2.435
3 25.549 25.514 22.61 22.565 -2.939 -2.949 -2.949 7.722 15.444 homozygote
25.478 22.519 -2.959
4 25.221 25.319 22.109 22.228 -3.112 -3.091 -3.091 8.518 17.036 homozygote
25.417 22.348 -3.069
5 25.298 25.342 Undet. Undet. Undet. WT
25.386 25.342 Undet. Undet.
6 25.758 25.751 Undet. Undet. Undet. WT
25.744 25.751 Undet. Undet.
7 25.033 25.135 23.079 22.933 -1.954 -2.202 -2.202 4.600 9.199 hemizygote
25.236 22.787 -2.449
8 25.193 25.212 23.239 23.086 -1.954 -2.127 -2.127 4.368 8.736 hemizygote
25.232 22.932 -2.3
9 25.077 25.094 21.832 21.927 -3.245 -3.167 -3.167 8.979 17.957 homozygote
25.111 22.023 -3.088
10 25.105 25.105 22.048 22.035 -3.057 -3.071 -3.071 8.401 16.801 homozygote
25.106 22.022 -3.084
11 25.291 25.268 21.845 21.941 -3.446 -3.326 -3.326 10.028 20.057 homozygote
25.244 22.038 -3.206




Human Placenta 25.734 25.938 26.306 26.418 0.572 0.48 0.570
26.143 26.531 0.388
DNA -ve control Undet. Undet. Undet.
Undet. Undet. Undet.




In the first instance, mice identified as homozygotes were set up into homozygote-
homozygote breeding pairs in order to generate a colony of homozygous mice for 
investigation of our hypotheses, removing the need to perform any further genotyping.  
However, it was identified early on that homozygous mice were subfertile with only 2 out of 
8 homozygote-homozygote pairings able to reproduce and the finding of small litter sizes (≤ 
6 pups).  Homozygote-hemizygote breeding pairs were set up as an alternative approach to 
maintaining a transgenic colony and were significantly more productive, giving rise to both 
hPTTG hemi- and homozygous colonies for subsequent studies.     
5.3.3.6 Further validation of hPTTG protein expression in transgenic mice 
 
Following establishment of a transgenic line, hPTTG protein expression was fully 
validated in both hemi- and homozygous hPTTG transgenic mice.  Having identified an 
optimal hPTTG antibody (Zymed laboratories), hPTTG protein expression in 6-week-old 
excised transgenic thyroid glands was demonstrated by Western Blot analyses, where there 
was an approximately 2-fold increase in homozygous mice compared to that of hemizygous 
mice, consistent with transgene copy number.  This observation was reproduced in a further 
Western Blot that simultaneously demonstrated the thyroid specificity of hPTTG protein 
over-expression, where hPTTG protein was completely undetectable in protein extracts from 
lung, kidney, spleen and liver controls (see Figure 5-17). 





Figure 5-17: Western blot analyses confirming thyroid-specific hPTTG protein expression in 
transgenic mice from line A.  A  Western blot analysis demonstrating an approximately 2-fold 
increase in hPTTG protein expression in hPTTG-Tg+/+ mice compared to hPTTG-Tg+/- mice with 
none being detected in WT mice.  B  Further Western blot analysis demonstrating hPTTG protein 
expression in the thyroid glands but not in any of the other organs of transgenic mice.  
 
Analysis of hPTTG protein expression in the thyroids of transgenic mice was further 
studied by immunohistochemistry techniques using paraffin embedded thyroid tissue from 
WT, hemi- and homozygous hPTTG mice.  As expected, hPTTG was undetectable in WT 
thyroid sections thereby confirming the specificity of the antibody to hPTTG.  There was 
significant staining of thyroid follicular cells in thyroid sections from hPTTG hemizygotes 
that was further intensified in those from hPTTG homozygotes.  At 100x magnification, it 
was clearly apparent that hPTTG was localised to both the cytoplasm and the nuclei of 
thyroid follicular epithelial cells, consistent with a role for hPTTG in both cellular 
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Figure 5-18: Immunohistochemistry demonstrating hPTTG expression and localisation in the 
thyroid glands of hPTTG transgenic mice.  A  Lack of brown staining indicative of absence of hPTTG 
expression in WT mice.  B-C  Significant brown staining in hPTTG-Tg+/- sections (B) with increased 
intensity of staining in hPTTG-Tg+/+ sections (C) consistent with thyroidal hPTTG protein expression 
levels dependent on transgene copy number.  D  Magnification at 100X clearly shows detection of 
hPTTG protein in both the cytoplasm and the nucleus of thyroid follicular cells in hPTTG transgenic 





The work reported in this chapter describes the successful generation of a murine 
model with thyroid targeted hPTTG over-expression.  Key stages of the development of this 
transgenic model raise important discussion points and considerations regarding the 
complexity and limitations of such a model.  Nevertheless, completion of this chapter of work 
represents an important milestone in the overall project, providing an in vivo model of 
hPTTG over-expression in the thyroid glands of mice for subsequent investigation of its role 
in thyroid pathogenesis and physiology.  
 
 








5.4.1 Considerations of human PTTG over-expression in murine thyroids 
As we set about our investigation, we had to decide whether to create a murine 
transgenic line with thyroidal over-expression of hPTTG or murine Pttg.  Since hPTTG was 
cloned (Zhang et al. 1999b; Kakar and Jennes 1999; Dominguez et al. 1998), most studies 
have focused on characterisation of the functions and interactions of hPTTG.  We therefore 
believed that the best approach to build on these studies was to over-express hPTTG, with the 
aim of validating some of the important findings of these previous studies.  hPTTG protein 
shares 66 % sequence homology with murine Pttg (Wang and Melmed 2000a) and so we 
could expect that hPTTG functions similarly to murine Pttg.  However, it was important for 
us to consider that the full functional properties of hPTTG may be compromised when over-
expressed in a murine organ.  Providing further confidence in our decision, two other groups 
observed phenotypes associated with over-expression  of hPTTG in the pituitary glands 
(Abbud et al. 2005) and ovarian epithelium (El-Naggar et al. 2007) of transgenic mice.  In 
addition, we believe that by over-expressing hPTTG, any phenotypes we observe will provide 
more compelling insight in relation to human thyroid disease.   
5.4.2 Validation of transgene construct 
 
Following a series of restriction enzyme digests and ligation steps, we successfully 
cloned hPTTG-FLAG into the pBSK plasmid downstream of the bovine thyroglobulin 
promoter.  At this stage, we sought to validate the activity and specificity of the transgene by 
analysing hPTTG expression following transient transfections in human cell lines.  Analysis 
by TaqMan RT-PCR revealed that hPTTG mRNA expression was specifically induced in 
FRTL5 cells, but not in non-thyroid cell lines.  Direct sequencing of the pBSK-hPTTG 
plasmid demonstrated the correct nucleotide sequence and orientation of the construct, 
providing us with further confidence.  Moreover, a parallel study by our own group 
successfully demonstrated transgenic PBF expression in the thyroids of transgenic mice, 




having used an identical cloning strategy to that described in this study (Read et al. 2011).  
Together, these results provided enough evidence for the validity of our transgenic construct 
for us to proceed with microinjections.   
5.4.3 Random integration of the transgene 
 
Microinjection of exogenous DNA into the male pronuclei of fertilised oocytes was 
first described by Gordon et al. in 1980 where recombinant plasmid DNA derived from the 
bacterial plasmid pBR322 was injected into the fertilised oocytes of CD-1 mice.   DNA is 
injected at an early stage into the single-cell zygote to avoid mosaicism and becomes 
randomly integrated into the genome, if at all (Gordon et al. 1980).  We observed around a 10 
% success rate of random integrations (9/95 potential founders identified as positive for our 
transgene), which was considered highly successful.  Interestingly, 8/9 of the lines derived 
from these transgenic founder mice failed to produce mice that over-expressed thyroid-
specific hPTTG protein, with 1 founder considered infertile and 7 lines failing to demonstrate 
either enhanced thyroid hPTTG transcription or translation despite successful transmission of 
the transgene.  This low success rate highlights the inefficiency and challenges faced in this 
approach to in vivo genetic manipulation.  It is apparent that successful random integration of 
the transgene does not necessarily confer its desired activity and expression.  Though the 
mechanisms are not fully understood, randomly inserted transgenes are highly susceptible to 
silencing and expression levels are thought to be influenced by the specific insertion site and 
the variable copy number inserted at this site (Clark et al. 1994; Dorer 1997; Garrick et al. 
1998).  However, we have successfully identified and established a transgenic line that 
overcomes this issue and expresses high levels of hPTTG in the thyroid glands of mice. 
Another important issue concerning random integration is that the transgene may 
localise to part of the coding or regulatory regions of endogenous genes or is in fact 
completely deleterious, causing disruption of their normal function and inducing secondary 




phenotypes.  It is possible that the subfertility observed in homozygous mice is due to 
transgene insertion at an undesirable locus, where male subfertility and infertility are 
frequently reported in other transgenic models (Jhappan et al. 1994; Magram and Bishop 
1991; Meng et al. 2002; Woychik and Alagramam 1998; Walters et al. 2009; Zhang et al. 
2011).  Alternatively, the effects of high thyroidal hPTTG expression may be embryonically 
lethal, resulting in reduced litter sizes.  The latter seems more likely as the subfertility was 
not gender specific.  Further investigations are required to provide a full explanation for this.  
However, it was important to consider the possibility of insertional mutagenesis during our 
characterisation studies (Chapter 6) as we tried to discern between specific and non-specific 
phenotypes.   
Elegant studies have combined the use of a thyroglobulin promoter with the Cre-lox 
expression system to specifically alter thyroid gene expression in vitro and in vivo (Lin et al. 
2004; Muller et al. 2011).  Indeed, recent studies have generated highly targeted and 
inducible transgenic models using homologous recombination of Cre-lox and FLP-FRT 
systems in embryonic stem cells (Zwaka and Thomson 2003; Urbach et al. 2004; Suzuki et 
al. 2008; Di Domenico et al. 2008; Irion et al. 2007; Davis et al. 2008; Ruby and Zheng 2009; 
Zou et al. 2009; Sakurai et al. 2010).  This approach enables site-specific insertion of a single 
copy of a transgene, thus overcoming mistargeting and multiple copy number issues, and we 
accept some of the limitations of the approach employed in this study.   
5.4.4 Transgene copy number and expression levels 
 
As mentioned above, a limitation of in vivo genetic modification by random 
integration of a transgene is that the total number of transgene copies inserted cannot be 
controlled.  In a TaqMan Real-Time PCR based zygosity assay, it was predicted by 
comparing to human DNA controls that in our transgenic model hemi- and homozygous mice 
possessed approximately 9 and 18 copies respectively.  The zygosity assay has proven to be 




highly reliable and we observed consistent predictions of transgene copy number across 
multiple generations resulting in consistent genotyping throughout the study.  Our results 
suggest that the founder mouse had ~9 transgene copy insertions on the same chromosome at 
the same integration site (probably in the form of head-tail concatemers, as is typically 
described in such models (Bishop and Smith 1989)) as opposed to 9 separate genome 
integration events in different genomic regions, which would have made for a highly complex 
transgenic model to manage.   
In some transgenic models, severity of phenotype is directly proportional to transgene 
copy number.  For example, high-copy RET/PTC1 transgenic mice have an earlier onset of 
papillary thyroid tumour formation, increased thyrocyte proliferation, aberrant follicle 
formation and reduced iodide uptake in comparison to low-copy number transgenics (Jhiang 
et al. 1998a).  Having decided to maintain a colony of both hemi- and homozygous hPTTG 
mice, it has been of interest in downstream investigations to compare phenotypes for both 
genotypes in order to determine whether they are copy number dependent.  Certainly, a clear 
increase in thyroid hPTTG protein expression was observed in homozygotes compared to 
hemizygotes, as determined by Western Blot and immunohistochemical analyses, and 
subsequent studies have sought to compare the functional outputs of this expression 
difference.  However, even hemizygotes in our transgenic line have high thyroid expression 
of hPTTG (up to 28,000-fold hPTTG mRNA expression) and it would have been interesting 
to study an alternative line with much lower expression levels.  Indeed, we might have 
expected to observe dose-dependent phenotypes of thyroid hPTTG over-expression given the 
in vitro findings in fetal brain NT-2 cells that low hPTTG over-expression causes enhanced 
proliferation while high levels of hPTTG over-expression has the opposite effect (Boelaert et 
al. 2003b). 




Given the discussed disadvantages of this model, an alternative transgenic line would 
have been useful for parallel investigations in order to validate key phenotypes as being 
specific to thyroid hPTTG over-expression, and Chapter 8 describes the generation of an 
alternative line for this purpose.  Unfortunately, with the failings of 8/9 transgenic founder 
lines, only one transgenic line was available for investigation at this stage.  
5.4.5 Thyroid-specificity of hPTTG expression 
In order to investigate the effects of increased thyroid hPTTG expression, it was of 
great importance to successfully target expression of the transgene specifically to the thyroid 
gland.  As described, we aimed to achieve this through the creation of a construct where 
hPTTG expression is driven by the upstream activation of the bovine thyroglobulin promoter.  
Hypothetically, the bovine thyroglobulin promoter should only be activated in thyroid cells 
by thyroid-specific transcription factors such as TTF1, TTF2 and PAX8 (Civitareale et al. 
1989; Mizuno et al. 1991; Lazzaro et al. 1991; Mascia et al. 1997; Plachov et al. 1990; di 
Magliano et al. 2000; Di Palma et al. 2003), but this promoter has not been fully 
characterised and it is possible that it has ‘leaky’ activity in non-thyroid cells, resulting in 
partial mistargeting of hPTTG expression.  Strong induction of hPTTG mRNA expression 
was demonstrated in the thyroid glands of our transgenic mouse line compared to 
background.  However, a relatively mild induction of hPTTG mRNA expression was detected 
in lung tissue from transgenic mice, where there was none in other control tissues.  The group 
that first characterised the tissue-specificity of the bovine thyroglobulin gene promoter did so 
by generating transgenic mice that express the bacterial enzyme chloramphenicol 
acetyltransferase (CAT), and they reported entirely thyroid-specific CAT activity (Ledent et 
al. 1990).  Subsequently other thyroid-specific transgenic models were generated using this 
promoter sequence (Ledent et al. 1991; Ledent et al. 1992).  Another study used the same 
promoter to generate a murine transgenic line with thyroid over-expression of mutant guanine 




nucleotide stimulatory factor (Gs) α-subunit, and specifically reported no expression in the 
lung tissue of transgenic mice following analysis of reverse transcripts by conventional PCR 
(Michiels et al. 1994).  Two more recent studies on thyroid cancer used the same promoter 
sequence to drive thyroid expression of the BRAF
V600E
 mutation and the RET/PTC1 gene 
rearrangement (Knauf et al. 2005; Jhiang et al. 1998a; Cho et al. 1999), and thyroid-
specificity was declared, though data were not shown.   
Taking these studies into account, it is tempting to speculate that our transgene has 
randomly inserted at a locus in close proximity to a promoter or enhancer that is specific to 
lung cells, thus causing some expression in the lung tissue of transgenic mice.  However, in 
our group’s murine model of thyroid targeted expression of PBF using the same promoter 
sequence, PBF mRNA expression was also detected in lung tissue from transgenic mice.  
Given that this model is likely to have originated from a random insertion at an altogether 
different locus, it seems that we are consistently detecting a specific activity of the bovine 
thyroglobulin promoter in the lung cells of mice.  Thyroid transcription factor 1 (TTF1) is 
expressed in the lung where it regulates the expression of lung-specific genes (Guazzi et al. 
1990; Boggaram 2009).  It is therefore a possible explanation that TTF1 is capable of limited 
activation of the bovine thyroglobulin promoter in lung cells, but that this promoter is more 
strongly activated in thyroid cells where other thyroid-specific transcription factors are 
present.  However, hPTTG protein expression was not demonstrated in lung tissue from 
transgenic mice, which was consistent with validation results in the PBF transgenic mouse 
study.  It is possible that the increase in lung hPTTG transcription does not result in hPTTG 
translation, and that the mRNA may be targeted for degradation.  Alternatively, the 
expression of lung hPTTG protein may be so low that it was undetectable by Western Blot 
analyses.  Irrespective of these possibilities, it was important to consider if mistargeted 




hPTTG expression was present, especially when characterising the hPTTG-Tg mouse 
phenotypes (Chapter 6).    
Furthermore, hPTTG protein expression was observed by immunohistochemistry in 
both the cytoplasm and the nucleus.  While hPTTG is predominantly a cytoplasmic protein 
(Chien and Pei 2000), its translocation to the nucleus facilitates its transforming and 
transactivational properties (see section 1.2.1.1).  The presence of hPTTG in the nuclei of 
transgenic mouse thyroid follicular cells may be indicative of fully functional hPTTG protein.  
Thus, we would expect the phenotype corresponding to hPTTG over-expression to manifest 
in subsequent characterisation work.   
5.4.6 Conclusion 
 
It is clear from the work completed in this chapter that in vivo transgenesis can 
provide a variety of challenges.  Through rigorous expression studies, development of a 
robust genotyping assay and strategic inbreeding, we were able to overcome some of these 
difficulties and generated a murine transgenic colony with thyroid-targeted hPTTG protein 
expression.  This model provided us with a platform to directly study the effects of thyroidal 
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Many studies to date have described that hPTTG acts as a critical transforming gene with 
significant oncogenic potential conferred by its induction of genetic instability and 
transactivation of other tumour promoting genes.  However, direct in vivo investigations of 
hPTTG’s tumourigenic capabilities are currently limited.  The successful generation of a 
transgenic mouse model with thyroid-specific over-expression of hPTTG described in 
Chapter 5 has allowed us to directly investigate the hypothesis that thyroidal hPTTG over-
expression induces thyroid growth and neoplasia.   
Currently, only two other studies have investigated the effects of organ specific hPTTG 
over-expression.  hPTTG was targeted to the pituitary glands of mice using the α-subunit of 
glycoprotein hormone (α-GSU) promoter, which is the earliest expressing pituitary hormone 
gene product.  Female αGSU.PTTG mice had significantly enlarged pituitary glands and 
elevated serum IGF-1 levels compared with WT mice.  However, the study focused on a 
more aggressive phenotype in male αGSU.PTTG mice, which demonstrated plurihormonal 
focal pituitary transgene expression with LH-, TSH- and GH-cell focal hyperplasia and 
adenoma, associated with increased serum LH, GH, testosterone, and IGF-I levels.  Some 
mice died prematurely due to obstruction of the urinary tract, caused by prostate and seminal 
vesicle hyperplasia due to elevated serum hormone levels.  Critically, this study provided 
evidence of a role for hPTTG over-expression in enhanced pituitary cell growth and 
specifically in the promotion of differentiated polyhormonal cell focal expansion (Abbud et 
al. 2005).   
  hPTTG is also over-expressed in ovarian cancers (Puri et al. 2001) and a transgenic 
model was generated to directly investigate the effect of hPTTG over-expression in the ovary 
(El-Naggar et al. 2007).  Increased hPTTG expression was evident in the ovarian surface 
epithelium and granulosa cells of transgenic mice, driven by the Mullerian inhibitory 




substance type II receptor gene promoter (MISIIR).  Although female MISIIR-PTTG 
transgenics did not develop ovarian tumours, the study reported an overall increased mass of 
the corpus luteum, generalised hypertrophy of the myometrium of uteri, with cystic glandular 
and hyperplasia of the endometrium.  The study concluded that hPTTG is involved with the 
initial transformation of ovarian epithelial cells and may be important in creating pre-
cancerous conditions, but its over-expression alone is not sufficient for ovarian 
tumourigenesis (El-Naggar et al. 2007).   
 In addition to a potential role in cell transformation, hPTTG has transactivational 
properties that can promote tumour progression as discussed in detail previously (see sections 
1.3.6 and 1.4).  Our group’s own studies have demonstrated hPTTG-mediated induction of 
FGF-2 and VEGF in thyroid cells (Boelaert et al. 2003a; Kim et al. 2006a) and we have 
elucidated further relationships between hPTTG, EGF, TGF-α and IGF-1 in thyroid cells, in 
studies described in Chapters 3 and 4.  In addition, our group previously performed an 
angiogenesis cDNA PCR array following over-expression of hPTTG in human primary 
thyroid follicular cells.  A number of pro-angiogenic genes such as ID3 (3.5-fold induction), 
and anti-angiogenic genes such as TSP-1 (2.5-fold reduction), demonstrated altered 
expression, indicating that hPTTG may represent a critical regulator of the angiogenic switch 
in thyroid tumourigenesis (Kim et al. 2006b).   
 Following on from the successful generation of a murine transgenic model (see 
Chapter 5), the aim of this study was to fully characterise this model to investigate the 
hypothesis that thyroid-targeted hPTTG over-expression will induce thyroid tumourigenesis.  
hPTTG-Tg mice were carefully monitored throughout the study and were evaluated 
macroscopically and histologically to determine phenotypes.  Qualitative RT-PCR, murine 
primary thyrocyte culture and ELISA assays were used in order to verify our in vitro 
observations including the induction of growth factors.  Further investigations were 




performed in order to contrast some of these observations in the thyroid glands of Pttg
-/-
 
knockout mice.  Angiogenesis cDNA PCR arrays were performed in order to broadly 
evaluate the effect of enhanced thyroidal hPTTG expression on genes involved in 
angiogenesis in vivo.   
 
6.2 Materials and methods 
 
6.2.1 Transgenic mice 
 
hPTTG-Tg mice were generated and validated as described in Chapter 5.  Pttg
-/-
 
knockout mice were kindly provided by Professor Melmed [UCLA, USA] (Wang et al. 
2001).  Transgenic hPTTG-Tg, Pttg
-/-
 knockout and WT mice were bred at the University of 
Birmingham and all experiments performed in accordance with U.K. Home Office 
regulations.   
6.2.2 Murine primary thyrocyte culture 
 
Murine thyroid follicular cells were isolated and cultured from WT and hPTTG-Tg 
thyroid glands as described previously in section 2.3.  This culture system was extensively 
validated in Chapter 7 (see section 7.3.2.2).     
6.2.3 Post-mortem and macroscopic evaluation of transgenic mice 
 
hPTTG-Tg mice that became ill were culled by cardiac puncture under terminal 
anaesthesia.  Subsequently, mice were dissected and thorough post-mortem analysis 
performed with the guidance of expert mouse pathologists at the Biomedical Services Unit, 
University of Birmingham.    
 
 




6.2.4 Mouse thyroid dissection 
A microdissection technique was developed to routinely excise mouse thyroid glands 
for downstream analyses.  In summary, the outer layer of fur and skin was removed to reveal 
the salivary glands, which are relatively large compared to their human counterparts.  The 
salivary glands were pulled laterally to reveal the infrahyoid muscles running across the 
trachea.  Using a dissecting microscope, these “strap muscles” were cut away to clearly 
expose the trachea, to which the thyroid gland is attached.  Thyroid glands were then 
carefully excised, weighed and stored in formalin (histology), RNA later (RNA analysis), 
liquid nitrogen (protein analysis) or PBS (primary cell culture) (see Figure 6-1). 
 
Figure 6-1: Mouse thyroid dissection.  A  Fur and skin are cut away to expose neck region.  B  
Salivary glands are pulled laterally to reveal infrahyoid muscles.  C  Infrahyoid muscles are cut away 
to expose thyroid lobes attached to the trachea.   
 
6.2.5 Histological evaluation of mouse thyroids 
 
Thyroid glands were removed from mice aged between 1.5 and 18 months using a 
dissecting microscope and stored in formalin.  Mouse thyroids were sectioned and subject to 
hematoxylin and eosin (H&E) staining performed by the Cellular Pathology Department, 
University Hospital Birmingham NHS Foundation Trust.  Stained thyroid tissue sections 
were viewed under a light-microscope (Zeiss) and images captured using Axiovision 











human thyroid histopathologist, Dr. Adrian Warfield (University Hospital Birmingham NHS 
Foundation Trust).   
6.2.6 Serum thyroid hormone concentration 
 
Mouse blood samples were extracted from mice by cardiac puncture and left to clot 
overnight at 4 ºC.  Subsequently, bloods were centrifuged at full speed for 30 minutes at 4 ºC 
and the supernatant (serum) was stored at -80 ºC.  Mouse serum TSH concentrations were 
determined by the laboratory of Professor Samuel Refetoff (University of Chicago). Details 
of this assay have been published (Pohlenz et al. 1999).    
Total T4 and total T3 in serum of WT and hPTTG-Tg mice were measured using 
radioimmunoassay kits (MP Biomedicals).  In brief, standards and mouse serum samples 
were added to tubes coated with either T4 or T3 monoclonal antibodies.  Subsequently, a 
tracer solution containing radiolabelled T4 or T3 was added to the tube.  Unlabeled and labeled 
analyte compete for a limited number of available binding sites on an antibody which has 
equal affinity for the standard and the analyte in the sample. Increasing quantities of 
unlabeled analyte reduce the amount of labeled analyte bound to antibody. The level of 
radioactivity bound is, therefore, inversely related to the concentration of analyte.  At the end 
of a 1 hour incubation period, tubes were decanted and rinsed with distilled water before the 
bound radioactivity on coated tubes was counted using a gamma counter.  The concentration 
of T4 or T3 in serum samples was determined by interpolation from a standard curve of % of 
Trace Level versus μg/dL T4 or T3.     
6.2.7 RNA extraction, reverse transcription and QT-PCR 
 
Total RNA was extracted from murine primary thyrocytes as described previously in 
section 2.4.  Mouse thyroid glands were stored in RNAlater RNA stabilisation reagent at  




-20 ºC before total RNA was extracted using the RNeasy microkit (Qiagen, UK), as per the 
manufacturer’s instructions.   
Subsequent reverse transcription and QT-PCR techniques were as described above (see 
sections 2.4 and 2.5).  Murine gene-specific expression assays for Pttg (Mm00479224_m1), 
Pbf (Mm00521473_m1), Vegf (Mm01281449_m1), Fgf-2 (Mm00433287_m1), Tshr 
(Mm00442027_m1), Tg (Mm01200340_m1), Nis (Mm01351811_m1), Egf 
(Mm00438696_m1), Igf-1 (Mm00439560_m1), Tgf-α (Mm00446232_m1), Egfr 
(Mm00433023_m1) and Igf1r (Mm00802831_m1) were purchased from Applied Biosystems 
(Warrington, UK).  Primers used to amplify hPTTG were those described in Table 3-1.   
6.2.8 Enzyme-linked immunosorbent assays (ELISAs) 
 
Conditioned medium was collected from WT and hPTTG-Tg murine primary 
thyrocytes 5 days following serum removal.  Cell culture supernatants were prepared as 
previously described (see section 4.2.5).  Egf and Igf-1 concentrations were assayed in 50 µl 
of the supernatant, using the Quantikine mouse EGF and mouse/rat IGF-1 enzyme-linked 
immunosorbent assays (R&D Systems, Inc.) as per the manufacturer’s instructions described 
in brief previously (see section 4.2.5).   
6.2.9 Angiogenesis-specific cDNA PCR arrays 
 
RNA from mouse thyroid glands was obtained as described in section 6.2.7.  RNA 
was converted to cDNA using the RT
2
 First Strand Kit (SA Biosciences) as per the 
manufacturer’s guidelines.  Briefly, 25 ng of RNA was mixed with 2 µl of Genomic DNA 
Elimination Mixture and water in 10 µl reactions, and incubated at 42 ºC for 5 minutes before 
being chilled on ice.  10 µl of RT cocktail containing RT buffer (BC3; 4 µl), Primer and 
external control mix (P2; 1 µl), RT enzyme mix (RE3; 2 µl) and water (3 µl) was added to 
each 10 µl RNA mixture.  Reactions were incubated at 42 ºC for 15 minutes before 




termination by heating at 95 ºC for 5 minutes.  Each 20 µl cDNA sample was diluted by 
addition of 91 µl of water.  cDNA quality and specific expression of hPTTG and Nis was 
determined in samples by TaqMan RT-PCR, as described in section 6.2.7.  Subsequently, 102 
µl of cDNA was added to 1350 µl of 2X RT
2
 SYBR Green qPCR Master Mix (SA 
Biosciences) and 1248 µl of water.  25 µl of experimental cocktails were loaded into each 
well of mouse angiogenesis-specific cDNA PCR array plates (96-well format) (# PAMM-
024, SA Biosciences).  PCR plates were sealed and centrifuged for 1 minute at 1000 g to 
remove bubbles.  PCR reactions were performed using an ABI 7900HT Fast Real-Time PCR 
System.  Reactions were as follows: 95 °C for 10 minutes; then 40 cycles of 95 °C for 15 
seconds and 60 °C for 1 minute.  Inspection of in-built controls determined that PCR array 
results were not affected by genomic DNA contamination or RNA impurities.  Data were 
compared using the ΔΔCt method described in section 2.5, but by comparing genes of 
interest to an average of multiple house-keeping genes.   
6.2.10 Statistical analysis 
 




6.3.1 Survival of hPTTG-Tg mice 
 
Overall, survival of hPTTG-Tg
+/-
 mice (75.7 ± 9.6 %, n = 43) was non-significantly 
decreased compared with WT mice (96.5 ± 2.4 %, n = 68) by 18 months of age (p = 0.147).  
In contrast, survival of hPTTG-Tg
+/+
 mice (28.5 ± 8.1 %, n = 57) was strikingly reduced 
compared with either WT (p < 0.0001) or hPTTG-Tg
+/-
 mice (p < 0.0001) by 18 months of 
age.  Notably, hPTTG-Tg
+/+
 mice became ill from ~3 months of age onwards, with 38.1 ± 6.8 
% dying by 6 months of age.  Comparison of survival trends between male (29.9 ± 10.5 %, n 
= 35) and female (24.2 ± 13.1 %, n = 31) hPTTG-Tg
+/+ 
mice demonstrated that both genders 




of this genotype have decreased survival, with no significant difference observed by 18 
months of age (p = 0.702) (see Figure 6-2).   
 
Figure 6-2: Kaplan-Meier survival analyses.  A  Survival curves for WT (blue, n =68), hPTTG- 
Tg+/-(green, n = 43), hPTTG-Tg+/+(red, n = 57) mice demonstrating significantly reduced survival 
rates of hPTTG-Tg+/+mice.  B Survival curves for male (n = 35) and female (n =31) hPTTG-
Tg+/+mice demonstrating gender-independent phenotype.  Circles represent censorsed event (mouse 
deliberately harvested for experiments), intersection represents spontaneous death of mouse (*** p < 
0.001, NS = non-significant). 
   
Wherever possible, ill mice were culled by cardiac puncture under terminal 
anaesthesia prior to post-mortem evaluation.  Subsequently, serum and histological analyses 
























































6.3.2 Total body weight of transgenic mice 
 
Total body weight data were collected by weighing mice at the time of harvest at 1.5, 
3, 6, 12 or 18 months of age.  Overall, there were no significant differences in the total body 
weight of female hPTTG-Tg mice, except at 3 months of age, where hPTTG-Tg
+/+
 females (n 
= 11) were significantly under-weight compared with WT females (9.5 % reduced weight, n 
= 23, p < 0.01).  In contrast, a number of significant differences in total body weight of 
hPTTG-Tg males were identified.  At 1.5 months of age, hPTTG-Tg
+/-
 males (n = 4) were 
significantly over-weight compared with WT controls (12.5 % excess weight, n = 39, p < 
0.05) and hPTTG-Tg
+/+ 
mice (14.2 % excess weight, n = 14, p < 0.01).  At 3 months, hPTTG-
Tg
+/+ 
males (n = 10) were significantly under-weight compared with WT controls (8.3 % 
reduced weight, n = 25, p < 0.05) and hPTTG-Tg
+/-
 mice (9.4 % reduced weight, n = 20, p < 
0.01).  At 6 and 12 months there were no significant differences, but at 18 months of age, 
hPTTG-Tg
+/+ 
males (n = 5) were significantly under-weight compared with hPTTG-Tg
+/-
 
males (17.7 % reduced weight, n = 13, p < 0.05) (see Figure 6-3 A).  However, throughout 
the study we observed great variation in weight data due to factors including parentage and 




 breeding pairs, we had an in-built 




littermates.  We consistently observed that between ~ 3 and 7 weeks of age that both male 
and female hPTTG-Tg
+/+ 
mice were significantly under-weight compared to hPTTG-Tg
+/- 
littermates.  Representative results are presented in Figure 6-3 B and C.   





Figure 6-3: Analysis of mouse total body weight data.  A  Bar chart displaying total body weight 
of WT, hPTTG-Tg
+/-
 and hPTTG- Tg
+/+
 mice (Males in shades of blue, females in shades of 
pink) at 1.5, 3, 6, 12 and 18 months of age.  B+ C  Representative total body weight analyses 
demonstrating reduced body weight of hPTTG- Tg
+/+
 males (B) and females (C) compared 
with hPTTG-Tg
+/-
 littermates.  Error bars represent the SEM (* p < 0.05, ** p < 0.01, NS = non-
significant).   
 




mice that became ill were culled by cardiac puncture under terminal 
anaesthesia.  Post-mortem examination of 3-8 month old hPTTG-Tg
+/+ 
mice that became ill 
rarely revealed any abnormalities that were macroscopically evident.  Many of these mice 
were lean, had a distended bladder and an abnormal caecum that was shrivelled and compact.  
However, this was later described by a mouse pathologist as typical features found in non-
specifically ill mice.  One 2.5 month old female hPTTG-Tg
+/+
 mouse that became ill had 
obvious enlargement of the salivary glands, kidneys, spleen and lymph nodes, and 
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 mouse presented with an abnormal intestine, the cause of which 
remains unknown.  Similarly, an 8 month old male hPTTG-Tg
+/+
 mouse had a distended 
stomach containing a large amount of undigested food, and again the cause remains 
unknown.  Crucially, thyroid glands in all ill hPTTG-Tg mice at this age (3-8 months) were 
of a normal size, with no macroscopic evidence of goitre or tumour formation (see Figure 
6-4). 





Figure 6-4: Macroscopic evaluation of ill hPTTG-Tg mice.  A  Dishevelled and hunched 
appearance of an ill mouse.  B  Representative photographs of a frequent observation in both male 
and female hPTTG-Tg
+/+
 mice that become ill between 3-8 months of age.  A distended bladder is 
indicated by the red arrow.  The caecum is indicated by the black arrow and is noticeably dark and 
compact in hPTTG-Tg+/+ mice (left).  C  Photographs of a hPTTG-Tg+/+ female with a B-cell 
lymphoma.  Red arrows indicate enlarged spleen (left) and salivary glands (right).  D  Photograph of 
hPTTG-Tg+/+ male with an abnormal intestine indicated by the red arrow.  E  Photograph of a 
hPTTG-Tg+/+ male with a distended stomach indicated by the red arrow and its undigested contents 
by a yellow arrow.  F  Representative photographs demonstrating no macroscopically evaluated 
differences between the thyroid glands of WT (left) and ill hPTTG-Tg+/+ (right) mice at ~ 3.5 months 









































 mice were aged to 12 and 18 months in order to study 
the long term effects of thyroidal over-expression of hPTTG.  As hPTTG-Tg mice 
approached the 18 month time point, there were a number of mice that presented with 
pathologies.  An 18 month old   hPTTG-Tg
+/- 
female had a large uterine tumour (2.3 g); two 
18 month old hPTTG-Tg
+/- 
males had lung tumours (0.98 g and 0.32 g); and one hPTTG-
Tg
+/+ 
female had a cancerous liver (7.1 g) (see Figure 6-5). 
 
 
Figure 6-5: Pathologies identified in aged hPTTG-Tg mice (indicated by red arrows).  A  18 
month old hPTTG-Tg
+/-
 female with a uterine tumour (2.3 g).  B  18 month old hPTTG-Tg
+/- 
male with a lung tumour (0.98 g).  C  Lung tumour from an 18 month old hPTTG-Tg
+/-
 male.  
D  17 month old hPTTG-Tg
+/+ 
female with a cancerous liver (7.1 g).   
 
  
6.3.4 Evaluation of thyroid weight in hPTTG mice 
 




mice appeared to be of normal 
size compared to age-matched WT mice, with no macroscopic evidence of goitre or tumour 
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Figure 6-6: Macroscopic evaluation of thyroid glands in aged hPTTG-Tg mice.  Representative 
photographs of thyroid glands in situ of WT (blue), hPTTG-Tg+/- (green) and hPTTG-Tg+/+(red) 
thyroids at 12 months (top row) and 18 months (bottom row).  The gender, body weight and thyroid 
weight of each animal is also indicated beneath each photograph.   
 
Thyroid glands were excised from mice and the weights were determined.  
Interestingly, hPTTG-Tg
 
thyroids were reduced in size compared with WT, with a stronger 




thyroids demonstrated a consistent 
trend of reduced size compared with WT controls at all ages, though this difference was only 
statistically significant at 12 months (p < 0.01), where hPTTG-Tg
+/- 
thyroids had a mean size 
of 2.68 ± 0.1 mg (n = 22) compared with 3.26 ± 0.13 for WT mice (n = 11).  hPTTG-Tg
+/+
 
mice had significantly smaller thyroids at 1.5 months (1.64 ± 0.06 mg, n = 30, p < 0.05), 3 
months (1.78 ± 0.05 mg, n = 23, p < 0.05), 6 months (1.98 ± 0.14 mg, n = 13, p < 0.01), 12 
months (2.5 ± 0.23, n = 6, p < 0.01) and 18 months (2.43 ± 0.15, n = 9, p < 0.01) compared 
with age-matched WT thyroids, which had mean weights of 1.80 ± 0.04 mg (n = 85), 1.96 mg 
± 0.06 (n = 48), 2.87 mg ± 0.22 (n = 6), 3.26 mg ± 0.13 (n = 10) and 3.23 mg ± 0.18 (n = 8) 





































































Given that hPTTG-Tg mice variously have reduced body weight (see section 6.3.2), it 
is possible that the reduced thyroid size observed is a consequence of the lower total body 
weight.  We therefore also analysed weight data by calculating the thyroid:total body weight 
ratio of mice.  Between 1.5 and 12 months of age hPTTG-Tg
+/- 
mice still demonstrated a 
generally lower mean thyroid:total body weight ratio compared with WT controls.  However, 
this was only statistically significant at 3 months (0.070 ± 0.004, n = 8, p < 0.05) and 12 
months (0.077 ± 0.002, n = 22, p < 0.01), compared with age-matched WT controls, with a 
mean of 0.079 ± 0.002 (n = 48) and 0.090 ± 0.005 (n = 11) respectively.  By 18 months of 
age, hPTTG-Tg
+/- 
mice (0.099 ± 0.006, n = 19, p = NS) had a thyroid:total body weight ratio 
comparable to WT controls (0.089 ± 0.004, n = 8).   
hPTTG-Tg
+/+ 
mice had significantly lower thyroid:total body weight ratios at 1.5 
months (0.080 ± 0.002, n = 30, p < 0.05), 6 months (0.069 ± 0.005, n = 13, p < 0.05) and 12 
months (0.076 ± 0.003, n = 6, p < 0.05) compared with age-matched WT controls, with mean 
ratios of 0.087 ± 0.001 (n = 85), 0.093 ± 0.003 (n = 6) and 0.077 ± 0.002 (n = 22), 
respectively.  At 3 months (0.080 ± 0.004, n = 21, p = NS) and 18 months (0.083 ± 0.005, n = 
9, p = NS) of age, there was no significant difference compared with WT control ratios of 
0.079 ± 0.002 (n = 48) and 0.089 ± 0.004 (n = 8), respectively.  See Figure 6-7 B. 
Thyroid:total body weight ratios were calculated for ill hPTTG-Tg mice to confirm 
that these mice did not have enlarged thyroids.  Data from ill mice was compared with WT 
data from the most relevant time point.   At 3 (0.077 ± 0.009, n = 5, p = NS), 6 (0.085 ± 
0.013, n = 5, p = NS) and 18 (0.083 ± 0.014, n = 3, p = NS) months of age, ill hPTTG-Tg 
mice showed no significant difference compared with WT ratios (detailed above).  At 12 
months of age, ill hPTTG-Tg mice demonstrated a significantly reduced mean ratio of  0.069 
± 0.005 (n = 3, p < 0.05) compared with 12 month WT mice (as above) (see Figure 6-7 C). 





Figure 6-7: Analysis of thyroid gland weights in hPTTG-Tg mice.  A  Comparison of raw thyroid 
weights in WT and hPTTG-Tg mice.  B   Comparison of thyroid:total body weight ratios in WT and 
hPTTG-Tg mice.  C  Bar chart form of data presented in B (3-18 months only), with additional 
comparative analysis of thyroid:total body weight ratio in ill hPTTG-Tg mice.  WT (blue), hPTTG-
Tg+/- (green), hPTTG-Tg+/+(red), ill hPTTG-Tg (black).  Error bars represent the SEM (* p < 0.05, ** 
p < 0.01, NS = non-significant).   
 
6.3.5 Histological evaluation of hPTTG-Tg mouse thyroids 
 
To examine mouse thyroid glands microscopically, we performed H&E staining on 
sections from hPTTG-Tg and WT mice.  Composite images of complete thyroid lobes 
demonstrated normal thyroid histology in ill hPTTG-Tg
+/+
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Figure 6-8: Histological analysis of thyroids from ill hPTTG-Tg+/+ mice.  A  Representative 
images of H&E stained thyroid sections from ill hPTTG-Tg+/+ mouse and WT mouse (4.5-6 months of 
age).  B  Coronal section of neck region from ill hPTTG-Tg+/+ mouse (age 3 months).  Scale bars: 100 
µm.  TC = Tracheal cartilage, TL = Tracheal lumen, CC = Cricoid cartilage, CT = Cricothyroid 
muscle, T = Thyroid cartilage (ic = inferior cornu, sc = superior cornu), A = Arytenoid cartilage, C 



































mice revealed no histological abnormalities and were comparable to age-
matched WT controls (see Figure 6-9). 
 
Figure 6-9: Histological analysis of thyroids from aged hPTTG-Tg mice.  Representative images 
of H&E stained thyroid sections from 12 and 18 month old WT (left), hPTTG-Tg+/- (middle) and 













6.3.6 Thyroid  hormone concentrations 
 
Serum thyroid hormone concentrations were determined in order to assess the effect 
of transgene expression on thyroid function.  Measurement of serum TSH concentration was 
restricted by sample availability (no samples available from ill hPTTG-Tg
+/+
 male mice or 18 
month old WT mice) and assay limitations.  We therefore focused on characterisation of 
thyroid function in hPTTG-Tg
+/- 
mice due to their increased rate of survival, but were able to 
include some samples from ill and aged hPTTG-Tg
+/+
 mice to give an indication of their 
thyroid status.  There was no significant difference in serum TSH concentrations in male 
hPTTG-Tg
+/- 
mice at either 6 weeks (57.4 ± 12.9 ng/mL, n = 6, p = NS) or 12 months (89.8 ± 
16.7 ng/mL, n = 3, p = NS) of age, compared with age-matched WT controls with average 
concentrations of 48.2 ± 13.9 ng/mL (n = 6) and 118.3 ± 7.2 ng/mL (n = 3), respectively.  In 
contrast, serum TSH concentrations were below the limits of detection in hPTTG-Tg
+/- 
females at 6 weeks of age.  In accord with the lowest detectable value in the assay, hPTTG-
Tg
+/- 
females were assigned a nominal mean of 10 ng/mL which was significantly lower (n = 
6, p < 0.05) compared with age-matched WT controls (24.1 ± 3.7 ng/mL, n = 6).  There was 
no significant difference in serum TSH concentration in 12 month old hPTTG-Tg
+/- 
females 
(25.4 ± 8.1 ng/mL, n = 3, p = NS) compared with age-matched WT females (28.2 ± 16.5 
ng/mL, n = 3).  Serum TSH concentrations in hPTTG-Tg
+/+
females that became ill at ~ 3.5 
months of age (29.7 ± 6.0 mg/mL, n = 5, p = NS) were comparable to those in 6 week old 
WT females (as above).  18 month old hPTTG-Tg
+/+ 
males (114.6 ± 44.6 mg/mL, n = 3, p = 
NS) and females (48.5 ± 1.6 mg/mL, n = 3, p = NS) had serum TSH concentrations that were 
comparable to 12 month old gender-matched WT controls (as described above) (see Figure 
6-10).   





Figure 6-10: Serum TSH concentrations in 6 week and 12 month old WT (males – light blue, 
females – light pink) and hPTTG-Tg+/- mice (males – dark blue, females – dark pink).  TSH 
concentrations in 3.5 month old ill hPTTG-Tg+/+ females (black) were compared against 6 week old 
WT females.  TSH concentrations in 18 month old hPTTG-Tg+/+ males (dark purple) and females 
(light purple) were compared against gender-matched 12 month old WT mice.  Error bars represent 
SEM (* p < 0.05, NS = non-significant).   
 
 Further analyses were performed to determine serum concentrations of total 
triiodothyronine (T3) and thyroxine (T4).  Once again, 3.5 month old ill hPTTG-Tg
+/+
 females 
were compared to 6 week old WT females, and since no 18 month old WT samples were 
available, 18 month old hPTTG-Tg mice were compared to gender matched 12 month old 
WT mice.  There were no significant alterations of serum T3 concentrations in hPTTG-Tg 
male or female mice at any time-point, compared with WT controls.  Similarly, there were no 
significant alterations of serum T4 concentrations in hPTTG-Tg female mice at any time-
points and there were no marked alterations of total T4 concentrations in aged hPTTG-Tg 
males.  However, 6 week old hPTTG-Tg
+/+ 
(15.8 ± 3.8 ng/dL, n = 5, p < 0.001) males had 
significantly higher total T4 concentrations compared with WT controls (2.0 ± 0.2 ng/dL, n = 
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Figure 6-11: Analysis of serum concentration of total triiodothyronine (T3) [A] and thyroxine (T4) 
[B].    WT (males – light blue, females – light pink), hPTTG-Tg+/- (males- middle blue, females – 
middle pink), hPTTG-Tg+/+ (males – dark blue, females – dark pink).  T3 and T4 concentration in 3.5 
month old ill hPTTG-Tg+/+ females (black) were compared against 6 week old WT females. T3 and T4 
levels in 18 month old hPTTG-Tg mice were compared against gender-matched 12 month old WT 
mice.  Error bars represent SEM (*** p < 0.001, NS = non-significant).  
   
 
6.3.7 Effects of thyroid-targeted hPTTG expression on gene expression 
 
To further characterise hPTTG-Tg mice, we analysed thyroidal expression of mRNAs 
encoding endogenous Pttg, markers of thyroid differentiation (Tshr, Tg and Nis) and of those 
genes that have been shown previously to be induced by hPTTG, including Pbf (Stratford et 
al. 2005), Vegf (Kim et al. 2006b; Kim et al. 2006a) and Fgf-2 (Boelaert et al. 2003a).  
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were unaltered in hPTTG-Tg
+/- 
mice (0.51-fold, n = 11, p = NS) and hPTTG-Tg
+/+ 
mice 
(1.44-fold, n = 3, p = NS) compared with WT controls (n = 9).  Similarly, Pbf levels were 
unaltered in hPTTG-Tg
+/- 
mice (0.74-fold, n = 11, p = NS) and hPTTG-Tg
+/+ 
mice (0.86-fold, 
n = 3, p = NS) compared with WT controls (n = 9).  Surprisingly, hPTTG-Tg
+/- 
mice (1.22-
fold, n = 12, p = NS) and hPTTG-Tg
+/+ 
mice (1.03-fold, n = 3, p = NS) had similar levels of 
Vegf compared with WT controls (n = 14).   While hPTTG-Tg
+/- 
mice had significantly 
elevated levels of Fgf-2 (1.88-fold, n = 12, p < 0.001), hPTTG-Tg
+/+ 
mice unexpectedly 
demonstrated contrasting data with unaltered levels of Fgf-2 (1.36-fold, n = 3, p = NS) 
compared with WT controls (n = 9).  hPTTG-Tg
+/+ 
mice showed unaltered levels of Tshr 
(1.41-fold, n = 3, p = NS) and Tg (1.31-fold, n = 3, p = NS) compared with WT controls (n = 
10) (see Figure 6-12).         
 
Figure 6-12: TaqMan RT-PCR data displaying expression levels of mRNAs encoding Pttg, Pbf, 
Vegf, Fgf-2, Tshr and Tg in 6 week old WT and hPTTG-Tg mice.  Error bars represent SEM (*** p < 
0.001, NS = non-significant).  
 
6.3.8 hPTTG regulation of Egf, Igf-1 and Tgf-α in vivo 
 
In Chapter 5, induction of EGF, IGF-1 and TGF-α mRNA by hPTTG was observed in 
human primary thyrocytes.  To test this in vivo, thyroidal expression of Egf, Igf-1 and Tgf-α 
were evaluated in 6 week old hPTTG-Tg mice.   Thyroids excised from hPTTG-Tg
+/- 
mice 
had similar levels of Egf (0.89-fold, n = 7, p = NS) and Igf-1 (0.84-fold, n = 7, p = NS) 
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fold, n = 13, p < 0.001) and Igf-1 (1.46-fold, n = 12, p < 0.05) levels were significantly 
elevated in hPTTG-Tg
+/+ 
mice compared with age-matched WT controls (n = 29).  Tgf-α 
expression levels were only evaluated in hPTTG-Tg
+/+ 
mice (1.26-fold, n = 10, p = NS) 
where levels were not significantly altered compared with WT controls (n =11) (see Figure 
6-13). 
 
Figure 6-13: TaqMan RT-PCR analysis demonstrating mRNA expression levels of Egf, Igf-1 and 
Tgf-α in 6 week old WT and hPTTG-Tg mice.  Error bars represent SEM (* p < 0.05, *** p < 0.001, 
NS = non-significant).  
 
 
Subsequently, mouse primary thyrocytes were isolated and cultured from 6 week old 
WT and hPTTG-Tg mice (see Chapter 7 for in-depth details on mouse thyroid cell culture), 
and the conditioned media collected 5 days after serum removal were analysed by ELISAs 
specific to Egf and Igf-1. Consistent with the mRNA expression data, there was no significant 
increase in Egf secretion by hPTTG-Tg
+/-
 transgenic thyrocytes (13.1 ± 2.1 pg/mL, n = 7, p = 
NS), but Egf secretion was significantly elevated in hPTTG-Tg
+/+
 transgenic thyrocytes (20.9 
± 3.4 pg/mL, n = 12, p < 0.01) compared with WT controls (9.5 ± 2.0 pg/mL, n = 17).  In 
contrast, thyroid cultures from either hPTTG-Tg
+/-
 (217.5 ± 53.4 pg/mL, n = 13, p = NS) or 
hPTTG-Tg
+/+
 (170.4 ± 20.0 pg/mL, n = 26, p = NS) transgenic mice showed no significant 
difference in Igf-1 secretion compared to WT controls (160.9 ± 23.5 pg/mL, n = 28) (see 








































Figure 6-14: Histograms showing secretion levels of Egf (A) and Igf-1 (B) respectively, from 
primary mouse thyrocytes derived from WT and hPTTG-Tg mice, determined by ELISA.  Data are 
presented as the mean growth factor concentration (pg/mL) ± SEM.  (** p < 0.01, NS = non-
significant). 
 
Further qualitative RT-PCR confirmed that mouse primary thyrocytes expressed both 
Egfr and Igf1r, and thus have all components required to facilitate autocrine mechanisms 
involving Pttg and growth factors.  There was no significant difference in Egfr or Igf1r 
expression between WT and hPTTG-Tg transgenic mice (see Figure 6-15).     
 
 
Figure 6-15: TaqMan RT-PCR analysis demonstrating mRNA expression levels of Egfr and Igf1r 
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6.3.9 Expression of Egf, Igf-1 and Tgf-α in Pttg-/- knockout mice 
 
To explore the effects of reduced endogenous PTTG expression in vivo, we next 
examined Egf, Tgf-α and Igf-1 mRNA expression in thyroid glands of Pttg-/- knockout mice 
(Wang et al. 2001). Qualtitative RT-PCR analysis revealed a significant reduction in Egf 
mRNA expression in thyroid glands of Pttg
-/-
 mice (0.4-fold, n = 5, p < 0.01), whereas Tgf-α 
(1.0-fold, n = 5, p =NS) and Igf-1 (1.6-fold, n = 5, p =NS) mRNA expression levels were 
unaltered compared to WT controls (n = 5) (see Figure 6-16). 
 
Figure 6-16: TaqMan RT-PCR demonstrating reduced Egf and unaltered Tgf-α and Igf-1 mRNA 
expression in the thyroid glands of Pttg-/- knockout mice.  Error bars represent the SEM (** p < 0.01, 
NS = non-significant). 
 
 
6.3.10 Angiogenesis PCR array analysis in hPTTG-Tg+/+ thyroids 
 
In order to analyse the effects of thyroidal hPTTG over-expression on the expression 
of genes involved in proliferation and angiogenesis, we performed angiogenesis cDNA PCR 
array analyses on mouse thyroid glands.  Four separate PCR arrays were performed 
comparing hPTTG-Tg
+/+
 mice (n = 2) with WT controls (n = 2).  Given the variability of 
mRNA results observed thus far, specific hPTTG-Tg
+/+ 
mouse thyroid cDNA samples were 
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expression in accordance with the phenotype described in detail in Chapter 7 (see Figure 
6-17).   
 
Figure 6-17: Validation of individual hPTTG-Tg+/+ thyroid cDNA samples for cDNA PCR array 
analyses.  TaqMan RT-PCR data demonstrating high expression levels of hPTTG mRNA (A) and 
reduced Nis mRNA expression (B) in individual hPTTG-Tg+/+ mouse thyroid glands.    
 
 Subsequent PCR array analysis revealed various alterations in gene expression in 
hPTTG-Tg
+/+ 
thyroids compared with WT.  These included changes in expression of 
Cytokine (C-X-C motif) ligand 1 (Cxcl1; 3.24-fold increase), Coagulation Factor II (F2; 
2.06-fold increase), Fibroblast growth factor 6 (Fgf-6; 11.1-fold reduction), Midkine (Mdk; 
2.34-fold increase), Matrix metallopeptidase 9 (Mmp9; 2.0-fold reduction), T-box 1 (Tbx1; 
3.8-fold reduction), T-box 4 (Tbx4; 14.3-fold reduction), Tumour necrosis factor (Tnf-α; 2.0-
fold reduction) and Tumor necrosis factor alpha-induced protein 2 (Tnfaip2; 2.16-fold 
increase).  We also looked closely at other genes of specific interest including Egf (1.33-fold 
reduction), Tgf-α (1.43-fold increase), Igf-1 (1.44-fold increase), Vegf (1.47-fold increase), 




































































Figure 6-18:  Angiogenesis cDNA PCR array analysis in hPTTG-Tg+/+ thyroids compared with 
WT.  Genes that demonstrated a  2.0-fold differential expression (either increased or reduced) in 
hPTTG-Tg+/+ thyroids compared with WT controls were identified as significant and these thresholds 
are indicated by black dashed lines.  Pro-angiogenic and anti-angiogenic gene expression alterations 
are shown in green and red respectively.  The average fold change of other genes of specific 




The mechanisms governing thyroid cell growth in hyperplasia and neoplasia remain to 
be fully defined, despite recent progress in our understanding of the role of other oncogenes 
such as BRAF (Knauf et al. 2005; Franco et al. 2011).  The aim of the present chapter was to 
investigate the hypothesis that thyroidal over-expression of hPTTG would induce thyroid 
growth and neoplasia.  Following the successful generation of a murine transgenic model 
with thyroid-targeted hPTTG expression (see Chapter 5), the current chapter of work 
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6.4.1 Survival of hPTTG-Tg mice 
 
Given that various murine models of thyroid cancer developed cancers from 6 months 
onwards (Knostman et al. 2007a; Kim and Zhu 2009), hPTTG-Tg mice were aged up to 18 
months in order to study the potential development of thyroid cancers.  In our concurrent 
investigation of transgenic mice with thyroidal PBF over-expression, PBF-Tg mice 
demonstrated a higher incidence of macrofollicular lesions and hyperplasia at 18 months of 
age compared with earlier time-points (Read et al. 2011).  Strikingly, only 28.5 % of hPTTG-
Tg
+/+ 
survived to 18 months of age and many became ill from ~ 3 months onwards.  In 
contrast, hPTTG-Tg
+/- 
mice generally survived to 18 months of age, with a survival trend 
comparable to WT mice.  There was no significant difference in survival trends between male 
and female hPTTG-Tg
+/+ 
mice suggesting that this phenotype was independent of gender.  Ill 
hPTTG-Tg
+/+ 
mice were subject to extensive investigations to determine a cause of death.  
Crucially, thyroids from ill hPTTG-Tg
+/+ 
mice were microscopically and histologically 
normal.  Further post-mortem evaluation with the support of expert mouse pathologists 
revealed no consistent cause of death in these mice, where frequent observation of a 
distended bladder or abnormal gut were dismissed as typical effects seen in any ill mouse. 
There were no consistent differences observed between genotypes of mice when 
evaluating mouse total body weight data across all time points, though general trends 
suggested both male and female hPTTG-Tg
+/+ 
mice were under-weight compared with WT 
and hPTTG-Tg
+/- 
mice.  Total body weight varied considerably and was dependent on factors 
such as litter size and parentage, and this was investigated more closely.  Following our 




breeding pairs (see section 5.3.3.5), total 




offspring were compared, which 
confirmed that male and female hPTTG-Tg
+/+ 
mice were consistently under-weight compared 
with hPTTG-Tg
+/- 
littermates between 3 and 7 weeks of age.   




In a mouse model of inherited hypothyroidism, hyt/hyt autosomal recessive mutants 
demonstrate similarly retarded growth from weaning age into adulthood, in association with 
low serum T4 and elevated serum TSH (Beamer et al. 1981).  However, analysis of serum 
thyroid hormone levels in ill hPTTG-Tg
+/+ 
females revealed that there was no significant 
difference in TSH, T3 or T4 concentrations compared with WT controls.  The reasons for 
illness and death in hPTTG-Tg
+/+ 
mice were therefore not identified after post-mortem 
analysis, histological evaluation and thyroid function analyses.  In the absence of any thyroid 
phenotype, it appears increasingly likely that this may have been a non-specific effect, 
possibly caused by the disruption of a critical gene at the insertion site of the transgene 
construct.  Supporting this logic, hPTTG-Tg
+/- 
mice demonstrated a similar survival pattern to 
WT mice, possibly explained by the fact that they would presumably possess one normal 
copy of the potentially disrupted gene that is sufficient for normal function and survival.  In 
order to verify this, it may be possible to determine the transgene insertion site by performing 
inverse-PCR analyses in order to amplify and subsequently sequence the flanking regions of 





mice was continued.   
The survival of 28.5 % of hPTTG-Tg
+/+ 
mice to 18 months raises further questions as 
to why some mice of this genotype become ill but others do not.  Aged hPTTG-Tg
+/+ 
mice 
continued to express hPTTG protein (data not shown) and therefore survival was not due to 
“switching off” of the transgene.  It is possible that disruption of a gene at the site of 
transgene insertion does not effect hPTTG-Tg
+/+ 
mice with 100 % penetrance.  Alternatively, 
reduced hPTTG-Tg
+/+ 
survival could be the fatal effect of toxicity caused by excessive over-
expression of the transgene, which is feasible given the multiple transgene copy numbers and 
high levels of hPTTG expression observed in this transgenic line (see Figure 5-14, 5-17, 5-18 




and 5-19).  On this basis, varying levels of total hPTTG expression in hPTTG-Tg
+/+ 
mice may 
determine death or survival.    
6.4.2 Characterisation of surviving hPTTG-Tg mice 
Despite many hPTTG-Tg
+/+ 
mice becoming ill before reaching an age at which 
enhanced thyroid growth would be expected,  we were able to investigate phenotypes in those 
that survived, and in hPTTG-Tg
+/- 
mice, which also demonstrated significant over-expression 
of hPTTG in the thyroid (see Figure 5-14, 5-17, 5-18, 5-19).  A number of aged hPTTG-Tg 
mice presented with different tumour types at around 18 months of age.  Given that a low 
level of mistargeted hPTTG mRNA expression was observed in the lungs of hPTTG-Tg mice 
(see Figure 5-14), it was interesting that two hPTTG-Tg
+/- 
mice developed lung tumours.   
However, the occurrence of lung tumours in 18 month old WT mice (data not shown) 
indicated that this was not a specific effect of hPTTG over-expression in the lung.  Indeed, 
spontaneous development of a variety of lesions, and of lung tumours in particular, has been 
reported in non-transgenic ageing FVB/N mice (Mahler et al. 1996).   
Microscopic analysis at the point of dissection revealed no visible evidence of goitre 




mice between 1.5 
and 18 months of age.  Furthermore, hPTTG-Tg thyroid glands were deemed histologically 
normal with no evidence of benign or malignant lesions.  Unexpectedly, thyroid weight 
analysis indicated that hPTTG-Tg
+/- 
thyroids were generally smaller than those of WT mice, 
though this was only statistically significant at 12 months of age.  hPTTG-Tg
+/+ 
thyroids were 
even smaller compared with WT and demonstrated statistical significance at every age 
investigated, indicating a copy number dependent phenotype of reduced thyrocyte 
proliferation.  However, following the observation that hPTTG-Tg
+/+ 
mice were under-
weight, thyroid weight data were also analysed in relation to total body weight.  Thyroid:total 
body weight ratios of hPTTG-Tg mice were still generally lower than that of WT mice, 




though this was not consistently observed or statistically significant at every time-point.  The 
inconsistency of results potentially reflects a subtle phenotype that has been difficult to 
elucidate given high levels of variation and difficulties in accurately determining thyroid 
weights.  Future studies should aim to verify or refute reduced cellular proliferation in 
hPTTG-Tg thyroids by analysis of mitotic markers such as PCNA and cyclin D1. 
  Nonetheless, the lack of enhanced thyroid growth was inconsistent with previous 
data showing that subcutaneous expression of murine fibroblasts over-expressing hPTTG 
induced high-grade malignant tumour formation in athymic nude mice (Zhang et al. 1999b; 
Kakar and Jennes 1999).  Furthermore, our observations contrast with other transgenic 
models of organ-specific hPTTG over-expression describing hPTTG-induced hyperplasia in 
the pituitary glands (Abbud et al. 2005) and ovaries (El-Naggar et al. 2007) of transgenic 
mice.  One study from our laboratory identified hPTTG as a critical regulator of proliferation 
in fetal neuronal NT-2 cells, showing that low transient expression of hPTTG resulted in a 
significant proliferative effect, whereas high levels of hPTTG expression inhibited cell 
turnover through its role as a securin (Boelaert et al. 2003b).  It is possible that a dose-





demonstrate high levels of hPTTG expression and reduced thyroid size.  Consistent with this 
theory, MISIIR-PTTG transgenic mice that develop hypertrophy of the corpus luteum have 
relatively low expression of transgenic hPTTG in the ovarian epithelium (El-Naggar et al. 
2007).  Alternatively, hPTTG-induced apoptosis (Yu et al. 2000a) might explain reduced 
thyroid size in hPTTG-Tg mice and this could be investigated through the use of apoptosis 
assays.    
The lack of thyrocyte transformation in hPTTG-Tg mice indicates that over-
expression of hPTTG alone is not sufficient for thyroid tumourigenesis.  Major pathogenetic 
factors associated with thyroid cancer include dietary iodine deficiency and exposure to 




external radiation (Schneider and Ron 2005; Nikiforov and Nikiforova 2011).  It would 
therefore be interesting to test whether hPTTG over-expression facilitates the transition to 
malignancy following induction of TSH-driven goitre formation in hPTTG-Tg mice on an 
iodine deficient diet.  Similarly, given the potential role of hPTTG in DNA damage response 
pathways (see section 1.3.5), and in particular the observation that over-expression of hPTTG 
can repress DNA repair (Kim et al. 2007b), it would be of significant interest to test whether 
exposure to ionizing radiation causes a greater incidence of thyroid tumour development in 
hPTTG-Tg mice compared with WT mice.  Alternatively, it is possible that another oncogene 
is required to facilitate hPTTG mediated thyroid cell transformation.  It has already been 
described that follicular thyroid tumours in TRβPV/PV mice demonstrated reduced 
proliferation and vascular invasion when Pttg was absent (TRβPV/PV/Pttg–/– mice) (Kim et al. 
2007a). It is therefore possible that hPTTG over-expression may lead to more aggressive 
phenotypes acting in concert with other oncogenes in other mouse models of thyroid cancer.   
It is often the case that the introduction of two oncogenes is required for 
tumourigenesis in transgenic models of disease.  For example, crossing of the Pten
L/L
;TPO-
Cre mouse with mice harboring a Kras oncogenic mutation led to invasive and metastatic 




 mouse model alone 
developed thyroid carcinomas (Miller et al. 2009).  The most obvious oncogenic partner for 
hPTTG is its binding factor PBF and to this effect, we have established a hPTTG.PBF-Tg 
bitransgenic colony which is currently being investigated in our laboratory.  While hPTTG 
and PBF have important functions that are independent of each other, PBF facilitates nuclear 
localisation and transactivational capabilities of hPTTG (Chien and Pei 2000) and their 
interaction at oncogenic expression levels may yield highly interesting phenotypes.  PBF-Tg 
mice develop goitres with 100 % penetrance (Read et al. 2011) and it will be of great interest 




to see whether concerted over-expression of hPTTG results in the development of thyroid 
malignancies.   
6.4.3 Serum thyroid hormone concentrations 
 
Serum concentrations of TSH were determined by the laboratory of Professor Samuel 
Refetoff (University of Chicago) in a method previously described (Pohlenz et al. 1999).  
Generally, there were no significant differences in serum TSH concentrations in either young 
or aged hPTTG-Tg mice.  However, TSH concentrations were undetectable in female 
hPTTG-Tg
+/- 
serum samples and thus significantly lower than WT controls.  This may have 
been a result of sample degradation and Professor Refetoff advised that assay measurements 
at the lower limit of detection are unreliable, and it is therefore unlikely that this is a true 
observation.  In addition, the phenotype of reduced thyroid size was not female specific, 
suggesting that low TSH concentration does not underly this phenotype in hPTTG-Tg mice.  
Serum levels of T3 were also similar in hPTTG-Tg and WT mice and although hPTTG-Tg 
mice demonstrated a general trend of increased serum T4 concentration, this was only 
significant at 6 weeks of age in hPTTG-Tg
+/+ 
males.  Elevated concentrations of serum T3 and 
T4 might reflect underlying hyperthyroidism, which could represent an explanation for 
reduced total body weight in 3-7 week old hPTTG-Tg
+/+ 
mice.  However, this was not 
accompanied by reduced serum TSH concentration, and relative T3 and T4 levels did not 
always correlate as would be expected.  Given the discrepancies and high variability of the 
data, it appears that hPTTG-Tg mice are euthyroid, though further measurements should seek 
to confirm this. 




 mice showed no changes in mRNA expression of Tshr and Tg 
compared with WT, indicating that hPTTG-Tg mice maintain thyroid differentiation.  






mice demonstrated similar levels of endogenous Pttg and Pbf compared with WT 
mice.  The lack of induction of Pbf expression by exogenous hPTTG in hPTTG-Tg mice was 
in contrast with previous in vitro observations (Stratford et al. 2005).  Although hPTTG 
protein shares 66 % homology with murine Pttg (Wang and Melmed 2000a), it is possible 
that the full transactivational capabilities of hPTTG are compromised in murine thyroid cells.  
Failure of hPTTG to transactivate other protooncogenes such as Pbf and c-Myc (not 
investigated in the current study) may contribute to the failure of thyroid cell transformation 
in hPTTG-Tg mice.  Given that PBF causes transformation independently of hPTTG in vivo 
(Stratford et al. 2005), it is conceivable that hPTTG-induced transformation is mediated via 
transactivation of PBF.  Indeed, a mutant form of hPTTG that does not induce PBF 
expression failed to transform NIH3T3 cells in vitro (Stratford et al. 2005).  The points raised 
here emphasise the importance of our ongoing investigation of phenotypes in hPTTG.PBF-Tg 
bitransgenic mice.   
The finding that hPTTG-Tg
 
mice had levels of Vegf and Fgf-2 thyroidal mRNA 
expression comparable to WT was inconsistent with studies from our own group 
demonstrating hPTTG induction of VEGF and FGF-2 mRNA expression in human thyroid 
cells in vitro (Boelaert et al. 2003a; Kim et al. 2006a).  Again, this may be attributed to the 
inability of hPTTG to induce these factors in murine thyroid cells.  In addition, we generally 
observed high variability in mRNA expression in mouse thyroids and Vegf and Fgf-2 
expression should be studied in greater numbers of hPTTG-Tg
 
mice to obtain more 
meaningful data.  Indeed, having decided to focus on validation of EGF, IGF-1 and TGF-α 
induction by hPTTG as described in Chapter 4, investigation of a large number of mice was 
required to overcome the high variability observed and elucidate important relationships.  We 
successfully demonstrated that WT and hPTTG-Tg thyroid tissues express Egf, Tgf-α and 
Igf-1, as well as their receptors, Egfr and Igf1r respectively.  While Egf and Igf-1 mRNA 




expression were unaltered in hPTTG-Tg
+/- 
mice, their expression was significantly increased 
in hPTTG-Tg
+/+ 
mice, indicating a copy number dependent phenotype.  However, Tgf-α 
mRNA expression was not significantly induced in hPTTG-Tg
+/+ 
mice.  Subsequent ELISAs 
demonstrated that Egf secretion was enhanced in cultures derived from hPTTG-Tg
+/+ 
mice 
compared with WT, whereas in contrast to mRNA expression data Igf-1 secretion was 
unaltered (there is currently no mouse Tgf-α assay available).  The failure of hPTTG to 
induce Tgf-α emphasises that the full transactivational capabilities of hPTTG may be 
compromised in this model.  In addition, increased transcription may not necessarily lead to 
increased translation and secretion of growth factors as was the case for Igf-1.  However, 
these observations confirm important pathways of interaction between hPTTG and EGF, and 
validate the in vitro findings in human primary thyrocytes described in Chapter 4.  
Supporting this further, Egf mRNA was under-expressed in Pttg
-/-
 thyroids, whereas Tgf-α 
and Igf-1 mRNA expression were not significantly altered. 
Following the observations in this chapter and in Chapter 4, that hPTTG induces the 
expression of various growth factors, angiogenesis-specific cDNA PCR array analyses were 
performed in mouse thyroid glands to broadly assess the effect of thyroidal hPTTG over-
expression on other genes involved in proliferation and angiogenesis.  Cxcl1, F2, Mdk and 
Tnfaip2 are all pro-angiogenic genes that demonstrated a greater than 2.0-fold upregulation in 
hPTTG-Tg
+/+ 
thyroids.  Interestingly, human homologues of Cxcl1 and Mdk were also 
induced in an angiogenesis-specific microarray following transient expression of hPTTG in 
human primary thyroid follicular cells (Kim et al. 2006b), and MDK is over-expressed in 
papillary thyroid carcinomas (Kato et al. 2000).  Tnf-α, an anti-angiogenic gene that promotes 
cell death and tumour regression (Carswell et al. 1975; Old 1985), was repressed in hPTTG-
Tg
+/+ 
thyroids.  Notably, hPTTG also downregulated several pro-angiogenic genes including 
Fgf-6, Mmp-9, Tbx-1 and Tbx-4.  Repression of Fgf-6 was in contrast to induction of FGF-6 




by hPTTG in the microarray analysis described above (Kim et al. 2006b).  Despite not 
reaching the 2.0-fold threshold, Fgf-2 and Igf-1 were induced by hPTTG, consistent with our 
detailed mRNA expression studies (see Figure 6-12 and 6-13).  In contrast with previous 
observations, Egf expression was repressed while Vegf and Tgf-α were induced in hPTTG-
Tg
+/+ 
thyroids (see Figure 6-12 and 6-13), illustrating the variability of mRNA expression 
results we have observed throughout the study.  Repression of the anti-angiogenic gene, TSP-
1, has been implicated in thyroid tumour progression (Tanaka et al. 2002).  The observation 
of hPTTG-induced Tsp-1 (below the threshold) was inconsistent with our group’s previous 
report of TSP-1 repression by hPTTG (Kim et al. 2006b).  Expression of the pro-angiogenic 
gene, Kdr, was induced by hPTTG albeit to levels below the 2.0-fold threshold, consistent 
with previous observations of KDR induction by hPTTG in follicular thyroid carcinoma FTC-
133 cells (Kim et al. 2006a).  Although extensive validation of these observations are 
required, it is clear that hPTTG may promote tumour progression by regulating the 
expression of multiple genes with both pro- and anti-angiogenic properties, and may thus be a 
key gene in triggering the angiogenic switch in thyroid tumorigenesis.   
6.4.5 Conclusions 
 
This in vivo investigation of transgenic mice with thyroid-targeted hPTTG expression 
has presented a variety of challenges.  Nonetheless, the data shows that transgenic mice with 
high levels of thyroidal hPTTG expression do not develop thyroid hyperplasia or neoplasia, 
but in fact have smaller thyroid glands.  The exact mechanisms underlying this phenotype 
remain to be determined.  It will be important to create an alternative transgenic line with low 
levels of thyroidal hPTTG over-expression to define the in vivo dose-dependent effects of 
hPTTG on thyroid cell proliferation and transformation.  Work towards this aim is described 
in Chapter 8.  Several important considerations have been discussed within this chapter, but 
the results suggest that ongoing study of hPTTG.PBF-Tg bitransgenic mice represents an 




important avenue of research whereby concerted over-expression of hPTTG and PBF may 
induce tumour formation.   
Importantly, several of our in vitro observations described in Chapter 4 were validated 
in the transgenic mouse model.  Chiefly, an important relationship between hPTTG and Egf 
in vivo was confirmed through studies in both hPTTG-Tg and Pttg
-/-
 knockout mice.  
Angiogenesis-specific cDNA PCR array analysis highlighted the potential relationship 
between hPTTG and a number of genes critically involved in tumour proliferation and 












7 CHAPTER SEVEN 
 
Regulation of Expression and Function of the Sodium Iodide 























The sodium iodide symporter (NIS) is an integral membrane glycoprotein which 
mediates active transport iodide (I
-
) into thyroid follicular cells, as the critical and rate-
limiting first step in thyroid hormone biosynthesis (Kogai et al. 2006; Dohan et al. 2003; 





Tc scintigraphic imaging as a diagnostic tool or by administering therapeutic 
doses of 
131
I for the treatment of patients with benign and malignant thyroid diseases, as well 
as their metastases, through ablation of pathological tissue in a highly targeted manner 
(Spitzweg et al. 2001; Dohan et al. 2003; Boelaert and Franklyn 2003; Riesco-Eizaguirre and 
Santisteban 2006; Kogai et al. 2006).      
However, I
- 
uptake is reduced in most thyroid cancers and their metastases compared 
with normal thyroid, thereby limiting the efficacy of radio-iodine therapies (Maxon and Smith 
1990).  Treatment with recombinant human TSH may be used to stimulate I
- 
uptake by the 
thyroid, but even then, 10-20 % of tumours remain incapable of sufficient I
- 
concentration for 
effective radio-ablation therapy (Kogai et al. 2006; Robbins et al. 1991; Schmutzler and 
Koehrle 2000).  It is therefore of critical importance to understand the mechanisms involved 
in repression of I
- 
uptake in thyroid cancer, in order to develop strategies to improve treatment 
with radioiodine.   
Various mRNA (Smanik et al. 1997; Lazar et al. 1999; Ringel et al. 2001; Arturi et al. 
2003; Park et al. 2000; Ryu et al. 1999; Ward et al. 2003) and protein studies using specific 
poly- and monoclonal antibodies (Jhiang et al. 1998b; Caillou et al. 1998; Castro et al. 1999a; 
Castro et al. 1999b; Faggiano et al. 2007; Gerard et al. 2003; Trouttet-Masson et al. 2004) 
have demonstrated reduced NIS expression in thyroid cancer tissue, suggesting repression of 
I
- 
uptake is caused by a reduction in the amount of NIS expression.  However, in several 
contrasting studies NIS expression was normal or increased (Arturi et al. 1998; Luciani et al. 




2003; Saito et al. 1998; Tanaka et al. 2000; Dohan et al. 2001; Wapnir et al. 2003), but 
immunohistochemical analysis of NIS cellular localisation showed that NIS was 
predominantly present in the cytoplasm, indicating that intracellular trafficking of NIS away 
from the basolateral membrane may be a further cause of reduced I
- 
uptake in malignancy 
(Castro et al. 1999b; Dohan et al. 2001; Wapnir et al. 2003).   
While TSH and I
- 
itself are well established major regulators of NIS expression and 
function, modulation of NIS activity is complicated and is effected by various factors (see 
section 1.6.3).  Both hPTTG and PBF have been implicated in regulation of NIS in vitro.  
Over-expression of hPTTG in rat thyroid FRTL-5 cells resulted in reduced NIS mRNA 
expression and I
- 
uptake.  This effect was at least partly dependent on hPTTG-induced FGF-2 
expression, providing further evidence for important interactions between hPTTG and growth 
factors (Heaney et al. 2001).  Subsequently, in a study confirming hPTTG expression as a 
prognostic indicator for persistent disease, immunohistochemical analysis of 16 human 
differentiated thyroid tumours demonstrated strong hPTTG over-expression that was 
associated with reduced  I
-
 uptake in patients (Saez et al. 2006).  Studies within our group 
demonstrated reduced NIS mRNA expression and I
-
 uptake in FRTL-5 cells and human 
primary thyrocytes following over-expression of hPTTG or PBF (Boelaert et al. 2007).  
Detailed promoter studies confirmed that this was a transcriptional effect mediated by specific 
binding of PBF or hPTTG to a PAX8-upstream stimulating factor 1 (USF1) response element 
within a 1 kb element in the NIS promoter known as the human upstream enhancer element 
(hNUE).  Once again, hPTTG repression of NIS was mediated partly through FGF-2 
induction, while PBF acted independently of FGF-2 to suppress NIS.  Increased hPTTG, PBF 
and FGF-2 expression was significantly correlated with reduced NIS expression in human 
thyroid cancers demonstrating the importance of these interactions in vivo (Boelaert et al. 
2007).  In an additional study, our group have demonstrated a further mechanism of NIS 




regulation by PBF, whereby PBF directly binds to and internalises NIS into intracellular 
vesicles.  The result of this mechanism was reduced NIS protein expression in the basolateral 
membrane and subsequent reduction of I
-
 uptake by FRTL-5 cells (Smith et al. 2009).  
Together, these findings suggest that over-expression of hPTTG and PBF in thyroid cancer 
(see sections 1.2.1.3 and 1.5.2) has significant implications for expression and function of 
NIS, thereby reducing the efficacy of 
131
I in the ablation and treatment of thyroid tumours. 
The aim of this study was to assess whether hPTTG and PBF over-expression affect 
the expression and function of NIS in vivo.  Thyroidal expression of NIS mRNA and protein 
was evaluated in our recently generated transgenic mouse models with thyroid-targeted 
expression of hPTTG (see Chapter 5) and PBF (see section 1.5.4).  Further, 
125
I radioiodine 
uptake assays were performed in murine primary thyroid cultures derived from transgenic 
mice.  siRNA knockdown studies were performed in transgenic murine primary thyrocytes 
and normal human primary thyrocytes to evaluate the potential of hPTTG and PBF as targets 
for enhancing NIS activity and therefore improving radioiodide therapies. 
 
7.2 Materials and methods 
 
7.2.1 Murine primary thyrocyte culture 
 
Murine thyroid follicular cells were isolated and cultured from WT, hPTTG-Tg and 
PBF-Tg thyroid glands as described previously in section 2.3.   
7.2.2 Human thyroid samples and primary culture 
 
Collection of thyroid samples was with approval of the Local Research Ethics 
committee and samples were cultured as described in section 2.2.   
7.2.3 siRNA transfection studies 
Between days 7-10 of culture, murine and human primary thyrocytes cells were 
transfected with siRNAs targeting hPTTG (100 nM # 46028) or human PBF (50 nM # 




147350, 50 nM # 14399) transcripts and controlled for by equivalent scrambled (100 nM # 
AM4635) siRNA transfections (Life Technologies, Grand Island, NY, USA).  All siRNA 
transfections were performed using the lipofectamine-2000 transfection agent (Invitrogen, 
UK) according to the manufacturer’s instructions.  Cell culture medium was replaced between 
4-6 hours to minimise the toxic effects of lipofectamine-2000.  After 72 hours, iodide uptake 
assays were performed and cell lysates were harvested in protein lysis buffer or 0.25 ml Tri 
Reagent (Life Technologies, Grand Island, NY, USA).   
7.2.4 RNA extraction, reverse transcription, QT-PCR 
 
Total RNA was extracted from murine and human primary thyrocytes as described 
previously in section 2.4.  Mouse thyroid glands and human thyroid tissue samples were 
stored in RNAlater RNA stabilisation reagent at – 20 ºC before total RNA was extracted using 
the RNeasy microkit (Qiagen, UK), as per the manufacturer’s instructions.  Subsequent 
reverse transcription and QT-PCR techniques were as described above (2.4 and 2.5).  hPTTG 
mRNA was detected using the primers and probe described above (Table 3-1).  Gene-specific 
expression assays for Pbf (Mm00521473_m1), Tshr (Mm00442027_m1) and Nis 
(Mm01351811_m1) were purchased from Applied Biosystems (Warrington, UK).   
7.2.5 Immunohistochemistry 
 
Immunohistochemical analysis of NIS protein expression in formalin-fixed, paraffin-
embedded sections of wild-type, hPTTG-Tg and hPBF-Tg mouse thyroid specimens was 
carried out as previously described in section 2.7.  A rabbit anti-rat NIS antibody was used 
(20 µg/mL) [# TIT11-A, Alpha Diagnostic International, SA, Texas, USA] (Josefsson et al. 
2002).   
 




7.2.6 Immunoperoxidase cell staining 
 
Murine primary thyrocytes were cultured on 8-well chamber slides [BD Biosciences 
Ltd.].  On day 7 of cultures, cells were fixed in ethanol for 10 minutes at room temperature.  
Cells were briefly washed in PBS before being incubated in 5 % normal goat serum (NGS) in 
PBS for 20 minutes at room temperature, followed by a specific primary anti-HA antibody 
(1:500) [# sc-805, Santa Cruz Biotechnology] for 1 hour at room temperature.  After two 5-
minute washes in PBS, cells were incubated in biotinylated anti-rabbit secondary Ab for 30 
minutes at room temperature.  Cells were again washed with PBS, before incubation with 3 % 
hydrogen peroxide for 10 minutes to block endogenous peroxidase activity.  After further 
PBS washes, the avidin-biotin-peroxidase complex was added to cells for at least 30 minutes, 
followed by further PBS washes before the reaction was developed using the DAB peroxidase 
substrate kit for 5-10 minutes and then counterstained in Mayer’s hematoxylin. Slides were 
dehydrated, cleared, and mounted.   
7.2.7 Western blot analysis 
 
Protein extraction, quantification and subsequent Western blotting methods were as 
described previously (see section 2.6).  For PBF detection, membranes were incubated with 
rabbit primary antibodies against PBF (1:1000) (Smith et al. 2009; Watkins et al. 2010) and 
HA (1:500) [# sc-805, Santa Cruz Biotechnology]. 
7.2.8 Iodide uptake assays 
 
Murine and human primary thyrocytes were grown in 12 well plates in 0.5 ml 
medium.  The incorporation of 
125
I was used as a standard marker of thyroid cell function and 




moles/l in human and 
murine cells, respectively) and 0.05 µCi 
125
I (Hartmann Analytic, Germany) per well for 2 
hours as previously described (Eggo et al. 1996; Boelaert et al. 2007).  The cell layer was 




rapidly washed with HBSS to remove unincorporated iodide and the cells lysed in 2 % SDS 
protein lysis buffer or 0.25 mL Tri Reagent.  Incorporated radioactivity was counted in a 
gamma counter.  Relative iodide uptake was corrected for protein concentration as measured 
by the Bradford assay. 
7.2.9 Statistical analysis 




7.3.1 hPTTG and PBF repress NIS expression in vivo 
 
To investigate the effects of thyroidal hPTTG and PBF over-expression on NIS in 
vivo, we performed investigations using hPTTG-Tg and hPBF-Tg mice.  Analysis of whole 
thyroid glands using Real-Time PCR revealed reduced NIS mRNA expression in 6-week-old 
age and gender matched hPTTG-Tg
+/-
 (0.62-fold, n = 5, p < 0.05), hPTTG-Tg
+/+
 (0.64-fold, n 
= 3, p < 0.05) and hPBF-Tg (0.52-fold, n = 10, p < 0.001) mice compared with WT controls 
(see Figure 7-1).   





Figure 7-1: hPTTG and PBF over-expression reduce NIS mRNA expression in vivo.  TaqMan RT-
PCR data showing relative thyroidal NIS mRNA expression in hPTTG-Tg+/- and hPTTG-Tg+/+ (A), 
and hPBF-Tg (B)mice compared with wild-type controls.  Error bars represent the SEM (* p < 0.05, 
*** p < 0.001). 
 
Assessment of NIS immunostaining in thyroid sections from 6-week-old age and 
gender matched mice, revealed a heterogeneity of NIS expression across whole thyroid lobes, 
but with an overall reduction in NIS protein expression in hPTTG-Tg and hPBF-Tg mice 







































































Figure 7-2: hPTTG and PBF over-expression reduce NIS protein expression in vivo.  A  Detection 
of NIS by immunohistochemistry of WT (ii), hPTTG-Tg+/- (iii) and hPTTG-Tg+/+ (iv) thyroids.  A no 
primary antibody control demonstrates the specificity of the HRP-conjugated secondary antibody (i).  
B   Detection of NIS by immunohistochemistry of WT (i) and hPBF-Tg (ii) thyroids.  Scale bars: 100 
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7.3.2 Analysis of NIS function in vivo 
 
Given that hPTTG-Tg and hPBF-Tg mice showed repressed NIS mRNA and protein 
expression, we set out to investigate NIS function in these transgenic mouse models.   
7.3.2.1 Establishment of murine thyrocyte cell culture 
 
We adopted an approach involving the routine culture of murine primary thyrocytes, 
using a technique adapted from previously described methods for murine and human primary 
thyroid culture.  The morphology of cell cultures was microscopically examined daily to help 
determine the optimal culture conditions, culminating in the final protocol described in the 
materials and methods (see section 2.3).  Isolated thyroid follicles (primary follicles) adhered 
to culture plates on day one and progressively flattened to form multiple layers of cells.  By 
day 5, most follicles had lost their 3-dimensional structure and a monolayer of thyrocytes 
began filling the inter-follicular spaces.  Cells continued to spread, becoming more confluent 
by day 10, at which point numerous secondary follicles appeared to form (see Figure 7-3). 
 





Figure 7-3: Murine primary thyroid cell culture.  A  Day one – isolated primary follicles adhere 
to cell culture plate.  B  Day 5 – Primary follicles have flattened and a monolayer of thyrocytes begins 
to fill inter-follicular spaces.  C/D  Day 10 – Cells have continued to spread and form secondary 
follicular structures.  
  
 
7.3.2.2 Validation of murine thyrocyte cell culture system 
 
Prior to carrying out full scale investigations, we performed several critical validation 
experiments to determine the suitability of murine primary thyrocyte cultures as a model for 
our studies.  We adopted two approaches to determine whether transgene expression is 
maintained by primary thyrocytes in culture, following digestion of whole thyroids.  Firstly, 
analysis of PBF-HA expression in murine primary thyrocytes by immunocytochemistry 















staining in WT cultures.  Secondly, Real-Time PCR analysis revealed strong hPTTG mRNA 
expression in hPTTG
+/-
 cultures, which was approximately double in hPTTG
+/+
 cultures, 
compared with completely undetectable levels in WT cultures.  Importantly, these results 
demonstrate that our cultures were thyroid-specific and maintain transgene expression (see 
Figure 7-4).  
 
Figure 7-4: Murine primary thyrocytes derived from transgenic thyroid glands maintain 
transgene expression in culture.  A  Immunohistochemistry demonstrating detection of hPBF-HA 
protein in hPBF-Tg but not WT primary thyrocytes.  B  TaqMan RT-PCR data showing detection of 
high hPTTG expression in hPTTG+/- and hPTTG+/+ primary thyrocytes. Error bars represent the SEM. 
 
 Subsequently, Real-Time PCR analysis determined that the TSH-R is expressed by 
murine primary thyrocytes (ΔCt = 13.56, n = 6) where WT cultures were used for this 
purpose.  Further Real-Time PCR analysis revealed that WT primary thyrocytes (0.9-fold, n = 
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3).    hPTTG-Tg
+/-
 (0.77-fold, n = 16, p = NS) and hPTTG-Tg
+/+
 (0.6-fold, n = 11, p = NS) 
mouse primary thyrocytes (n = 14) demonstrated a trend of reduced NIS mRNA expression 
compared with WT cultures, similar to that described in whole thyroid glands in section 7.3.1.  
In this instance, the trend was non-significant due to highly variable results observed in the 
cultures.  Importantly, these results indicated that murine primary thyrocytes maintained NIS 
expression in culture and were likely to be responsive to TSH in the culture medium – a 
critical regulator of NIS expression and function (see Figure 7-5).  Preliminary iodide (
125
 I) 
uptake assays in WT cultures verified that our murine primary thyrocyte cultures were 
functional, demonstrating an average uptake of 4222.1 cpm/µg protein (n = 20).   
 
Figure 7-5: TaqMan RT-PCR data demonstrating maintained NIS mRNA expression in WT and 
hPTTG-Tg murine primary thyrocytes.  Error bars represent the SEM (NS = non-signifcant).   
 
 
7.3.2.3 hPTTG and PBF repress NIS function in vivo 
 
Having demonstrated our capability to culture functional murine primary thyrocytes 
that maintain transgene expression, we examined NIS function in our transgenic mouse 













































assays after 7 days of culture.  Results were corrected for protein concentration and revealed 
potent and significant repression of 
125
I uptake in hPTTG-Tg
+/-
 (0.57-fold, n = 15, p < 0.05), 
hPTTG-Tg
+/+
 (0.35-fold, n = 14, p < 0.001) and hPBF-Tg mice (0.27-fold, n = 14, p < 0.001) 
compared with WT (n = 14) (see Figure 7-6). 
 
Figure 7-6: Relative 125I uptake in primary thyrocyte cultures from WT (n = 14), hPTTG-Tg+/- (n 
= 15), hPTTG-Tg+/+ (n = 14) and hPBF-Tg mice (n =14).  Error bars represent the SEM (* p < 0.05, 
*** p < 0.001, NS = non-significant).  
 
 
7.3.3 PBF knockdown rescues NIS phenotype 
 
Adequate radioiodide uptake is a critical determinant of successful treatment of benign 
and malignant thyroid disease.  We set out to investigate whether repressed 
125
I uptake in 
hPTTG-Tg and hPBF-Tg thyroid cultures could be ameliorated.  Primary thyrocyte cultures 
from hPTTG-Tg or hPBF-Tg mice were transfected with siRNA targeted to hPTTG and 
human PBF respectively.  Unfortunately, we were unable to consistently knockdown 
transgenic hPTTG expression in hPTTG-Tg thyrocytes (data not shown).  However, 
following successful PBF knockdown in hPBF-Tg thyrocytes, 
125
I uptake increased 2.4 ± 
0.64-fold (n = 20, p < 0.05) to levels indistinguishable from WT (n = 8, p = NS), whereas 
transfection using a scrambled siRNA did not alter 
125
I uptake (n = 20, p = NS) (see Figure 









































Figure 7-7: NIS function is restored following knockdown of PBF in hPBF-Tg primary thyrocytes.  
A + B  Western blot analyses demonstrating successful knockdown of transgenic PBF expression in 
hPBF-Tg primary thyrocytes, using either a PBF (A) or an HA (B) antibody.  C  Histogram displaying 
restoration of 125I uptake in hPBF-Tg primary thyrocytes following PBF knockdown, to levels similar 
to those in WT cultures. Error bars represent the SEM (* p < 0.05, ** p < 0.05, NS = non-significant).  
 
 
7.3.4 PBF and hPTTG as therapeutic targets 
 
To investigate the potential of PBF and hPTTG as therapeutic targets in human 
thyroid hyperplasia and neoplasia, we performed radioiodide uptake studies in primary 
cultures of normal human thyrocytes following transient knockdown of PBF or hPTTG.  As 
in murine cultures, Western blot analysis confirmed successful repression of PBF protein 
expression in human thyrocytes.  Reduced PBF expression was associated with a significant 
increase in NIS mRNA expression (2.1-fold, n = 9, p < 0.05) at 72 hours post-transfection.  
Crucially, targeted repression of endogenous PBF expression in human thyrocytes resulted in 
PBF    30kDa























































a significant increase in radioiodide uptake (2.0-fold, n = 11, p < 0.001), compared with 
scrambled controls (n = 11) (see Figure 7-8). 
 
Figure 7-8: PBF as a therapeutic target in human thyroid disease.  A  Western blot analysis 
demonstrating successful knockdown of endogenous PBF in normal human primary thyrocytes.  B  
TaqMan PCR data demonstrating increased NIS mRNA expression in normal human primary 
thyrocytes following PBF knockdown.  C  Histogram displaying enhanced 125I uptake by normal 
human primary thyrocytes following repression of PBF.  N = 4 experiments.  Error bars represent the 
SEM (* p < 0.05, ** p < 0.001).   
 
 Transfection with a specific hPTTG siRNA resulted in approximately 50 % 
knockdown of hPTTG protein expression in human primary thyrocytes, as determined by 
Western blot analysis.  Although radioiodide uptake was elevated following hPTTG protein 
depletion, there was no significant difference in comparison to scrambled transfection 
controls (1.4-fold, n = 12, p = NS) (see Figure 7-9).   
PBF    30kDa










































































Figure 7-9: hPTTG as a therapeutic target in human thyroid disease.  A  Western blot analysis 
demonstrating partial knockdown of endogenous hPTTG in normal human primary thyrocytes.  B  
Histogram displaying 125I uptake levels by normal human primary thyrocytes following repression of 
hPTTG.  N = 3 experiments.  Error bars represent the SEM (NS = non-significant).   
 
7.3.5 PBF-Tg murine primary thyrocyte control study 
 
In the PBF siRNA studies described in section 7.3.3, a commercial siRNA against 
human PBF was used, where we had no knowledge of its activity against endogenous mouse 
PBF transcripts.  Following the above observations that repression of endogenous PBF results 
in enhanced NIS expression and function in normal human primary thyrocytes, we performed 
a control experiment in WT murine primary thyrocytes to attempt to discern the effects 
caused by repression of either endogenous or transgenic PBF expression.  Real-Time PCR 
analysis following transfection of WT murine primary thyrocytes with human PBF siRNA 
revealed that neither endogenous mouse Pbf (1.09-fold, n = 6, p = NS) or Nis (1.69-fold, n = 
6, p = NS) mRNA expression was significantly altered.  Crucially, there was no significant 
difference observed in 
125
I uptake between PBF (1.03-fold, n = 20, p =NS) and scrambled (n = 
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reversal of hPBF-Tg NIS phenotypes described in section 7.3.3 was due to specific repression 
of transgenic human PBF expression.  See Figure 7-10. 
 
Figure 7-10: Effect of PBF siRNA transfections on endogenous mouse PBF and NIS expression and 
function in WT murine primary thyrocytes.  A + B  TaqMan RT-PCR demonstrating that endogenous 
mouse PBF (A) and NIS (B) mRNA expression are unaltered in WT murine primary thyrocytes 
following transfection with hPBF siRNA. C  Histogram displaying no alteration in 125I uptake in WT 
cultures following transfection with hPBF siRNA.  Error bars represent the SEM (NS = non-



















































































































  Radioiodine ablation therapies are central to the treatment of thyroid cancer and toxic 
nodular hyperthyroidism, and are also increasingly used as first-line therapy in Graves’ 
disease (Weetman 2007) and to induce size reduction of benign goiters (Hegedus et al. 2003).  
The sodium iodide symporter (NIS) facilitates delivery of radioiodine but expression and 
activity of NIS are often repressed in thyroid cancers (Dohan et al. 2003; Boelaert and 
Franklyn 2003; Kogai et al. 2006).  In vitro studies have demonstrated that hPTTG and PBF 
repress NIS transcription (Heaney et al. 2001; Boelaert et al. 2007) and that PBF also 
regulates intracellular localisation of NIS (Smith et al. 2009), both resulting in reduced I
-
 
uptake by thyroid cells.  In this chapter of work, we have conducted studies in transgenic mice 
with thyroid-targeted hPTTG and PBF expression to investigate whether these interactions 
exist in vivo.  This, together with our knowledge that hPTTG (Heaney et al. 2001; Boelaert et 
al. 2003a) and PBF (Stratford et al. 2005) are over-expressed in thyroid cancer, suggests they 
represent potential targets for enhancing active NIS expression and radioiodide therapies in 
thyroid disease.  To explore this, we performed siRNA knockdown studies in murine and 
human primary thyroid cells to determine if targeting PBF and hPTTG expression enhances 
NIS expression and activity.   
7.4.1 NIS expression and function in hPTTG-Tg and PBF-Tg mice 
 
Given that hPTTG and PBF regulate NIS expression and activity in vitro, we analysed 
expression levels of NIS in our transgenic mouse models with thyroid-targeted over-
expression of hPTTG and hPBF (Heaney et al. 2001; Boelaert et al. 2007; Smith et al. 2009).  
TaqMan RT-PCR analysis revealed that NIS mRNA expression was reduced by 




thyroids, and by approximately 





and hPBF-Tg thyroids was confirmed by immunohistochemical analysis.   




To investigate the functional consequence of reduced NIS expression in our transgenic 
mouse models, we established a protocol for routine culture of murine primary thyroid 
follicular cells and performed extensive validation studies to ascertain its suitability as an 
experimental model.  Microscopic analysis of murine thyroid cultures demonstrated our 
ability to isolate thyroid follicular cells that adhere, spread and form secondary follicular 
structures, as previously described (Jeker et al. 1999).  Critically, transgene expression was 
maintained in murine primary cultures derived from transgenic thyroid glands, as determined 
by immuncytochemistry and TaqMan RT-PCR, suggesting that we could expect any in vivo 
transgene effects to be preserved in ex vivo cultures.  In addition, given that transgene 
expression is theoretically confined to thyrocytes, this confirmed the purity of our cultures, 
specifically containing mouse thyroid follicular cells with minimal contamination by 
fibroblasts.    
TSH is the major hormonal regulator of thyroid cell function (Dohan et al. 2003; 
Boelaert and Franklyn 2003; Kogai et al. 2006) and TaqMan RT-PCR analysis demonstrated 
expression of TSH-R in WT cultures, indicating that our murine primary thyroid cells would 
be responsive to TSH in the culture medium.  Further TaqMan RT-PCR analysis 
demonstrated that expression of NIS mRNA in WT cultures was comparable to that of WT 
whole thyroid glands, indicating our ex vivo cell culture system was representative of in vivo 
biology and possessed the major components required for I
- 





cultures demonstrated a trend of reduced NIS mRNA expression compared 
with WT cultures, similar to that described in whole thyroid glands in section 7.3.1.  In this 
instance, the trend was non-significant due to the relatively variable results observed in the 





uptake assays demonstrated significant uptake by WT murine primary 
thyrocytes with an average of 4222.1 cpm/µg protein, thereby confirming functionality.   













fold) and PBF-Tg (0.27-fold) thyroid cultures compared with WT, confirming that reduced 
NIS mRNA and protein expression in transgenic mice caused reduced I
- 
uptake.  PBF-Tg 
cultures showed a 73 % repression of I
- 
uptake, which in combination with our observation of 
~50 % inhibition of NIS mRNA expression, suggests that repressed I
- 
uptake in PBF-Tg 
cultures may additionally encompass altered subcellular localisation of NIS in accord with our 
group’s in vitro observations (Smith et al. 2009).  Thyroid hyperplasia in PBF-Tg mice is 
driven by activation of the TSH-R and AKT (Read et al. 2011); thus, repression of NIS 
expression and function in PBF-Tg thyroids may be partly mediated by activation of PI3-
Kinase, which has been implicated in downregulating NIS expression (Zaballos et al. 2008; 
Kogai et al. 2008) and trafficking to the basolateral membrane (Knostman et al. 2007b).   
7.4.2 PBF and hPTTG as targets to improve I- uptake in thyroid disease 
 
hPTTG (Heaney et al. 2001; Boelaert et al. 2003a) and PBF (Stratford et al. 2005) are 
over-expressed in thyroid cancer, and while hPTTG expression is unaltered in multinodular 
goitre (MNG) (Boelaert et al. 2003a), PBF expression is increased in MNG in association 
with reduced NIS expression (Read et al. 2011).  PBF-Tg mice have normal thyroid function 
and exhibit a striking enlargement of the thyroid gland associated with hyperplastic and 
macrofollicular lesions, bearing similarities to human MNG (Read et al. 2011), while no 
thyroid growth was observed in hPTTG-Tg mice (see Chapter 6).   
Following confirmation of reduced I
- 
uptake in transgenic thyroid cultures, we set out 
to investigate hPTTG and PBF expression as potential therapeutic targets by performing 
siRNA knockdown studies.  Unfortunately, we were unable to consistently knockdown 
hPTTG protein expression in hPTTG-Tg thyroid cultures, even with a high dose of 100 nM 
hPTTG siRNA.  Future repeats of this study should focus on optimisation of hPTTG 
knockdown in hPTTG-Tg primary thyrocytes.  However, PBF protein expression was 




strongly and reproducibly repressed following transfection with PBF siRNA.  Critically, PBF 




uptake by PBF-Tg 
primary thyrocytes was restored to levels comparable to those of WT cultures.  This exciting 
result verifies the specificity of the PBF-induced NIS phenotype and highlights PBF as a 
potential therapeutic target.   
In order to investigate whether PBF represents a potential therapeutic target in human 
thyroid disease, we used primary cultures of normal human thyrocytes, and investigated the 
effects of altered PBF expression on radioiodide uptake.  PBF depletion resulted in a ~2.0-




uptake by human primary thyrocytes in association with increased 
expression of NIS mRNA, providing further evidence for the functional interaction between 
PBF and NIS.  In a parallel study, we investigated the therapeutic potential of hPTTG.  In 
contrast to studies performed in hPTTG-Tg murine primary thyrocytes, moderate knockdown 




uptake.  It is possible that 
knockdown of hPTTG was not strong enough to elicit an alteration in NIS function.  
Alternatively, hPTTG regulation of NIS transcription could be an acquired function that is 
only active when hPTTG is over-expressed as it is in thyroid malignancies, but does not 
regulate NIS when expressed at physiological levels as it is in normal thyroid tissue or MNG 
(Boelaert et al. 2003a).  In contrast, PBF appears to regulate NIS expression and activity in 
normal thyroid tissue and this function is enhanced when PBF is over-expressed in thyroid 
disease (Read et al. 2011; Stratford et al. 2005).   
7.4.3 Conclusion 
 
Overall, these results provide critical in vivo evidence that both hPTTG and PBF 
downregulate thyroidal NIS expression and reduce I
- 
uptake, which has important implications 
for the efficacy of radiodine therapies in thyroid disease where hPTTG and PBF are over-
expressed.  The resemblance between PBF-Tg mouse phenotypes and human MNG indicates 




that PBF may be important in the aetiology and treatment of hyperplastic thyroid diseases, in 
addition to its more established role in thyroid cancer.  While further investigations are 
required to determine the benefits to radioiodide uptake by targeting hPTTG expression, we 
have crucially demonstrated that the binding partner of hPTTG, PBF, represents a novel 
therapeutic target to overcome radioiodine resistance in thyroid tumors and their metastases, 











8 CHAPTER EIGHT 
 
Creation of a Transgene Construct for the Generation of an 































In Chapters 5 and 6 we described the generation and characterisation of a murine 
transgenic model with thyroid-targeted over-expression of hPTTG (hPTTG-Tg mice).  The 
major limitation of this study was that only one transgenic line was available for 
investigation.  Our observation that hPTTG-Tg mice had smaller thyroids compared with WT 
mice was in contrast to studies reporting hPTTG-induced tumour formation in athymic nude 
mice (Zhang et al. 1999b; Kakar and Jennes 1999), and hPTTG-induced hyperplasia in the 
pituitary glands (Abbud et al. 2005) and ovaries (El-Naggar et al. 2007) of transgenic mice.  
In a study from our own group, low levels of hPTTG over-expression caused increased 
proliferation in fetal neuronal NT-2 cells, while high levels of hPTTG resulted in inhibited 
cell growth (Boelaert et al. 2003b).  Accordingly, hPTTG-Tg mice demonstrated high levels 
of thyroidal hPTTG over-expression associated with reduced thyroid size.  This observation 
prompted the hypothesis that hPTTG effects on thyroid cell proliferation in vivo may be 
dependent on expression levels.  In order to test this hypothesis, we set out to create 
alternative transgenic lines and aimed to investigate thyroid phenotypes in a model with low 
levels of thyroidal hPTTG over-expression. 
Having previously failed to detect hPTTG-FLAG using FLAG antibodies (Chapter 5), 
the aim of the work described in this chapter was to adapt the Tg-hPTTG-FLAG transgene 
construct to replace the FLAG epitope with an HA epitope (Tg-hPTTG-HA).  This work 
provides another transgene construct for pronuclear injection in order to generate alternative 
transgenic lines with varying levels of thyroidal hPTTG expression.  In turn, this will allow us 
to define if phenotypes are dependent upon the level of thyroidal hPTTG over-expression in 








8.2 Materials and methods 
 
8.2.1 Site-directed mutagenesis of pBSK-Tg-hPTTG-FLAG 
 
pBSK-Tg-hPTTG-FLAG was as described in Chapter 5 (see Figure 5-4 and 5-7).  The 
C-terminal FLAG sequence was converted to an HA sequence through site-directed 
mutagenesis (see Figure 8-1), using the QuickChange site-directed mutagenesis kit 
(Stratagene, UK), as per the manufacturer’s instructions.  Briefly, 50 µl mutagenesis reactions 
contained 40 ng of plasmid dsDNA, 5 µl 10 x reaction buffer, 1 µl dNTP mix, 125 ng of 
forward and reverse mutagenic primers, water and 1 µl PfuTurbo DNA polymerase (2.5 
U/μl).  Mutagenic primers were as described in Figure 8-1 C and D.  Mutagenic PCR 
reactions were performed using a Mastercycler gradient (Eppendorf, Hamburg, Germany).  
Reactions were as follows: 95 °C for 30 seconds; then 17 cycles of 95 °C for 30 seconds, 55 
°C for 1 minute, and 68 °C for 6 minutes (1 minute/1 kb plasmid DNA).  Subsequently, 1 µl 
of DpnI restriction enzyme (10 U/µl) was added to reaction products and incubated at 37 °C 
for 1 hour in order to digest digest the parental DNA template and to select for mutation-
containing synthesised DNA. 
 
8.2.2 Transformation into DH5α cells 
Transformation of 1 µl of mutation-containing synthesised DNA into 50 µl DH5α 
cells was performed as decribed in section 5.2.1.4.   
 
8.2.3 Plasmid DNA purification and sequence verification  
Bacterial colonies were cultured overnight as described in section 5.2.1.5.  Plasmid 
DNA was purified from these cultures using the Wizard
®
 Plus SV Minipreps DNA 
Purification System (Promega) as described in section 5.2.1.5. 
 




8.2.4 DNA sequencing of miniprep DNA 
DNA sequencing was performed as described in section 5.2.1.6 in order to confirm 
incorporation of the desired mutations.  Sequencing primers F and L (see Figure 5-6 B) were 
used for this purpose.   
8.2.5 Maxiprep of pBSK-Tg-hPTTG-HA 
Following confirmation of successful mutation, bacterial cultures originating from the 
same colonies were set up and larger quantities of DNA were purified by maxiprep as 
described in section 5.2.1.7.   
8.2.6 DNA sequencing of pBSK-Tg-hPTTG-HA 
The correct nucleotide sequence and orientation was confirmed using the primers 
described in the table in Figure 5-6 B and by DNA sequencing analysis as described in section 
5.2.1.6. 
8.2.6.1 Isolation of transgene for pronuclear injection 
The final linearised transgene construct was isolated using restriction enzyme digest 
reactions and diagnostic agarose gels.  Restriction enzyme digest of pBSK-TG-hPTTG-FLAG 
was performed in reactions similar to those described in section 5.2.1.3  using Xho 1, Spe 1 
and Pvu 1.  The reaction product following digestion with Xho 1, Spe 1 and Pvu 1 was 
electrophoresed on a 1.5 % agarose gel and the presence of a DNA fragment for the predicted 
size of ~3500 bp was gel extracted and purified as described in section 5.2.1.2.   
8.2.6.2 Isolation of transgene for pronuclear injection 
The final linearised transgene construct was isolated using restriction enzyme digest 
reactions and diagnostic agarose gels as previously described (see section 5.2.1.11). 
 






8.3.1 Strategy for generation of hPTTG-HA transgene construct 
 
Following failure to detect hPTTG-FLAG in hPTTG-Tg mice using FLAG antibodies 
(Chapter 5), we decided to create alternative transgenic lines using a construct consisting of 
hPTTG cDNA with a C-terminus HA-tag.  Other components of the transgene construct 
remained identical.  The pBSK-Tg-hPTTG-FLAG created in Chapter 5 (see Figure 5-4 and 5-
6), was mutated directly to avoid other cloning steps.  A two-step site-directed mutagenesis 
strategy was adopted to mutate 16 base pairs within the FLAG sequence, converting this to a 
sequence encoding the HA-epitope.  See Figure 8-1.   





Figure 8-1: Generation of the Tg-hPTTG-HA transgene construct.  A  Schematic diagram 
illustrating the strategy for generation and isolation of the Tg-hPTTG-HA construct (1. Site-directed 
mutagenesis, 2. Restriction enzyme digest, 3. Isolated Tg-hPTTG-HA construct).  B  Nucleotide 
sequences of FLAG (red) and HA (orange) epitopes, with amino-acid sequences underneath (blue).  C 
+ D  Mutagenic primers for step 1 (C) and step 2 (D).  Mutated base pairs following step 1 are 
indicated in purple, while those from step 2 are indicated in pink.   
 
8.3.2 Verification of construct by DNA sequencing 
 
Following each mutagenesis step, sequencing of DNA minipreps using Primers F and 
L (see Figure 5-6 B) confirmed that reactions had successfully incorporated the desired 
mutations.  Having extensively validated activity of the pBSK-Tg-hPTTG-FLAG construct in 
vitro and in vivo in Chapter 5, we did not perform any further in vitro validation studies at this 
stage with the pBSK-Tg-hPTTG-HA contstruct.  However, as undesired spontaneous 
5’ – GTG ACA TAG ATA TTT ACC CAT ACG ACG ATG ACG ACA AGT AAG – 3’




5’ – CCC ATA CGA CGT CCC AGA CTA CGC TTA AGG ATC CAG ATC – 3’











5’ – GAC TAC AAA GAC GAT GAC GAC AAG– 3’
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mutations can occur during site-directed mutagenesis and DNA maxi-preps, we used the same 
primers as detailed previously (see Figure 5-6 B) to verify the correct nucleotide sequence and 
orientation of all construct components (see Figure 8-2). 
 
Figure 8-2: Direct sequencing of the pBSK-Tg-hPTTG-HA construct confirmed the correct 
nucleotide sequence and orientation of the construct.  The nucleotide sequence for the transgene 
construct from the Spe 1 to Xho I restriction sites (3566 bp) is shown.  Sequencing primer details are 
given in Figure 5-6 B.   
  
8.3.3 Isolation and preparation of the transgene construct 
A linearised transgene construct was isolated using restriction enzyme digest reactions 
and diagnostic agarose gels.  As described previously (Chapter 5), digestion with only Xho 1 
and Spe 1 resulted in two bands of DNA migrating very closely together, representing the 
~3500 bp transgene and a similarly sized fragment from the remainder of the plasmid.  
Additional digestion with Pvu 1 caused cuts at two further sites within the pBSK plasmid so 
                                                                        BOVINE THYROGLOBULIN PROMOTER                   Spe I site ACTAGT 
 BETA GLOBIN INTRON II                    BamH1 site GGATCC 
                                                                        T7 PROMOTER                       Cla I site ATCGAT 
HUMAN PTTG                   EcoR1 site GAATTC  
                 HA-TAG                                                         Xho 1 site CTCGAG 
POLY-A TAIL                                  Sal 1 site GTCGAC 
                STOP SITE  TAA 
 
ATTAACCCTCACTAAAGGGA.....................ACTAGTGGATCC AGGAGGGAGAGGTGAGAGGGCC AGAGGTGAGGAGCCTGC AGAGAGG ATGGAGACCC AAGC CAGGAGCGG
GCTC ACGGAGGCC AGACC AAGGAGTTGGTGC TGAGTTTCCGTAGAGC ATCCTCCTGGCTC AC GAGGC ATC AGATGATGGTAGGAGCTGAGTC ATCGTGAGAAAGAGGTTTTC
AC GGTGTGGAGGC AGCGCCTGGC ATGGCTC TCTCC AAGC TC ATCGCTTC ATTGC TGGAGTGGAGAGAAGC ACC TCTCC TTCC AGGTAC ACTGTTTTGAC TC AGAAGGAAGCC
CGGGCGGCTCTCACCCTCACTGACTCTGCTGTGCCTC TTCCC AGGGGCC AGGCC AGGGAGAATGAC TC AGC AC AC AAGCTGGCCTGTGC AAGACCCTGCCTGC ATGC ATGG
GTGGGGGAAGC ATGAGGAGTGGGC TTTC TGGTAGACC TC AGTC ATGGTCTC AGC ATTATTTTTTAAAAGGATTTTATTTATTTGTTTTGATGTGGACC AGTTTTAAAATCTTTATT
GAATTTGTTACC ATGTTGC TTC TGTTTTATGTTTTGGTTTTTTGGCC ACGAGGC ATGGGGGATGTTAGCTCCCCGACC AGGGACTGAACCCTTGCCCCCTGC ATGGAAAGGTC A
AGTCTTAAC TTCTTGAC TGCC TAGGAAGTCCCGGTTTC AAC ATTTTAGAAAATTC ATC TGCTTTAGAAC ACCTGGACCTGGAGAGCTGGC AAGGGCTGC AC ATGGCC AGGC TC
AC GGTAAT ATTAC AGCGTC TCC ATAGCCTGGGC AGAACTTGGCTTGTGTGATTGGGGC TGTGGGC TCCCCAGGTGGTGCTAGTGGTAAAGAACCCTTCTGCCAGTGC AGGAG
AC AT AAGAGATGCGGGTTC TATCCCTGGATC AGGAAGATCCCCTGGAGAAGGAAATGGC AACCTGCTCC AGGATTC TTGCCTGGAGAATCCC AAGGAC AGAAGAGCCTGGC
GGGCCGTAGTCC ATGGCGTTGC AAAGAGTC AGAC AC AACCGAAGC GAC TTAGC ACCC AATGGGGGCTGGAGAGGGCC AAGC TGGGGGATTC TAATTCTCC AGTAAATGCC A
GC ATGTC TTCTC AAATC ATCTTTACC TAAAACC TAAGGCTC ATTGTGATCTCCCTC AC TCCC AAGTGCTCTCCCACACCTGCCCACCTACCTTCTGAAC ACCC ATGGAGCCTGT
CTCC ATCCCCC ACCCCTTTAATGGGAGAAGCC ACTGGAGAAAGC TC AC TGATGTAC AGGC TTTATGTGGAAGAC AAGCTTCCTGCTGCCTTTTGGTTGTC TGACGTCCTGGGA
CAGAGGGGAAAGGGGGATGAC TAC GAGTATGACTGTGCGTGTGTTTGGC TTATCTC ATC AAAATCTC TAC ATTC TGTGTTAATGGATC TGCC TGTTTTGTTCCCTGCC ATATCC
TC ATGGCC TAGAAT AGTGTC TGC TTC TCTATC AGAC TCTAAAGAAAC ATTGCTAGGAGGGAAGGAAGGAGC ATGGATGAGGAGGGAGGGAGC ATTGTGTTTC TCTC AC GGTG
GGCCTGAACGTGTGGCCC ACC AAGTTGTTAAC TTTGGCCTTTACCCCTGAAGATGAATTATGAAGCC AC ACCCCC AGTTCTTCCTTGGTGGCTC AGATGGTC AAGAATCC ACC
TGC AATGCGGGAGACC TGGGTTTGATCCCTGGGTTGGGAAGATCCCCTGGAGAAGGGAATGGCTACCCACTCC AGTATTC TGGCCTGGAGAATCCC ATGGAC AGAGGAGCC
TGGCGGGATGC AGTCC ATGGGGTCTC AGAGAGTC AGATGTGAC TGAGCGAC TTTC AC AC AC ATTCGTCCCTGGTTCTGCTCCCCTAC AGCCTCC AC AAGATTTTC ACCCC AC A
CTGGCC AC ATGAGTGTCC TCC AGGGGAAC AGACGC AGGTGGAGGACCTCCTTGTGACC AGC AGAGAAAAC AGGGTGGGC AC TGC TTCCCTGAGTGCCTGTGGGTGGGGGC
TAAGTACCC AC AGCAGTGCTATAAAGGCTCCTTGGCC AGAGCCCTAAGGTGGGC AGC AGGGGATCCCCCGGGC TGC AGGAATTC GATAtC AAGC TTATCGAT CCTGAGAACT
TC AGGGTGAGTTTGGGGACCCTTGATTGTTCTTTC TTTTTCGCTATTGTAAAATTC ATGTTATATGGAGGGGGC AAAGTTTTC AGGGTGTTGTTTAGAATGGGAAGATGTCCCTT
GTATC ACC ATGGACCCTC ATGAT AATTTTGTTTCTTTC ACTTTCTACTC TGTTGAC AACC ATTGTC TCCTC TTATTTTCTTTTC ATTTTCTGTAAC TTTTTCGTTAAACTTTAGCTTG
CATTTGTAACGAATTTTTAAATTC AC TTTTGTTTATTTGTC AGATTGTAAGTACTTTCTC TAATC AC TTTTTTTTC AAGGC AATC AGGGTAT ATTATATTGTAC TTC AGC AC AGTTTT
AGAGAAC AATTGTTATAATTAAATGAT AAGGTAGAATATTTC TGC ATAT AAATTC TGGCTGGCGTGGAAATATTCTTATTGGTAGAAACAACTACATCCTGGTCATC ATCC TGCC
TTTC TCTTTATGGTTAC AATGATATAC ACTGTTTGAGATGAGGATAAAAT ACTC TGAGTCC AAACCGGGCCCCTCTGC TAACC ATGTTC ATGCCTTCTTC TTTTTCCTAC AGCTC
CTGGGC AACGTGC TGGTTATTGTGC TGTCTC ATC ATTTTGGC AAAGAATTG TAATACGACTC ACTATAGGGCGAATTC ATGGCTACTC TGATC TATGTTGAT AAGGAAAATGGA
GAACC AGGC ACCCGTGTGGTTGC TAAGGATGGGC TGAAGC TGGGGTCTGGACC TTC AATCAAAGCCTTAGATGGGAGATC TC AAGTTTC AAC ACC ACGTTTTGGC AAAACGT
TCGATGCCCC ACC AGCCTTACCTAAAGCTAC TAGAAAGGC TTTGGGAAC TGTC AAC AGAGCTAC AGAAAAGTCTGTAAAGACC AAGGGACCCCTC AAAC AAAAAC AGCC AA
GCTTTTCTGCC AAAAAGATGAC TGAGAAGAC TGTTAAAGC AAAAAGCTC TGTTCCTGCCTC AGATGATGCC TATCC AGAAATAGAAAAATTC TTTCCCTTC AAT CCTCTAGAC T
TTGAGAGTTTTGACC TGCCTGAAGAGCACCAGATTGCGCACCTCCCCTTGAGTGGAGTGCCTCTCATGATCC TTGAC GAGGAGAGAGAGCTTGAAAAGC TGTTTC AGC TGGG
CCCCCCTTC ACC TGTGAAGATGCCCTC TCC ACC ATGGGAATCC AATC TGTTGC AGTC TCCTTC AAGC ATTCTGTCGACCCTGGATGTTGAATTGCC ACC TGTTTGCTGTGAC AT
AGATATTTACCC ATACGACGTCCC AGACTACGC TTAAGGATCC AGATC TTATTAAAGC AGAAC TTGTTTATTGC AGC TTATAATGGTTAC AAATAAAGC AAT AGCATC AC AAAT
TTC AC AAATAAAGC ATTTTTTTC ACTGC ATTCTAGTTGTGGTTTGTCC AAAC TC ATC AATGTATC TTATC ATGTC TGC TCGAGGTCGAC...............AATGGGTTGAATTAGCGGAA 




that the transgene fragment was more easily isolated on an agarose gel.  The reaction products 
obtained following multiple digestions using Xho 1, Spe 1 and Pvu 1 were migrated on an 
agarose gel and the presence of DNA fragments for the predicted size of ~3500 bp were 
confirmed.  The transgene fragments were excised from the gel and subject to gel extraction 
and purification before being passed on to the Biomedical Services Unit for further 
purification and microinjection as described in section 5.3.2.2 (see Figure 8-3). 
 
Figure 8-3: Isolation of the linearised Tg-hPTTG-HA transgene construct.  A  Diagnostic agarose 
gel illustrating the products of various restriction digest reactions.  Red circle demonstrates the 
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highlights the identification of the transgene fragment (~3500 bp) following digestion with Xho 1, Spe 
1 and Pvu 1.  B  Agarose gel demonstrating migration and excision of transgene fragments (Green 
circles) following digestion with Xho 1, Spe 1 and Pvu 1.  C  Agarose gel showing migration of 1, 2 
and 3 µl samples of the linearised transgene following excision from original agarose gels and a 
purification step.  The clean, sharp appearance of the band indicates a pure and non-denatured DNA 





The work reported in this chapter describes the successful creation of a transgene 
construct containing hPTTG cDNA with a C-terminal HA-epitope downstream of the bovine 
thyroglobulin promoter.  The linearised transgene construct was isolated and purified in 
preparation for pronuclear microinjection.  Subsequent generation of alternative transgenic 
lines with thyroid-targeted hPTTG over-expression will facilitate the investigation of relative 
hPTTG over-expression levels on thyroid phenotypes in vivo.  From this point onwards, 












9 CHAPTER NINE 
 





























The work in this thesis has investigated some of the roles of the proto-oncogene 
hPTTG in the growth and function of thyroid cells.  Based on the hypothesis that hPTTG 
affects thyroid neoplasia by the initiation as well as the promotion of tumourigenesis, the 
complex interplay between hPTTG, growth factors and other key genes was examined in 
thyroid cells in vitro and in vivo.  In vivo investigations were facilitated by the successful 
generation of a murine transgenic line with thyroid-targeted hPTTG over-expression.  
Furthermore, due to the key roles of hPTTG and PBF in the regulation of NIS expression and 
function, the expression of these oncogenes as potential therapeutic targets for enhancing 
radioiodine treatments was investigated.   
9.1 Autocrine interactions between hPTTG and growth factors 
 
Expression and phosphorylation of hPTTG was induced by EGF, TGF-α and IGF-1 
following activation of pathways involving MAPK and PI3K in both malignant and non-
malignant human thyroid cells.  These effects were independent of known regulators of 
hPTTG expression and phosphorylation, SP1 and CDC2 respectively.  Interestingly, CDC2 
was identified as an independent regulator of hPTTG expression.  Subsequently, we 
confirmed that in turn, hPTTG over-expression causes upregulation of EGF, TGF-α and IGF-
1 expression and secretion in human follicular thyroid cells via its SH3-interacting domain, 
and enhanced levels of growth factors caused autocrine induction of hPTTG.  Collectively, 
these studies define the existence of autocrine pathways of interaction between hPTTG and 





knockout mice confirmed a particularly important 
interaction between hPTTG and EGF in vivo.  
Continued investigations into the exact mechanisms by which growth factors regulate 
hPTTG expression and phosphorylation may elucidate novel potential targets to reduce 




hPTTG expression in thyroid cancer.  To this effect, further siRNA knockdown studies of 
other transcription factors  implicated in the regulation of hPTTG including OCT-1 (Zhou et 
al. 2008), AP1 and AP2 (Kakar 1999), may provide further insights and identify novel 
strategies in this respect.   
CDC2 is the only reported regulator of hPTTG phosphorylation (Ramos-Morales et al. 
2000), which is in contrast with the work described in this thesis.  Future studies should aim 
to identify alternative mechanisms of hPTTG phosphorylation.  Given reports of a direct 
interaction between MAPK and PI3K with hPTTG (Chamaon et al. 2005), and the fact that 
Mapk directly phosphorylates rat Pttg (Pei 2000), it would be of specific interest to 
investigate whether MAPK and PI3K directly phosphorylate hPTTG in thyroid cells in 
response to growth factors. 
Whilst a moderate correlation between transcripts of hPTTG and growth factors was 
observed in normal human thyroid tissue, it would be interesting to perform correlation 
studies in thyroid cancer specimens.  We would propose to assess expression of hPTTG, EGF, 
TGF-α and IGF-1 in our group’s recently collected cohort of “matched” thyroid cancer 
specimens.  Thus, we would be able to verify the relationship between hPTTG and these 
growth factors in human thyroid cancer and determine whether the expression of these growth 
factors is, in addition to FGF-2 (Boelaert et al. 2003a), useful in predicting aggressive thyroid 
tumour behaviour.     
9.2 Further investigations of thyroid-targeted hPTTG over-expression 
 
We generated a murine transgenic model with thyroid-targeted over-expression of 
hPTTG (hPTTG-Tg mice) in order to directly investigate the tumourigenic effects of thyroidal 
hPTTG over-expression in vivo.  Unexpectedly, transgenic mice with high levels of thyroidal 
hPTTG expression do not develop thyroid hyperplasia or neoplasia, but in fact have smaller 
thyroid glands.   




Future studies should aim to verify reduced proliferation in thyroids from hPTTG-Tg 
mice through expression analyses of proliferation markers such as PCNA and cyclin-D1.  In 
addition, following on from work described in Chapter 8, we are currently generating and 
characterising alternative murine transgenic lines with thyroid-targeted hPTTG expression.  
These studies will enable us to define the in vivo dose-dependent effects of hPTTG on thyroid 
cell proliferation and transformation, and to test the hypothesis that low levels of thyroidal 
hPTTG over-expression results in thyroid tumourigenesis.  Furthermore, additional transgenic 
lines with higher levels of thyroidal hPTTG over-expression will provide the means to 
validate and give credence to the conclusions derived from our studies in current hPTTG 
transgenic mice.   
 We recently sourced a low-iodine mouse chow (Teklad Laboratories) for ongoing 
studies using our standard model of goitre induction (Ramsden et al. 2005) in WT, hPTTG-Tg 
and Pttg
-/-
 knockout mice to investigate the effects of thyroidal hPTTG over- and under-
expression on TSH-driven goitrogenesis.  In addition, we are performing preliminary 
experiments to investigate whether we can successfully target mouse thyroid glands in situ, 
with doses of ionising radiation using the irradiator facility at the Biomedical Services Unit 
(University of Birmingham).  These studies will provide important insight into the oncogenic 
potential of thyroidal hPTTG over-expression in the context of elevated serum TSH levels or 
DNA damage following exposure to external radiation.   
Ongoing characterisation of hPTTG.PBF-Tg bitransgenic mice remains an 
investigation of priority.  Given the striking hyperplasia observed in PBF-Tg mice (Read et al. 
2011) and that PBF facilitates the nuclear translocation and transactivational capability of 
hPTTG (Chien and Pei 2000), it will be interesting to see if tumourigenesis is facilitated by 
their concerted over-expression in the thyroid.  In addition, given the reported roles of hPTTG 
and PBF in causing genetic instability, investigations using fluorescent inter-simple sequence 




repeat PCR (FISSR-PCR) are being conducted to determine the relative levels of genetic 
instability in hPTTG-Tg, PBF-Tg and hPTTG.PBF-Tg mice compared with WT controls.  
This study may provide important insight concerning genetic aberrations that underlie key 
phenotypes.   
9.3 hPTTG and regulation of other angiogenic genes 
 
Angiogenesis-specific cDNA PCR array analysis highlighted the potential relationship 
between hPTTG and a number of genes critically involved in tumour proliferation and 
angiogenesis, and has opened up opportunities for further research.   
hPTTG upregulation of the pro-angiogenic genes Cxcl1 and Mdk, and repression of 
the anti-angiogenic gene Tnf-α, was of particular interest.  We propose that thyroidal 
expression changes of these genes should be validated in greater numbers of hPTTG-Tg mice 
using gene-specific TaqMan RT-PCR assays (Applied Biosystems) and 
immunohistochemistry on paraffin embedded thyroid sections.  Upon validation of these 
alterations in hPTTG-Tg mice, expression analyses should also be performed in our cohort of 
‘matched’ human thyroid specimens.   
9.4 hPTTG and PBF as therapeutic targets for enhancing treatment with radioiodine 
 
Work described in this thesis confirmed that both hPTTG and PBF downregulate 
thyroidal NIS expression and reduce I
- 
uptake in vivo, which has important implications for 
the efficacy of radiodine therapies in thyroid disease where hPTTG and PBF are over-
expressed.  Crucially, we demonstrated that PBF represents a novel therapeutic target to 
overcome radioiodine resistance in thyroid tumors and their metastases, as well as more 
generally in other thyroid diseases.   
Our inability to consistently achieve strong repression of hPTTG expression in hPTTG-
Tg thyrocytes or human primary thyrocytes hampered our investigations of hPTTG as a 








uptake.  Successful knockdown of PBF was 
achieved by using a combination of siRNAs targeting PBF transcripts.  We propose that a 
similar strategy should be adopted to optimise knockdown of hPTTG expression in order to 
fully determine the potential of hPTTG as a therapeutic target to alleviate NIS repression in 
thyroid cancer.   
Following demonstration of these critical phenotypes in an ex vivo primary culture 
system, it would be interesting to confirm these findings through in vivo visualisation of 
124
I 
accumulation using positron emission topography (PET) imaging, as has been described 
previously (Roepke et al. 2009).  Further, studies of non-thyroid cancers have used novel 
approaches using hPTTG siRNA to reduce hPTTG expression in vivo, resulting in inhibition 
of tumour development (Kakar and Malik 2006; Jung et al. 2006).  Therefore, an exciting 
prospective study would be to combine in vivo siRNA treatments with PET-imaging in 
hPTTG-Tg and PBF-Tg mice to demonstrate the therapeutic potential of targeting hPTTG and 
PBF over-expression in live mice.  In the future, this approach may evolve into a therapeutic 
approach, with progress continuing in the development of siRNA delivery techniques that 
allow over-expressed genes to be specifically targeted in cancer cells without affecting normal 
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